{
  "doc_id": "15",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识",
          "start_idx": 0,
          "end_idx": 31,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T1",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T2",
              "entity": "动脉粥样硬化性心血管疾病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 19,
              "entity_en": "Atherosclerotic cardiovascular disease"
            },
            {
              "entity_id": "T3",
              "entity": "动脉",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 9,
              "entity_en": "artery"
            },
            {
              "entity_id": "T4",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R0",
              "head_entity_id": "T1",
              "tail_entity_id": "T0"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R1",
              "head_entity_id": "T3",
              "tail_entity_id": "T2"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R2",
              "head_entity_id": "T4",
              "tail_entity_id": "T2"
            }
          ],
          "sentence_en": "Expert consensus on the use of glucose-lowering drugs in patients with type 2 diabetes and atherosclerotic cardiovascular disease"
        }
      ],
      "paragraph_en": "Expert consensus on the use of glucose-lowering drugs in patients with type 2 diabetes and atherosclerotic cardiovascular disease"
    },
    {
      "paragraph_id": "1",
      "paragraph": "随着经济高速发展、生活方式改变及人口老龄化，我国糖尿病患病率呈快速上升趋势。2007~2008年流行病学调查显示，我国20岁以上成人糖尿病患病率为9.7%。2010年流行病学调查显示，我国18岁以上成人糖尿病患病率为11.6%。在我国糖尿病患者中，90%以上为2型糖尿病(T2DM)。动脉粥样硬化性心血管疾病(ASCVD)包括冠心病、缺血性卒中及外周动脉疾病。T2DM与ASCVD关系密切，两者共存可进一步增加心血管事件和死亡风险，半数以上糖尿病患者的死亡与ASCVD相关。近年来，随着临床研究证据的不断积累和更新，关于降糖药物与T2DM患者心血管结局之间的关系也日益明确。因此，合理规范应用降糖药物对于T2DM合并ASCVD患者显得尤为重要。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "随着经济高速发展、生活方式改变及人口老龄化，我国糖尿病患病率呈快速上升趋势。2007~2008年流行病学调查显示，我国20岁以上成人糖尿病患病率为9.7%。2010年流行病学调查显示，我国18岁以上成人糖尿病患病率为11.6%。在我国糖尿病患者中，90%以上为2型糖尿病(T2DM)。动脉粥样硬化性心血管疾病(ASCVD)包括冠心病、缺血性卒中及外周动脉疾病。T2DM与ASCVD关系密切，两者共存可进一步增加心血管事件和死亡风险，半数以上糖尿病患者的死亡与ASCVD相关。近年来，随着临床研究证据的不断积累和更新，关于降糖药物与T2DM患者心血管结局之间的关系也日益明确。因此，合理规范应用降糖药物对于T2DM合并ASCVD患者显得尤为重要。",
          "start_idx": 0,
          "end_idx": 322,
          "entities": [
            {
              "entity_id": "T5",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T6",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 69,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T7",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 104,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T8",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 120,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T9",
              "entity": "2型糖尿病(T2DM)",
              "entity_type": "Disease",
              "start_idx": 130,
              "end_idx": 141,
              "entity_en": "Type 2 diabetes mellitus (T2DM)"
            },
            {
              "entity_id": "T10",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 130,
              "end_idx": 132,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T11",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 136,
              "end_idx": 138,
              "entity_en": "T2"
            },
            {
              "entity_id": "T12",
              "entity": "动脉粥样硬化性心血管疾病(ASCVD)",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 161,
              "entity_en": "Atherosclerotic cardiovascular disease (ASCVD)"
            },
            {
              "entity_id": "T13",
              "entity": "动脉",
              "entity_type": "Anatomy",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": "artery"
            },
            {
              "entity_id": "T14",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 149,
              "end_idx": 152,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T15",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 166,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T16",
              "entity": "缺血性卒中",
              "entity_type": "Disease",
              "start_idx": 167,
              "end_idx": 172,
              "entity_en": "Ischemic stroke"
            },
            {
              "entity_id": "T17",
              "entity": "外周动脉疾病",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 179,
              "entity_en": "Peripheral arterial disease"
            },
            {
              "entity_id": "T18",
              "entity": "外周动脉",
              "entity_type": "Anatomy",
              "start_idx": 173,
              "end_idx": 177,
              "entity_en": "Peripheral arteries"
            },
            {
              "entity_id": "T19",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 180,
              "end_idx": 184,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T20",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 180,
              "end_idx": 182,
              "entity_en": "T2"
            },
            {
              "entity_id": "T21",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 185,
              "end_idx": 190,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T22",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 220,
              "end_idx": 223,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T23",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 229,
              "end_idx": 234,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T24",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T25",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 265,
              "end_idx": 267,
              "entity_en": "T2"
            },
            {
              "entity_id": "T26",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 302,
              "end_idx": 306,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T27",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 302,
              "end_idx": 304,
              "entity_en": "T2"
            },
            {
              "entity_id": "T28",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 308,
              "end_idx": 313,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T29",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 205,
              "end_idx": 210,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T30",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 205,
              "end_idx": 208,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T31",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 271,
              "end_idx": 274,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T10",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R4",
              "head_entity_id": "T11",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R5",
              "head_entity_id": "T13",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R6",
              "head_entity_id": "T14",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R7",
              "head_entity_id": "T18",
              "tail_entity_id": "T17"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R8",
              "head_entity_id": "T20",
              "tail_entity_id": "T19"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R9",
              "head_entity_id": "T25",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R10",
              "head_entity_id": "T31",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R11",
              "head_entity_id": "T27",
              "tail_entity_id": "T26"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R12",
              "head_entity_id": "T30",
              "tail_entity_id": "T29"
            }
          ],
          "sentence_en": "With the rapid economic development, lifestyle changes and population aging, the prevalence of diabetes in my country has been increasing rapidly. An epidemiological survey from 2007 to 2008 showed that the prevalence of diabetes in adults over 20 years old in my country was 9.7%. An epidemiological survey in 2010 showed that the prevalence of diabetes in adults over 18 years old in my country was 11.6%. Among diabetic patients in my country, more than 90% have type 2 diabetes (T2DM). Atherosclerotic cardiovascular disease (ASCVD) includes coronary heart disease, ischemic stroke and peripheral arterial disease. T2DM and ASCVD are closely related. The coexistence of the two can further increase the risk of cardiovascular events and death. More than half of the deaths of diabetic patients are related to ASCVD. In recent years, with the continuous accumulation and updating of clinical research evidence, the relationship between hypoglycemic drugs and cardiovascular outcomes in patients with T2DM has become increasingly clear. Therefore, the rational and standardized use of hypoglycemic drugs is particularly important for patients with T2DM and ASCVD."
        }
      ],
      "paragraph_en": "With the rapid economic development, lifestyle changes and population aging, the prevalence of diabetes in my country has been increasing rapidly. An epidemiological survey from 2007 to 2008 showed that the prevalence of diabetes in adults over 20 years old in my country was 9.7%. An epidemiological survey in 2010 showed that the prevalence of diabetes in adults over 18 years old in my country was 11.6%. Among diabetic patients in my country, more than 90% have type 2 diabetes (T2DM). Atherosclerotic cardiovascular disease (ASCVD) includes coronary heart disease, ischemic stroke and peripheral arterial disease. T2DM and ASCVD are closely related. The coexistence of the two can further increase the risk of cardiovascular events and death. More than half of the deaths of diabetic patients are related to ASCVD. In recent years, with the continuous accumulation and updating of clinical research evidence, the relationship between hypoglycemic drugs and cardiovascular outcomes in patients with T2DM has become increasingly clear. Therefore, the rational and standardized use of hypoglycemic drugs is particularly important for patients with T2DM and ASCVD."
    },
    {
      "paragraph_id": "2",
      "paragraph": "为了指导我国临床医师对T2DM合并ASCVD患者进行规范化管理，并且充分了解T2DM合并ASCVD患者的综合管理策略、降糖治疗原则、血糖控制目标及常用降糖药物合理应用，由我国内分泌科、心内科、肾内科及临床流行病学专家联合制定了本共识。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "为了指导我国临床医师对T2DM合并ASCVD患者进行规范化管理，并且充分了解T2DM合并ASCVD患者的综合管理策略、降糖治疗原则、血糖控制目标及常用降糖药物合理应用，由我国内分泌科、心内科、肾内科及临床流行病学专家联合制定了本共识。",
          "start_idx": 0,
          "end_idx": 117,
          "entities": [
            {
              "entity_id": "T32",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T33",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "T2"
            },
            {
              "entity_id": "T34",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 22,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T35",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T36",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 38,
              "end_idx": 40,
              "entity_en": "T2"
            },
            {
              "entity_id": "T37",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 49,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T38",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 66,
              "end_idx": 68,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R13",
              "head_entity_id": "T33",
              "tail_entity_id": "T32"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R14",
              "head_entity_id": "T36",
              "tail_entity_id": "T35"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R15",
              "head_entity_id": "T38",
              "tail_entity_id": "T35"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R16",
              "head_entity_id": "T38",
              "tail_entity_id": "T37"
            }
          ],
          "sentence_en": "In order to guide Chinese clinical physicians to carry out standardized management of patients with T2DM and ASCVD, and to fully understand the comprehensive management strategies, hypoglycemic treatment principles, blood sugar control targets and rational use of common hypoglycemic drugs for patients with T2DM and ASCVD, this consensus was jointly developed by experts in endocrinology, cardiology, nephrology and clinical epidemiology."
        }
      ],
      "paragraph_en": "In order to guide Chinese clinical physicians to carry out standardized management of patients with T2DM and ASCVD, and to fully understand the comprehensive management strategies, hypoglycemic treatment principles, blood sugar control targets and rational use of common hypoglycemic drugs for patients with T2DM and ASCVD, this consensus was jointly developed by experts in endocrinology, cardiology, nephrology and clinical epidemiology."
    },
    {
      "paragraph_id": "3",
      "paragraph": "一、T2DM合并ASCVD的流行病学",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、T2DM合并ASCVD的流行病学",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [
            {
              "entity_id": "T39",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T40",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "T2"
            },
            {
              "entity_id": "T41",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "ASCVD"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R17",
              "head_entity_id": "T40",
              "tail_entity_id": "T39"
            }
          ],
          "sentence_en": "1. Epidemiology of T2DM and ASCVD"
        }
      ],
      "paragraph_en": "1. Epidemiology of T2DM and ASCVD"
    },
    {
      "paragraph_id": "4",
      "paragraph": "2006年中国心脏调查发现，52.9%的冠心病住院患者合并糖尿病。另一方面，在全国三甲医院住院T2DM患者中，17.1%合并心血管疾病，13.2%合并脑血管疾病。在我国大型城市住院T2DM患者中，25.1%合并冠心病，17.3%合并脑血管疾病。中国“3B”研究显示，门诊就诊的T2DM患者中，14.6%合并心血管疾病，10.1%合并包括缺血性卒中在内的脑血管疾病。上述研究数据表明，我国T2DM患者合并ASCVD的情况非常普遍，已日益成为糖尿病管理的一个巨大挑战，值得临床医生给予高度重视。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2006年中国心脏调查发现，52.9%的冠心病住院患者合并糖尿病。另一方面，在全国三甲医院住院T2DM患者中，17.1%合并心血管疾病，13.2%合并脑血管疾病。",
          "start_idx": 0,
          "end_idx": 81,
          "entities": [
            {
              "entity_id": "T42",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T43",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T44",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T45",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "T2"
            },
            {
              "entity_id": "T50",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T51",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 62,
              "end_idx": 65,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T52",
              "entity": "脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 80,
              "entity_en": "Cerebrovascular disease"
            },
            {
              "entity_id": "T53",
              "entity": "脑血管",
              "entity_type": "Anatomy",
              "start_idx": 75,
              "end_idx": 78,
              "entity_en": "Cerebrovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R18",
              "head_entity_id": "T45",
              "tail_entity_id": "T44"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R21",
              "head_entity_id": "T51",
              "tail_entity_id": "T50"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R22",
              "head_entity_id": "T53",
              "tail_entity_id": "T52"
            }
          ],
          "sentence_en": "The 2006 Chinese Heart Survey found that 52.9% of hospitalized patients with coronary heart disease had diabetes. On the other hand, among patients with T2DM hospitalized in tertiary hospitals nationwide, 17.1% had cardiovascular disease and 13.2% had cerebrovascular disease."
        },
        {
          "sentence_id": "1",
          "sentence": "在我国大型城市住院T2DM患者中，25.1%合并冠心病，17.3%合并脑血管疾病。",
          "start_idx": 81,
          "end_idx": 122,
          "entities": [
            {
              "entity_id": "T54",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T55",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "T2"
            },
            {
              "entity_id": "T56",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T57",
              "entity": "脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 40,
              "entity_en": "Cerebrovascular disease"
            },
            {
              "entity_id": "T58",
              "entity": "脑血管",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 38,
              "entity_en": "Cerebrovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R23",
              "head_entity_id": "T55",
              "tail_entity_id": "T54"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R24",
              "head_entity_id": "T58",
              "tail_entity_id": "T57"
            }
          ],
          "sentence_en": "Among hospitalized T2DM patients in large cities in my country, 25.1% had coronary heart disease and 17.3% had cerebrovascular disease."
        },
        {
          "sentence_id": "2",
          "sentence": "中国“3B”研究显示，门诊就诊的T2DM患者中，14.6%合并心血管疾病，10.1%合并包括缺血性卒中在内的脑血管疾病。",
          "start_idx": 122,
          "end_idx": 182,
          "entities": [
            {
              "entity_id": "T46",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 20,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T47",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "T2"
            },
            {
              "entity_id": "T59",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 36,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T60",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T61",
              "entity": "缺血性卒中",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 51,
              "entity_en": "Ischemic stroke"
            },
            {
              "entity_id": "T62",
              "entity": "脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 59,
              "entity_en": "Cerebrovascular disease"
            },
            {
              "entity_id": "T63",
              "entity": "脑血管",
              "entity_type": "Anatomy",
              "start_idx": 54,
              "end_idx": 57,
              "entity_en": "Cerebrovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R19",
              "head_entity_id": "T47",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R25",
              "head_entity_id": "T60",
              "tail_entity_id": "T59"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R26",
              "head_entity_id": "T63",
              "tail_entity_id": "T62"
            }
          ],
          "sentence_en": "China's \"3B\" study showed that among T2DM patients visiting outpatient clinics, 14.6% had cardiovascular disease and 10.1% had cerebrovascular disease including ischemic stroke."
        },
        {
          "sentence_id": "3",
          "sentence": "上述研究数据表明，我国T2DM患者合并ASCVD的情况非常普遍，已日益成为糖尿病管理的一个巨大挑战，值得临床医生给予高度重视。",
          "start_idx": 182,
          "end_idx": 245,
          "entities": [
            {
              "entity_id": "T48",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T49",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "T2"
            },
            {
              "entity_id": "T64",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T65",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R20",
              "head_entity_id": "T49",
              "tail_entity_id": "T48"
            }
          ],
          "sentence_en": "The above research data show that the combination of ASCVD in T2DM patients in my country is very common and has increasingly become a huge challenge for diabetes management, which deserves the high attention of clinicians."
        }
      ],
      "paragraph_en": "The 2006 Chinese Heart Survey found that 52.9% of hospitalized patients with coronary heart disease had diabetes. On the other hand, among T2DM patients hospitalized in tertiary hospitals nationwide, 17.1% had cardiovascular disease and 13.2% had cerebrovascular disease. Among T2DM patients hospitalized in large cities in my country, 25.1% had coronary heart disease and 17.3% had cerebrovascular disease. The Chinese \"3B\" study showed that among T2DM patients who visited outpatient clinics, 14.6% had cardiovascular disease and 10.1% had cerebrovascular disease including ischemic stroke. The above research data show that the combination of ASCVD in T2DM patients in my country is very common and has increasingly become a huge challenge for diabetes management, which deserves the high attention of clinicians."
    },
    {
      "paragraph_id": "5",
      "paragraph": "二、T2DM患者中ASCVD危险因素的综合管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、T2DM患者中ASCVD危险因素的综合管理",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T66",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T67",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "T2"
            },
            {
              "entity_id": "T68",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "ASCVD"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R27",
              "head_entity_id": "T67",
              "tail_entity_id": "T66"
            }
          ],
          "sentence_en": "II. Comprehensive management of ASCVD risk factors in patients with T2DM"
        }
      ],
      "paragraph_en": "II. Comprehensive management of ASCVD risk factors in patients with T2DM"
    },
    {
      "paragraph_id": "6",
      "paragraph": "除高血糖外，T2DM患者往往合并有高血压、血脂异常、肥胖等多重心血管危险因素。因此，对于大多数T2DM患者，特别是合并ASCVD的患者，应采取综合管理策略，在控制血糖的同时，全面管理好各种心血管危险因素，具体措施包括生活方式干预、降压、调脂、抗血小板治疗、减重等，以期最大程度降低心血管事件和死亡风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "除高血糖外，T2DM患者往往合并有高血压、血脂异常、肥胖等多重心血管危险因素。因此，对于大多数T2DM患者，特别是合并ASCVD的患者，应采取综合管理策略，在控制血糖的同时，全面管理好各种心血管危险因素，具体措施包括生活方式干预、降压、调脂、抗血小板治疗、减重等，以期最大程度降低心血管事件和死亡风险。",
          "start_idx": 0,
          "end_idx": 151,
          "entities": [
            {
              "entity_id": "T69",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T70",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "T2"
            },
            {
              "entity_id": "T71",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T72",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Dyslipidemia"
            },
            {
              "entity_id": "T73",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T74",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T75",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "T2"
            },
            {
              "entity_id": "T76",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 64,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T77",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 81,
              "end_idx": 83,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T78",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 108,
              "end_idx": 114,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T79",
              "entity": "降压",
              "entity_type": "Treatment",
              "start_idx": 115,
              "end_idx": 117,
              "entity_en": "Blood pressure reduction"
            },
            {
              "entity_id": "T80",
              "entity": "调脂",
              "entity_type": "Treatment",
              "start_idx": 118,
              "end_idx": 120,
              "entity_en": "Lipid regulation"
            },
            {
              "entity_id": "T81",
              "entity": "抗血小板治疗",
              "entity_type": "Treatment",
              "start_idx": 121,
              "end_idx": 127,
              "entity_en": "Antiplatelet therapy"
            },
            {
              "entity_id": "T82",
              "entity": "减重",
              "entity_type": "Treatment",
              "start_idx": 128,
              "end_idx": 130,
              "entity_en": "Weight loss"
            },
            {
              "entity_id": "T83",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 140,
              "end_idx": 145,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T84",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 140,
              "end_idx": 143,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T85",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T86",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R28",
              "head_entity_id": "T70",
              "tail_entity_id": "T69"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R29",
              "head_entity_id": "T86",
              "tail_entity_id": "T69"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R30",
              "head_entity_id": "T75",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R31",
              "head_entity_id": "T77",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R32",
              "head_entity_id": "T77",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R33",
              "head_entity_id": "T84",
              "tail_entity_id": "T83"
            }
          ],
          "sentence_en": "In addition to hyperglycemia, T2DM patients often have multiple cardiovascular risk factors such as hypertension, dyslipidemia, and obesity. Therefore, for most T2DM patients, especially those with ASCVD, a comprehensive management strategy should be adopted to comprehensively manage various cardiovascular risk factors while controlling blood sugar. Specific measures include lifestyle intervention, blood pressure reduction, lipid regulation, antiplatelet therapy, weight loss, etc., in order to minimize the risk of cardiovascular events and death."
        }
      ],
      "paragraph_en": "In addition to hyperglycemia, T2DM patients often have multiple cardiovascular risk factors such as hypertension, dyslipidemia, and obesity. Therefore, for most T2DM patients, especially those with ASCVD, a comprehensive management strategy should be adopted to comprehensively manage various cardiovascular risk factors while controlling blood sugar. Specific measures include lifestyle intervention, blood pressure reduction, lipid regulation, antiplatelet therapy, weight loss, etc., in order to minimize the risk of cardiovascular events and death."
    },
    {
      "paragraph_id": "7",
      "paragraph": "(一)生活方式干预",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)生活方式干预",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T87",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Lifestyle interventions"
            }
          ],
          "relations": [],
          "sentence_en": "1. Lifestyle intervention"
        }
      ],
      "paragraph_en": "1. Lifestyle intervention"
    },
    {
      "paragraph_id": "8",
      "paragraph": "对于所有T2DM合并ASCVD患者，生活方式干预应作为综合管理策略的基础性措施，并贯穿于综合治疗的全过程。生活方式干预包括健康教育、戒烟限酒、限盐(<6g/d)、合理饮食、规律运动、注意保持心理平衡等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于所有T2DM合并ASCVD患者，生活方式干预应作为综合管理策略的基础性措施，并贯穿于综合治疗的全过程。",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T88",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 8,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T89",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "T2"
            },
            {
              "entity_id": "T90",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T91",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 18,
              "end_idx": 24,
              "entity_en": "Lifestyle interventions"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R34",
              "head_entity_id": "T89",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R35",
              "head_entity_id": "T91",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R36",
              "head_entity_id": "T91",
              "tail_entity_id": "T90"
            }
          ],
          "sentence_en": "For all patients with T2DM and ASCVD, lifestyle intervention should be the basic measure of the comprehensive management strategy and should be integrated into the entire process of comprehensive treatment."
        },
        {
          "sentence_id": "1",
          "sentence": "生活方式干预包括健康教育、戒烟限酒、限盐(<6g/d)、合理饮食、规律运动、注意保持心理平衡等。",
          "start_idx": 53,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T92",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T93",
              "entity": "健康教育",
              "entity_type": "Treatment",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Health Education"
            },
            {
              "entity_id": "T94",
              "entity": "戒烟",
              "entity_type": "Treatment",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "Quitting smoking"
            },
            {
              "entity_id": "T95",
              "entity": "合理饮食",
              "entity_type": "Treatment",
              "start_idx": 28,
              "end_idx": 32,
              "entity_en": "Eat a healthy diet"
            },
            {
              "entity_id": "T96",
              "entity": "规律运动",
              "entity_type": "Treatment",
              "start_idx": 33,
              "end_idx": 37,
              "entity_en": "Regular exercise"
            },
            {
              "entity_id": "T97",
              "entity": "注意保持心理平衡",
              "entity_type": "Treatment",
              "start_idx": 38,
              "end_idx": 46,
              "entity_en": "Keep a mental balance"
            },
            {
              "entity_id": "T98",
              "entity": "限盐(<6g/d)",
              "entity_type": "Treatment",
              "start_idx": 18,
              "end_idx": 27,
              "entity_en": "Salt restriction (<6 g/d)"
            },
            {
              "entity_id": "T99",
              "entity": "限酒",
              "entity_type": "Treatment",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "Alcohol restriction"
            }
          ],
          "relations": [],
          "sentence_en": "Lifestyle interventions include health education, smoking cessation, alcohol restriction, salt restriction (<6g/d), proper diet, regular exercise, and attention to maintaining psychological balance."
        }
      ],
      "paragraph_en": "For all patients with T2DM and ASCVD, lifestyle intervention should be the basic measure of comprehensive management strategy and should be carried out throughout the whole process of comprehensive treatment. Lifestyle intervention includes health education, smoking cessation, alcohol restriction, salt restriction (<6g/d), reasonable diet, regular exercise, and attention to maintaining psychological balance."
    },
    {
      "paragraph_id": "9",
      "paragraph": "(二)降压治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)降压治疗",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "2. Antihypertensive treatment"
        }
      ],
      "paragraph_en": "2. Antihypertensive treatment"
    },
    {
      "paragraph_id": "10",
      "paragraph": "高血压与高血糖并存可使ASCVD发生和发展风险显著增加，从而增加T2DM患者的病死率。研究显示，控制高血压可显著降低ASCVD发生和发展的风险，降压治疗的心血管获益主要源自血压控制本身。因此，对于大多数T2DM合并高血压患者，血压控制目标为<140/80mmHg；对于年轻、没有并发症、合并白蛋白尿或糖尿病慢性肾脏病(CKD)患者，可将收缩压控制在<130mmHg。选择降压药物时，应综合考虑疗效、心肾保护作用、安全性、依从性、对代谢的影响等因素。大多数患者需要至少两种不同作用机制的降压药物的联合治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "高血压与高血糖并存可使ASCVD发生和发展风险显著增加，从而增加T2DM患者的病死率。研究显示，控制高血压可显著降低ASCVD发生和发展的风险，降压治疗的心血管获益主要源自血压控制本身。因此，对于大多数T2DM合并高血压患者，血压控制目标为<140/80mmHg；对于年轻、没有并发症、合并白蛋白尿或糖尿病慢性肾脏病(CKD)患者，可将收缩压控制在<130mmHg。",
          "start_idx": 0,
          "end_idx": 183,
          "entities": [
            {
              "entity_id": "T100",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T101",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T102",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T103",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T104",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "T2"
            },
            {
              "entity_id": "T105",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 53,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T106",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T107",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T108",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 101,
              "end_idx": 103,
              "entity_en": "T2"
            },
            {
              "entity_id": "T109",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 110,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T110",
              "entity": "<140/80mmHg",
              "entity_type": "Test_Value",
              "start_idx": 120,
              "end_idx": 131,
              "entity_en": "<140/80 mmHg"
            },
            {
              "entity_id": "T111",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 145,
              "end_idx": 149,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T112",
              "entity": "糖尿病慢性肾脏病(CKD)",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 163,
              "entity_en": "Diabetic chronic kidney disease (CKD)"
            },
            {
              "entity_id": "T113",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 86,
              "end_idx": 88,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T114",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 113,
              "end_idx": 115,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T115",
              "entity": "收缩压",
              "entity_type": "Test",
              "start_idx": 168,
              "end_idx": 171,
              "entity_en": "Systolic blood pressure"
            },
            {
              "entity_id": "T116",
              "entity": "<130mmHg",
              "entity_type": "Test_Value",
              "start_idx": 174,
              "end_idx": 182,
              "entity_en": "<130 mmHg"
            },
            {
              "entity_id": "T117",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 155,
              "end_idx": 157,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T118",
              "entity": "慢性",
              "entity_type": "Class",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "Chronic"
            },
            {
              "entity_id": "T119",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 77,
              "end_idx": 80,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R37",
              "head_entity_id": "T104",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R38",
              "head_entity_id": "T119",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R39",
              "head_entity_id": "T113",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R40",
              "head_entity_id": "T108",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R41",
              "head_entity_id": "T114",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R42",
              "head_entity_id": "T114",
              "tail_entity_id": "T109"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R43",
              "head_entity_id": "T115",
              "tail_entity_id": "T111"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R44",
              "head_entity_id": "T115",
              "tail_entity_id": "T112"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R45",
              "head_entity_id": "T117",
              "tail_entity_id": "T112"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R46",
              "head_entity_id": "T118",
              "tail_entity_id": "T112"
            }
          ],
          "sentence_en": "The coexistence of hypertension and hyperglycemia can significantly increase the risk of ASCVD occurrence and development, thereby increasing the mortality rate of patients with T2DM. Studies have shown that controlling hypertension can significantly reduce the risk of ASCVD occurrence and development, and the cardiovascular benefits of antihypertensive therapy mainly come from blood pressure control itself. Therefore, for most patients with T2DM and hypertension, the blood pressure control target is <140/80 mmHg; for young patients without complications, with albuminuria or diabetic chronic kidney disease (CKD), systolic blood pressure can be controlled at <130 mmHg."
        },
        {
          "sentence_id": "1",
          "sentence": "选择降压药物时，应综合考虑疗效、心肾保护作用、安全性、依从性、对代谢的影响等因素。",
          "start_idx": 183,
          "end_idx": 224,
          "entities": [],
          "relations": [],
          "sentence_en": "When selecting antihypertensive drugs, factors such as efficacy, cardiorenal protection, safety, compliance, and effects on metabolism should be considered comprehensively."
        },
        {
          "sentence_id": "2",
          "sentence": "大多数患者需要至少两种不同作用机制的降压药物的联合治疗。",
          "start_idx": 224,
          "end_idx": 252,
          "entities": [],
          "relations": [],
          "sentence_en": "Most patients require combination therapy with at least two antihypertensive drugs with different mechanisms of action."
        }
      ],
      "paragraph_en": "The coexistence of hypertension and hyperglycemia can significantly increase the risk of ASCVD occurrence and development, thereby increasing the mortality rate of patients with T2DM. Studies have shown that controlling hypertension can significantly reduce the risk of ASCVD occurrence and development, and the cardiovascular benefits of antihypertensive therapy mainly come from blood pressure control itself. Therefore, for most patients with T2DM and hypertension, the blood pressure control target is <140/80mmHg; for young patients without complications, combined with albuminuria or diabetic chronic kidney disease (CKD), systolic blood pressure can be controlled at <130mmHg. When selecting antihypertensive drugs, factors such as efficacy, cardiorenal protection, safety, compliance, and effects on metabolism should be considered comprehensively. Most patients require combination therapy with at least two antihypertensive drugs with different mechanisms of action."
    },
    {
      "paragraph_id": "11",
      "paragraph": "(三)调脂治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)调脂治疗",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "(III) Lipid-lowering therapy"
        }
      ],
      "paragraph_en": "(III) Lipid-lowering therapy"
    },
    {
      "paragraph_id": "12",
      "paragraph": "T2DM患者通常合并多项血脂异常，主要表现为TG升高、LDL-C升高及HDL-C降低、三者均与T2DM患者ASCVD发生风险增高相关。T2DM合并ASCVD患者属于极高危人群，调脂治疗的首要干预靶点IDL-C目标值为<1.8mmol/L，次要干预靶点非HDL-C目标值为<2.6mmol/L，为了达到上述目标-应首选他汀类药物。经他汀类治疗后，如非HDL-C仍不能达到目标值.可在他汀类基础上加用贝特类、高纯度鱼油制剂。对于严重高TG血症(空腹TG≥5.7mmol/L)患者，应首先考虑使用贝特类、高纯度鱼油制剂或烟酸类药物治疗，以预防急性胰腺炎的发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM患者通常合并多项血脂异常，主要表现为TG升高、LDL-C升高及HDL-C降低、三者均与T2DM患者ASCVD发生风险增高相关。T2DM合并ASCVD患者属于极高危人群，调脂治疗的首要干预靶点IDL-C目标值为<1.8mmol/L，次要干预靶点非HDL-C目标值为<2.6mmol/L，为了达到上述目标-应首选他汀类药物。经他汀类治疗后，如非HDL-C仍不能达到目标值.可在他汀类基础上加用贝特类、高纯度鱼油制剂。对于严重高TG血症(空腹TG≥5.7mmol/L)患者，应首先考虑使用贝特类、高纯度鱼油制剂或烟酸类药物治疗，以预防急性胰腺炎的发生。",
          "start_idx": 0,
          "end_idx": 277,
          "entities": [
            {
              "entity_id": "T120",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T121",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "T2"
            },
            {
              "entity_id": "T122",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Dyslipidemia"
            },
            {
              "entity_id": "T123",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "TG"
            },
            {
              "entity_id": "T124",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T125",
              "entity": "HDL-C",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 40,
              "entity_en": "HDL-C"
            },
            {
              "entity_id": "T126",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T127",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T128",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "reduce"
            },
            {
              "entity_id": "T129",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T130",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "T2"
            },
            {
              "entity_id": "T131",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 58,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T132",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T133",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "T2"
            },
            {
              "entity_id": "T134",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 73,
              "end_idx": 78,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T135",
              "entity": "IDL-C",
              "entity_type": "Test_items",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "IDL-C"
            },
            {
              "entity_id": "T136",
              "entity": "<1.8mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 108,
              "end_idx": 118,
              "entity_en": "<1.8mmol/L"
            },
            {
              "entity_id": "T137",
              "entity": "非HDL-C",
              "entity_type": "Test_items",
              "start_idx": 125,
              "end_idx": 131,
              "entity_en": "Non-HDL-C"
            },
            {
              "entity_id": "T138",
              "entity": "<2.6mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 135,
              "end_idx": 145,
              "entity_en": "<2.6mmol/L"
            },
            {
              "entity_id": "T139",
              "entity": "他汀类药物",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T140",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 165,
              "end_idx": 168,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T141",
              "entity": "非HDL-C",
              "entity_type": "Test_items",
              "start_idx": 173,
              "end_idx": 179,
              "entity_en": "Non-HDL-C"
            },
            {
              "entity_id": "T142",
              "entity": "不能达到目标值",
              "entity_type": "Test_Value",
              "start_idx": 180,
              "end_idx": 187,
              "entity_en": "Unable to reach target value"
            },
            {
              "entity_id": "T143",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 193,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T144",
              "entity": "贝特类",
              "entity_type": "Drug",
              "start_idx": 198,
              "end_idx": 201,
              "entity_en": "Fibrates"
            },
            {
              "entity_id": "T145",
              "entity": "高纯度鱼油制剂",
              "entity_type": "Drug",
              "start_idx": 202,
              "end_idx": 209,
              "entity_en": "High purity fish oil preparation"
            },
            {
              "entity_id": "T146",
              "entity": "高TG血症",
              "entity_type": "Disease",
              "start_idx": 214,
              "end_idx": 219,
              "entity_en": "Hypertriglyceridemia"
            },
            {
              "entity_id": "T147",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 212,
              "end_idx": 214,
              "entity_en": "serious"
            },
            {
              "entity_id": "T148",
              "entity": "空腹TG",
              "entity_type": "Test_items",
              "start_idx": 220,
              "end_idx": 224,
              "entity_en": "Fasting TG"
            },
            {
              "entity_id": "T149",
              "entity": "≥5.7mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 224,
              "end_idx": 234,
              "entity_en": "≥5.7mmol/L"
            },
            {
              "entity_id": "T150",
              "entity": "贝特类",
              "entity_type": "Drug",
              "start_idx": 245,
              "end_idx": 248,
              "entity_en": "Fibrates"
            },
            {
              "entity_id": "T151",
              "entity": "高纯度鱼油制剂",
              "entity_type": "Drug",
              "start_idx": 249,
              "end_idx": 256,
              "entity_en": "High purity fish oil preparation"
            },
            {
              "entity_id": "T152",
              "entity": "烟酸类药物",
              "entity_type": "Drug",
              "start_idx": 257,
              "end_idx": 262,
              "entity_en": "Niacin drugs"
            },
            {
              "entity_id": "T153",
              "entity": "急性胰腺炎",
              "entity_type": "Disease",
              "start_idx": 268,
              "end_idx": 273,
              "entity_en": "Acute pancreatitis"
            },
            {
              "entity_id": "T154",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 268,
              "end_idx": 270,
              "entity_en": "acute"
            },
            {
              "entity_id": "T155",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 270,
              "end_idx": 272,
              "entity_en": "pancreas"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R47",
              "head_entity_id": "T121",
              "tail_entity_id": "T120"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R48",
              "head_entity_id": "T123",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R49",
              "head_entity_id": "T124",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R50",
              "head_entity_id": "T125",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R51",
              "head_entity_id": "T130",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R52",
              "head_entity_id": "T133",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R53",
              "head_entity_id": "T135",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R54",
              "head_entity_id": "T137",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R55",
              "head_entity_id": "T139",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R56",
              "head_entity_id": "T135",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R57",
              "head_entity_id": "T137",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T139",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R59",
              "head_entity_id": "T148",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R60",
              "head_entity_id": "T150",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R61",
              "head_entity_id": "T151",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R62",
              "head_entity_id": "T152",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R63",
              "head_entity_id": "T155",
              "tail_entity_id": "T153"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R64",
              "head_entity_id": "T154",
              "tail_entity_id": "T153"
            }
          ],
          "sentence_en": "T2DM patients usually have multiple dyslipidemias, mainly manifested as elevated TG, elevated LDL-C, and decreased HDL-C, all of which are associated with an increased risk of ASCVD in T2DM patients. T2DM patients with ASCVD belong to an extremely high-risk group. The primary intervention target of lipid-lowering therapy, IDL-C, is <1.8mmol/L, and the secondary intervention target, non-HDL-C, is <2.6mmol/L. In order to achieve the above goals, statins should be the first choice. After statin treatment, if non-HDL-C still cannot reach the target value, fibrates and high-purity fish oil preparations can be added to statins. For patients with severe hypertriglyceridemia (fasting TG ≥ 5.7mmol/L), fibrates, high-purity fish oil preparations, or niacin drugs should be considered first to prevent the occurrence of acute pancreatitis."
        }
      ],
      "paragraph_en": "T2DM patients usually have multiple dyslipidemias, mainly manifested as elevated TG, elevated LDL-C, and decreased HDL-C, all of which are associated with an increased risk of ASCVD in T2DM patients. T2DM patients with ASCVD belong to an extremely high-risk group. The primary intervention target of lipid-lowering therapy, IDL-C, is <1.8mmol/L, and the secondary intervention target, non-HDL-C, is <2.6mmol/L. In order to achieve the above goals, statins should be the first choice. After statin treatment, if non-HDL-C still cannot reach the target value, fibrates and high-purity fish oil preparations can be added to statins. For patients with severe hypertriglyceridemia (fasting TG ≥ 5.7mmol/L), fibrates, high-purity fish oil preparations, or niacin drugs should be considered first to prevent the occurrence of acute pancreatitis."
    },
    {
      "paragraph_id": "13",
      "paragraph": "(四)抗血小板治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(四)抗血小板治疗",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "(IV) Antiplatelet therapy"
        }
      ],
      "paragraph_en": "(IV) Antiplatelet therapy"
    },
    {
      "paragraph_id": "14",
      "paragraph": "T2DM患者的高凝血状态是发生心血管事件的重要原因之一。在ASCVD或伴有心血管高危因素的患者中，阿司匹林可有效预防卒中、心肌梗死等心脑血管事件。对于T2DM合并ASCVD患者应常规使用阿司匹林作为二级预防措施，最佳剂量为75~150mg/d；对于阿司匹林过敏或不耐受的患者，可考虑使用氯吡格雷(75mg/d)作为替代治疗。对于急性冠状动脉综合征(ACS)患者，可使用阿司匹林和氯吡格雷双联抗血小板治疗1年。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM患者的高凝血状态是发生心血管事件的重要原因之一。在ASCVD或伴有心血管高危因素的患者中，阿司匹林可有效预防卒中、心肌梗死等心脑血管事件。对于T2DM合并ASCVD患者应常规使用阿司匹林作为二级预防措施，最佳剂量为75~150mg/d；对于阿司匹林过敏或不耐受的患者，可考虑使用氯吡格雷(75mg/d)作为替代治疗。对于急性冠状动脉综合征(ACS)患者，可使用阿司匹林和氯吡格雷双联抗血小板治疗1年。",
          "start_idx": 0,
          "end_idx": 204,
          "entities": [
            {
              "entity_id": "T156",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T157",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "T2"
            },
            {
              "entity_id": "T158",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T159",
              "entity": "高凝血状态",
              "entity_type": "Reason",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Hypercoagulable state"
            },
            {
              "entity_id": "T160",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T161",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T162",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "aspirin"
            },
            {
              "entity_id": "T163",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 60,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T164",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 65,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T165",
              "entity": "心脑血管事件",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 72,
              "entity_en": "Cardiovascular and cerebrovascular events"
            },
            {
              "entity_id": "T166",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T167",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 66,
              "end_idx": 70,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T168",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 79,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T169",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "T2"
            },
            {
              "entity_id": "T170",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 86,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T171",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 97,
              "entity_en": "aspirin"
            },
            {
              "entity_id": "T172",
              "entity": "75~150mg/d",
              "entity_type": "Amount",
              "start_idx": 111,
              "end_idx": 121,
              "entity_en": "75–150 mg/day"
            },
            {
              "entity_id": "T173",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128,
              "entity_en": "aspirin"
            },
            {
              "entity_id": "T174",
              "entity": "过敏",
              "entity_type": "ADE",
              "start_idx": 128,
              "end_idx": 130,
              "entity_en": "allergy"
            },
            {
              "entity_id": "T175",
              "entity": "不耐受",
              "entity_type": "ADE",
              "start_idx": 131,
              "end_idx": 134,
              "entity_en": "Intolerance"
            },
            {
              "entity_id": "T176",
              "entity": "氯吡格雷",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 147,
              "entity_en": "Clopidogrel"
            },
            {
              "entity_id": "T177",
              "entity": "75mg/d",
              "entity_type": "Amount",
              "start_idx": 148,
              "end_idx": 154,
              "entity_en": "75 mg/day"
            },
            {
              "entity_id": "T178",
              "entity": "急性冠状动脉综合征(ACS)",
              "entity_type": "Disease",
              "start_idx": 164,
              "end_idx": 178,
              "entity_en": "Acute Coronary Syndrome (ACS)"
            },
            {
              "entity_id": "T179",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 164,
              "end_idx": 166,
              "entity_en": "acute"
            },
            {
              "entity_id": "T180",
              "entity": "冠状动脉",
              "entity_type": "Anatomy",
              "start_idx": 166,
              "end_idx": 170,
              "entity_en": "Coronary arteries"
            },
            {
              "entity_id": "T181",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 184,
              "end_idx": 188,
              "entity_en": "aspirin"
            },
            {
              "entity_id": "T182",
              "entity": "氯吡格雷",
              "entity_type": "Drug",
              "start_idx": 189,
              "end_idx": 193,
              "entity_en": "Clopidogrel"
            },
            {
              "entity_id": "T183",
              "entity": "1年",
              "entity_type": "Duration",
              "start_idx": 201,
              "end_idx": 203,
              "entity_en": "1 year"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R65",
              "head_entity_id": "T157",
              "tail_entity_id": "T156"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R66",
              "head_entity_id": "T159",
              "tail_entity_id": "T158"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R67",
              "head_entity_id": "T160",
              "tail_entity_id": "T158"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R68",
              "head_entity_id": "T162",
              "tail_entity_id": "T163"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R69",
              "head_entity_id": "T162",
              "tail_entity_id": "T164"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R70",
              "head_entity_id": "T162",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R71",
              "head_entity_id": "T166",
              "tail_entity_id": "T164"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R72",
              "head_entity_id": "T167",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R73",
              "head_entity_id": "T169",
              "tail_entity_id": "T168"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R74",
              "head_entity_id": "T171",
              "tail_entity_id": "T168"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R75",
              "head_entity_id": "T171",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R76",
              "head_entity_id": "T172",
              "tail_entity_id": "T171"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R77",
              "head_entity_id": "T174",
              "tail_entity_id": "T173"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R78",
              "head_entity_id": "T175",
              "tail_entity_id": "T173"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R79",
              "head_entity_id": "T177",
              "tail_entity_id": "T176"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T180",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T179",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R82",
              "head_entity_id": "T181",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R83",
              "head_entity_id": "T182",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R84",
              "head_entity_id": "T183",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R85",
              "head_entity_id": "T183",
              "tail_entity_id": "T182"
            }
          ],
          "sentence_en": "The hypercoagulable state of patients with T2DM is one of the important causes of cardiovascular events. In patients with ASCVD or high cardiovascular risk factors, aspirin can effectively prevent cardiovascular and cerebrovascular events such as stroke and myocardial infarction. Aspirin should be routinely used as a secondary prevention measure for patients with T2DM and ASCVD, with the optimal dose of 75-150 mg/d. For patients who are allergic to or intolerant of aspirin, clopidogrel (75 mg/d) can be considered as an alternative treatment. For patients with acute coronary syndrome (ACS), dual antiplatelet therapy with aspirin and clopidogrel can be used for 1 year."
        }
      ],
      "paragraph_en": "The hypercoagulable state of patients with T2DM is one of the important causes of cardiovascular events. In patients with ASCVD or high cardiovascular risk factors, aspirin can effectively prevent cardiovascular and cerebrovascular events such as stroke and myocardial infarction. Aspirin should be routinely used as a secondary prevention measure for patients with T2DM and ASCVD, with the optimal dose of 75-150 mg/d. For patients who are allergic to or intolerant of aspirin, clopidogrel (75 mg/d) can be considered as an alternative treatment. For patients with acute coronary syndrome (ACS), dual antiplatelet therapy with aspirin and clopidogrel can be used for 1 year."
    },
    {
      "paragraph_id": "15",
      "paragraph": "(五)体重管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(五)体重管理",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T184",
              "entity": "体重管理",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Weight Management"
            }
          ],
          "relations": [],
          "sentence_en": "5. Weight management"
        }
      ],
      "paragraph_en": "5. Weight management"
    },
    {
      "paragraph_id": "16",
      "paragraph": "超重或肥胖、腹型肥胖可增加胰岛素抵抗(IR)，使ASCVD发生风险显著增加。体重控制目标包括体重指数(BMI)<24kg/m2和腰围(WC)达标(男<90cm，女<85cm)。不同降糖药对体重和内脏脂肪的影响存在差异，胰岛素、磺脲类药物(SUs)及噻唑烷二酮类(TZDs)可导致体重增加；二甲双胍可减轻体重，对内脏脂肪的影响尚不明确；胰升糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂既可减轻体重，又可减少内脏脂肪。因此，对于合并超重或肥胖(尤其是腹型肥胖)的T2DM患者，应优先考虑使用兼具减轻体重和减少内脏脂防的降糖药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "超重或肥胖、腹型肥胖可增加胰岛素抵抗(IR)，使ASCVD发生风险显著增加。体重控制目标包括体重指数(BMI)<24kg/m2和腰围(WC)达标(男<90cm，女<85cm)。不同降糖药对体重和内脏脂肪的影响存在差异，胰岛素、磺脲类药物(SUs)及噻唑烷二酮类(TZDs)可导致体重增加；二甲双胍可减轻体重，对内脏脂肪的影响尚不明确；胰升糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂既可减轻体重，又可减少内脏脂肪。因此，对于合并超重或肥胖(尤其是腹型肥胖)的T2DM患者，应优先考虑使用兼具减轻体重和减少内脏脂防的降糖药物。",
          "start_idx": 0,
          "end_idx": 281,
          "entities": [
            {
              "entity_id": "T185",
              "entity": "腹型肥胖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Abdominal obesity"
            },
            {
              "entity_id": "T186",
              "entity": "超重",
              "entity_type": "Reason",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T187",
              "entity": "肥胖",
              "entity_type": "Reason",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T188",
              "entity": "胰岛素抵抗(IR)",
              "entity_type": "Pathogenesis",
              "start_idx": 13,
              "end_idx": 22,
              "entity_en": "Insulin resistance (IR)"
            },
            {
              "entity_id": "T189",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T190",
              "entity": "腰围(WC)",
              "entity_type": "Test",
              "start_idx": 64,
              "end_idx": 70,
              "entity_en": "Waist circumference (WC)"
            },
            {
              "entity_id": "T191",
              "entity": "达标(男<90cm，女<85cm)",
              "entity_type": "Test_Value",
              "start_idx": 70,
              "end_idx": 87,
              "entity_en": "Meet the standard (male <90cm, female <85cm)"
            },
            {
              "entity_id": "T192",
              "entity": "体重控制",
              "entity_type": "Treatment",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Weight Control"
            },
            {
              "entity_id": "T193",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 112,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T194",
              "entity": "磺脲类药物(SUs)",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 123,
              "entity_en": "Sulfonylureas (SUs)"
            },
            {
              "entity_id": "T195",
              "entity": "噻唑烷二酮类(TZDs)",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 136,
              "entity_en": "Thiazolidinediones (TZDs)"
            },
            {
              "entity_id": "T196",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 139,
              "end_idx": 143,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T197",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 148,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T198",
              "entity": "胰升糖素样肽1(GLP-1)受体激动剂",
              "entity_type": "Drug",
              "start_idx": 167,
              "end_idx": 186,
              "entity_en": "Glucagon-like peptide-1 (GLP-1) receptor agonists"
            },
            {
              "entity_id": "T199",
              "entity": "钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 187,
              "end_idx": 210,
              "entity_en": "Sodium-glucose cotransporter 2 (SGLT-2) inhibitors"
            },
            {
              "entity_id": "T200",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 233,
              "end_idx": 235,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T201",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 236,
              "end_idx": 238,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T202",
              "entity": "腹型肥胖",
              "entity_type": "Disease",
              "start_idx": 242,
              "end_idx": 246,
              "entity_en": "Abdominal obesity"
            },
            {
              "entity_id": "T203",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 248,
              "end_idx": 252,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T204",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 248,
              "end_idx": 250,
              "entity_en": "T2"
            },
            {
              "entity_id": "T205",
              "entity": "腹型",
              "entity_type": "Class",
              "start_idx": 242,
              "end_idx": 244,
              "entity_en": "Abdominal"
            },
            {
              "entity_id": "T206",
              "entity": "腹型",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "Abdominal"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R86",
              "head_entity_id": "T206",
              "tail_entity_id": "T185"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R87",
              "head_entity_id": "T186",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R88",
              "head_entity_id": "T187",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R89",
              "head_entity_id": "T188",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R90",
              "head_entity_id": "T196",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R91",
              "head_entity_id": "T196",
              "tail_entity_id": "T194"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R92",
              "head_entity_id": "T196",
              "tail_entity_id": "T195"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R93",
              "head_entity_id": "T205",
              "tail_entity_id": "T202"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R94",
              "head_entity_id": "T204",
              "tail_entity_id": "T203"
            }
          ],
          "sentence_en": "Overweight or obesity, abdominal obesity can increase insulin resistance (IR), significantly increasing the risk of ASCVD. Weight control goals include body mass index (BMI) <24kg/m2 and waist circumference (WC) (male <90cm, female <85cm). Different glucose-lowering drugs have different effects on body weight and visceral fat. Insulin, sulfonylureas (SUs) and thiazolidinediones (TZDs) can cause weight gain; metformin can reduce body weight, but its effect on visceral fat is still unclear; glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors can reduce both body weight and visceral fat. Therefore, for patients with T2DM who are overweight or obese (especially abdominal obesity), glucose-lowering drugs that can reduce both body weight and visceral fat should be given priority."
        }
      ],
      "paragraph_en": "Overweight or obesity, abdominal obesity can increase insulin resistance (IR), significantly increasing the risk of ASCVD. Weight control goals include body mass index (BMI) <24kg/m2 and waist circumference (WC) (male <90cm, female <85cm). Different glucose-lowering drugs have different effects on body weight and visceral fat. Insulin, sulfonylureas (SUs) and thiazolidinediones (TZDs) can cause weight gain; metformin can reduce body weight, but its effect on visceral fat is still unclear; glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors can reduce both body weight and visceral fat. Therefore, for patients with T2DM who are overweight or obese (especially abdominal obesity), glucose-lowering drugs that can reduce both body weight and visceral fat should be given priority."
    },
    {
      "paragraph_id": "17",
      "paragraph": "(六)血糖管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(六)血糖管理",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T207",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "6. Blood sugar management"
        }
      ],
      "paragraph_en": "6. Blood sugar management"
    },
    {
      "paragraph_id": "18",
      "paragraph": "糖尿病是ASCVD的独立危险因素，不同类型的高血糖状态，包括空腹血糖(FPG)、餐后血糖(PPG)以及HbA1c的升高，均是ASCVD的危险因素。因此，血糖管理是T2DM合并ASCVD患者综合管理策略中的重要组成部分，以下将对此进行详细阐述。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病是ASCVD的独立危险因素，不同类型的高血糖状态，包括空腹血糖(FPG)、餐后血糖(PPG)以及HbA1c的升高，均是ASCVD的危险因素。因此，血糖管理是T2DM合并ASCVD患者综合管理策略中的重要组成部分，以下将对此进行详细阐述。",
          "start_idx": 0,
          "end_idx": 121,
          "entities": [
            {
              "entity_id": "T208",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T209",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T210",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T211",
              "entity": "空腹血糖(FPG)",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 39,
              "entity_en": "Fasting blood glucose (FPG)"
            },
            {
              "entity_id": "T212",
              "entity": "餐后血糖(PPG)",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 49,
              "entity_en": "Postprandial blood glucose (PPG)"
            },
            {
              "entity_id": "T213",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 56,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T214",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T215",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T216",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 76,
              "end_idx": 78,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T217",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 85,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T218",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 81,
              "end_idx": 83,
              "entity_en": "T2"
            },
            {
              "entity_id": "T219",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 87,
              "end_idx": 92,
              "entity_en": "ASCVD"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R95",
              "head_entity_id": "T211",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R96",
              "head_entity_id": "T212",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R97",
              "head_entity_id": "T213",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R98",
              "head_entity_id": "T216",
              "tail_entity_id": "T217"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R99",
              "head_entity_id": "T216",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R100",
              "head_entity_id": "T218",
              "tail_entity_id": "T217"
            }
          ],
          "sentence_en": "Diabetes is an independent risk factor for ASCVD. Different types of hyperglycemia, including fasting blood glucose (FPG), postprandial blood glucose (PPG), and elevated HbA1c, are risk factors for ASCVD. Therefore, blood glucose management is an important part of the comprehensive management strategy for patients with T2DM and ASCVD, which will be elaborated in detail below."
        }
      ],
      "paragraph_en": "Diabetes is an independent risk factor for ASCVD. Different types of hyperglycemia, including fasting blood glucose (FPG), postprandial blood glucose (PPG), and elevated HbA1c, are risk factors for ASCVD. Therefore, blood glucose management is an important part of the comprehensive management strategy for patients with T2DM and ASCVD, which will be elaborated in detail below."
    },
    {
      "paragraph_id": "19",
      "paragraph": "三、T2DM合并ASCVD患者的血糖管理策略和控制目标",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、T2DM合并ASCVD患者的血糖管理策略和控制目标",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T220",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T221",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "T2"
            },
            {
              "entity_id": "T222",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T223",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R101",
              "head_entity_id": "T221",
              "tail_entity_id": "T220"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R102",
              "head_entity_id": "T223",
              "tail_entity_id": "T220"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R103",
              "head_entity_id": "T223",
              "tail_entity_id": "T222"
            }
          ],
          "sentence_en": "3. Glycemic management strategies and control targets for patients with T2DM and ASCVD"
        }
      ],
      "paragraph_en": "3. Glycemic management strategies and control targets for patients with T2DM and ASCVD"
    },
    {
      "paragraph_id": "20",
      "paragraph": "对于T2DM合并ASCVD患者，血糖管理的总原则是必须兼顾降糖有效性和心血管安全性，并且优先考虑选择具有心血管获益证据的降糖药物。英国糖尿病前瞻性研究(UKPDS)及其后续的10年随访研究显示，在新诊断的T2DM患者中，严格血糖控制(HbA1c<7.0%)对降低心血管事件的远期风险非常重要。然而，退伍军人糖尿病研究(VADT)、控制糖尿病患者心血管风险行动研究(ACCORD)、糖尿病与血管疾病行动研究(AD-VANCE)等随机对照临床试验(RCTs)均显示，在年龄较大、病程较长或合并ASCVD的T2DM患者中，强化降糖治疗并不能显著降低心血管事件风险。此外，对于合并ASCVD的T2DM患者，一旦发生低血糖还可能诱发心律失常、心肌梗死、卒中、猝死等。因此，对于这类患者而言，降糖治疗的安全性可能比降糖疗效更为重要，应尽量在避免低血糖的前提下使血糖控制达标。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于T2DM合并ASCVD患者，血糖管理的总原则是必须兼顾降糖有效性和心血管安全性，并且优先考虑选择具有心血管获益证据的降糖药物。英国糖尿病前瞻性研究(UKPDS)及其后续的10年随访研究显示，在新诊断的T2DM患者中，严格血糖控制(HbA1c<7.0%)对降低心血管事件的远期风险非常重要。然而，退伍军人糖尿病研究(VADT)、控制糖尿病患者心血管风险行动研究(ACCORD)、糖尿病与血管疾病行动研究(AD-VANCE)等随机对照临床试验(RCTs)均显示，在年龄较大、病程较长或合并ASCVD的T2DM患者中，强化降糖治疗并不能显著降低心血管事件风险。此外，对于合并ASCVD的T2DM患者，一旦发生低血糖还可能诱发心律失常、心肌梗死、卒中、猝死等。",
          "start_idx": 0,
          "end_idx": 328,
          "entities": [
            {
              "entity_id": "T224",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T225",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "T2"
            },
            {
              "entity_id": "T226",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T227",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T228",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 70,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T229",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 106,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T230",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 102,
              "end_idx": 104,
              "entity_en": "T2"
            },
            {
              "entity_id": "T231",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 112,
              "end_idx": 114,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T232",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 117,
              "end_idx": 122,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T233",
              "entity": "<7.0%",
              "entity_type": "Test_Value",
              "start_idx": 122,
              "end_idx": 127,
              "entity_en": "<7.0%"
            },
            {
              "entity_id": "T234",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 136,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T235",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 131,
              "end_idx": 134,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T236",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 153,
              "end_idx": 156,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T237",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 167,
              "end_idx": 170,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T238",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 190,
              "end_idx": 193,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T239",
              "entity": "血管疾病",
              "entity_type": "Disease",
              "start_idx": 194,
              "end_idx": 198,
              "entity_en": "Vascular disease"
            },
            {
              "entity_id": "T240",
              "entity": "血管",
              "entity_type": "Anatomy",
              "start_idx": 194,
              "end_idx": 196,
              "entity_en": "Blood vessel"
            },
            {
              "entity_id": "T241",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 244,
              "end_idx": 249,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T242",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 250,
              "end_idx": 254,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T243",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 250,
              "end_idx": 252,
              "entity_en": "T2"
            },
            {
              "entity_id": "T244",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 271,
              "end_idx": 276,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T245",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 271,
              "end_idx": 274,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T246",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 286,
              "end_idx": 291,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T247",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 292,
              "end_idx": 296,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T248",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 292,
              "end_idx": 294,
              "entity_en": "T2"
            },
            {
              "entity_id": "T249",
              "entity": "低血糖",
              "entity_type": "Reason",
              "start_idx": 303,
              "end_idx": 306,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T250",
              "entity": "心律失常",
              "entity_type": "Disease",
              "start_idx": 311,
              "end_idx": 315,
              "entity_en": "Arrhythmias"
            },
            {
              "entity_id": "T251",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 316,
              "end_idx": 320,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T252",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 316,
              "end_idx": 318,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T253",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 321,
              "end_idx": 323,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T254",
              "entity": "猝死",
              "entity_type": "Disease",
              "start_idx": 324,
              "end_idx": 326,
              "entity_en": "sudden death"
            },
            {
              "entity_id": "T257",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 172,
              "end_idx": 175,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T258",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 311,
              "end_idx": 312,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R104",
              "head_entity_id": "T225",
              "tail_entity_id": "T224"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R105",
              "head_entity_id": "T227",
              "tail_entity_id": "T224"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R106",
              "head_entity_id": "T227",
              "tail_entity_id": "T226"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R107",
              "head_entity_id": "T230",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R108",
              "head_entity_id": "T231",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R109",
              "head_entity_id": "T232",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R110",
              "head_entity_id": "T235",
              "tail_entity_id": "T234"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R111",
              "head_entity_id": "T257",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R112",
              "head_entity_id": "T240",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R113",
              "head_entity_id": "T243",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R114",
              "head_entity_id": "T245",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R115",
              "head_entity_id": "T248",
              "tail_entity_id": "T247"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R116",
              "head_entity_id": "T249",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R117",
              "head_entity_id": "T249",
              "tail_entity_id": "T251"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R118",
              "head_entity_id": "T249",
              "tail_entity_id": "T253"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R119",
              "head_entity_id": "T249",
              "tail_entity_id": "T254"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R120",
              "head_entity_id": "T258",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R121",
              "head_entity_id": "T252",
              "tail_entity_id": "T251"
            }
          ],
          "sentence_en": "For patients with T2DM and ASCVD, the general principle of blood sugar management is to take into account both blood sugar-lowering effectiveness and cardiovascular safety, and give priority to choosing blood sugar-lowering drugs with evidence of cardiovascular benefits. The United Kingdom Prospective Diabetes Study (UKPDS) and its subsequent 10-year follow-up study showed that strict blood sugar control (HbA1c <7.0%) is very important for reducing the long-term risk of cardiovascular events in newly diagnosed T2DM patients. However, randomized controlled clinical trials (RCTs) such as the Veterans Affairs Diabetes Study (VADT), the Action to Control Cardiovascular Risk in Diabetes (ACCORD), and the Action for Diabetes and Vascular Disease (AD-VANCE) have shown that intensive blood sugar-lowering therapy does not significantly reduce the risk of cardiovascular events in older T2DM patients with a longer course of disease or ASCVD. In addition, for T2DM patients with ASCVD, hypoglycemia may also induce arrhythmia, myocardial infarction, stroke, sudden death, etc."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，对于这类患者而言，降糖治疗的安全性可能比降糖疗效更为重要，应尽量在避免低血糖的前提下使血糖控制达标。",
          "start_idx": 328,
          "end_idx": 381,
          "entities": [
            {
              "entity_id": "T255",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 48,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T256",
              "entity": "控制达标",
              "entity_type": "Test_Value",
              "start_idx": 48,
              "end_idx": 52,
              "entity_en": "Control compliance"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, for such patients, the safety of hypoglycemic treatment may be more important than its efficacy, and they should try their best to control their blood sugar to the target while avoiding hypoglycemia."
        }
      ],
      "paragraph_en": "For patients with T2DM and ASCVD, the general principle of blood glucose management is to take into account both the effectiveness of blood glucose reduction and cardiovascular safety, and give priority to the selection of blood glucose-lowering drugs with evidence of cardiovascular benefits. The United Kingdom Prospective Diabetes Study (UKPDS) and its subsequent 10-year follow-up study showed that strict blood glucose control (HbA1c < 7.0%) is very important for reducing the long-term risk of cardiovascular events in newly diagnosed T2DM patients. However, randomized controlled clinical trials (RCTs) such as the Veterans Affairs Diabetes Study (VADT), the Action for Controlling Cardiovascular Risk in Diabetes (ACCORD), and the Action for Diabetes and Vascular Disease (AD-VANCE) have shown that intensive blood glucose-lowering therapy does not significantly reduce the risk of cardiovascular events in older T2DM patients with a longer course of disease or ASCVD. In addition, for T2DM patients with ASCVD, hypoglycemia may induce arrhythmia, myocardial infarction, stroke, sudden death, etc. Therefore, for such patients, the safety of blood glucose-lowering therapy may be more important than the efficacy of blood glucose-lowering therapy, and blood glucose control should be achieved as much as possible while avoiding hypoglycemia."
    },
    {
      "paragraph_id": "21",
      "paragraph": "本共识建议，T2DM合并ASCVD患者的血糖控制目标应该遵循个体化原则-综合考虑患者的年龄、糖尿病病程、ASCVD病史、其他并发症或合并症、低血糖风险等因素，充分平衡严格血糖控制的利弊得失。基于现有的循证医学证据，本共识推荐T2DM合并ASCVD患者的血控制目标如下：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "本共识建议，T2DM合并ASCVD患者的血糖控制目标应该遵循个体化原则-综合考虑患者的年龄、糖尿病病程、ASCVD病史、其他并发症或合并症、低血糖风险等因素，充分平衡严格血糖控制的利弊得失。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T259",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T260",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "T2"
            },
            {
              "entity_id": "T261",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T262",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T263",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T264",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 57,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T265",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 70,
              "end_idx": 73,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T266",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 85,
              "end_idx": 87,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R122",
              "head_entity_id": "T260",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R123",
              "head_entity_id": "T262",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R124",
              "head_entity_id": "T262",
              "tail_entity_id": "T261"
            }
          ],
          "sentence_en": "This consensus suggests that the blood sugar control target for patients with T2DM and ASCVD should follow the principle of individualization - comprehensively considering factors such as the patient's age, duration of diabetes, history of ASCVD, other complications or comorbidities, and risk of hypoglycemia, and fully balancing the pros and cons of strict blood sugar control."
        },
        {
          "sentence_id": "1",
          "sentence": "基于现有的循证医学证据，本共识推荐T2DM合并ASCVD患者的血控制目标如下：",
          "start_idx": 95,
          "end_idx": 134,
          "entities": [
            {
              "entity_id": "T267",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T268",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T269",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R125",
              "head_entity_id": "T269",
              "tail_entity_id": "T267"
            }
          ],
          "sentence_en": "Based on the existing evidence-based medicine, this consensus recommends the following blood control targets for patients with T2DM and ASCVD:"
        }
      ],
      "paragraph_en": "This consensus recommends that the blood sugar control target for patients with T2DM and ASCVD should follow the principle of individualization - comprehensively considering factors such as the patient's age, duration of diabetes, history of ASCVD, other complications or comorbidities, and risk of hypoglycemia, and fully balancing the pros and cons of strict blood sugar control. Based on existing evidence-based medicine, this consensus recommends the following blood sugar control targets for patients with T2DM and ASCVD:"
    },
    {
      "paragraph_id": "22",
      "paragraph": "1.对于大多数患者，HbA1c目标应控制在<7.0%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.对于大多数患者，HbA1c目标应控制在<7.0%。",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T270",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T271",
              "entity": "<7.0%",
              "entity_type": "Test_Value",
              "start_idx": 21,
              "end_idx": 26,
              "entity_en": "<7.0%"
            }
          ],
          "relations": [],
          "sentence_en": "1. For most patients, the HbA1c target should be controlled at <7.0%."
        }
      ],
      "paragraph_en": "1. For most patients, the HbA1c target should be controlled at <7.0%."
    },
    {
      "paragraph_id": "23",
      "paragraph": "2.对于年龄较大、糖尿病病程较长、存在低血糖高危因素的患者，HbA1c目标应控制在<7.5%或<8.0%.",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.对于年龄较大、糖尿病病程较长、存在低血糖高危因素的患者，HbA1c目标应控制在<7.5%或<8.0%.",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T272",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T273",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T274",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T275",
              "entity": "<7.5%或<8.0%",
              "entity_type": "Test_Value",
              "start_idx": 41,
              "end_idx": 52,
              "entity_en": "<7.5% or <8.0%"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R126",
              "head_entity_id": "T274",
              "tail_entity_id": "T272"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R127",
              "head_entity_id": "T274",
              "tail_entity_id": "T273"
            }
          ],
          "sentence_en": "2. For older patients, those with a longer duration of diabetes, and those at high risk of hypoglycemia, the HbA1c target should be controlled at <7.5% or <8.0%."
        }
      ],
      "paragraph_en": "2. For older patients, those with a longer duration of diabetes, and those at high risk of hypoglycemia, the HbA1c target should be controlled at <7.5% or <8.0%."
    },
    {
      "paragraph_id": "24",
      "paragraph": "3.对于慢性疾病终末期患者，如纽约心脏学会(NYHA)心功能Ⅲ-IV级、终末期肾病、恶性肿瘤伴有转移、中重度认知功能障碍等，HbA1c控制目标可适当放宽至<8.5%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.对于慢性疾病终末期患者，如纽约心脏学会(NYHA)心功能Ⅲ-IV级、终末期肾病、恶性肿瘤伴有转移、中重度认知功能障碍等，HbA1c控制目标可适当放宽至<8.5%。",
          "start_idx": 0,
          "end_idx": 83,
          "entities": [
            {
              "entity_id": "T276",
              "entity": "心功能Ⅲ-IV级",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 35,
              "entity_en": "Heart function level Ⅲ-IV"
            },
            {
              "entity_id": "T277",
              "entity": "Ⅲ-IV级",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": "Grade III-IV"
            },
            {
              "entity_id": "T278",
              "entity": "终末期肾病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 41,
              "entity_en": "End-stage renal disease"
            },
            {
              "entity_id": "T279",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "Terminal stage"
            },
            {
              "entity_id": "T280",
              "entity": "恶性肿瘤伴有转移",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 50,
              "entity_en": "Malignant tumor with metastasis"
            },
            {
              "entity_id": "T281",
              "entity": "中重度认知功能障碍",
              "entity_type": "Disease",
              "start_idx": 51,
              "end_idx": 60,
              "entity_en": "Moderate to severe cognitive impairment"
            },
            {
              "entity_id": "T282",
              "entity": "中重度",
              "entity_type": "Class",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "Moderate to severe"
            },
            {
              "entity_id": "T283",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T284",
              "entity": "<8.5%",
              "entity_type": "Test_Value",
              "start_idx": 77,
              "end_idx": 82,
              "entity_en": "<8.5%"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R128",
              "head_entity_id": "T283",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R129",
              "head_entity_id": "T277",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R130",
              "head_entity_id": "T283",
              "tail_entity_id": "T278"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R131",
              "head_entity_id": "T279",
              "tail_entity_id": "T278"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R132",
              "head_entity_id": "T283",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R133",
              "head_entity_id": "T283",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R134",
              "head_entity_id": "T282",
              "tail_entity_id": "T281"
            }
          ],
          "sentence_en": "3. For patients with end-stage chronic diseases, such as New York Heart Association (NYHA) heart function class III-IV, end-stage renal disease, malignant tumors with metastasis, moderate to severe cognitive impairment, etc., the HbA1c control target can be appropriately relaxed to <8.5%."
        }
      ],
      "paragraph_en": "3. For patients with end-stage chronic diseases, such as New York Heart Association (NYHA) heart function class III-IV, end-stage renal disease, malignant tumors with metastasis, moderate to severe cognitive impairment, etc., the HbA1c control target can be appropriately relaxed to <8.5%."
    },
    {
      "paragraph_id": "25",
      "paragraph": "四、T2DM合并ASCVD患者的降糖药物治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、T2DM合并ASCVD患者的降糖药物治疗",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T285",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T286",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "T2"
            },
            {
              "entity_id": "T287",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "ASCVD"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R135",
              "head_entity_id": "T286",
              "tail_entity_id": "T285"
            }
          ],
          "sentence_en": "4. Glycemic-lowering drug treatment for patients with T2DM and ASCVD"
        }
      ],
      "paragraph_en": "4. Glycemic-lowering drug treatment for patients with T2DM and ASCVD"
    },
    {
      "paragraph_id": "26",
      "paragraph": "(一)降糖药物的心血管安全性评价",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)降糖药物的心血管安全性评价",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [],
          "relations": [],
          "sentence_en": "1. Evaluation of cardiovascular safety of hypoglycemic drugs"
        }
      ],
      "paragraph_en": "1. Evaluation of cardiovascular safety of hypoglycemic drugs"
    },
    {
      "paragraph_id": "27",
      "paragraph": "2008年，美国食品药品监督管理局(FDA)发布了强制性指导意见，要求所有新批准上市的降糖药都必须进行心血管安全性评估。根据这一要求.目前全球已开展了一系列新型降糖药物的心血管结局研究(CVOT)。传统降糖药物由于不受这条强制性要求的制约，故缺少CVOT证据，其心血管安全性评估通常基于针对降糖治疗策略的大型RCT数据或基于针对降糖疗效的多项RCTs荟萃分析结果。根据目前已有的CVOT证据(表1)，本共识将降糖药物的心血管安全性分为获益、中性及其他3大类。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2008年，美国食品药品监督管理局(FDA)发布了强制性指导意见，要求所有新批准上市的降糖药都必须进行心血管安全性评估。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [],
          "relations": [],
          "sentence_en": "In 2008, the U.S. Food and Drug Administration (FDA) issued mandatory guidance requiring that all newly approved antidiabetic drugs undergo cardiovascular safety assessment."
        },
        {
          "sentence_id": "1",
          "sentence": "根据这一要求.目前全球已开展了一系列新型降糖药物的心血管结局研究(CVOT)。",
          "start_idx": 60,
          "end_idx": 99,
          "entities": [],
          "relations": [],
          "sentence_en": "Based on this requirement, a series of cardiovascular outcome studies (CVOTs) of new glucose-lowering drugs have been carried out around the world."
        },
        {
          "sentence_id": "2",
          "sentence": "传统降糖药物由于不受这条强制性要求的制约，故缺少CVOT证据，其心血管安全性评估通常基于针对降糖治疗策略的大型RCT数据或基于针对降糖疗效的多项RCTs荟萃分析结果。",
          "start_idx": 99,
          "end_idx": 182,
          "entities": [],
          "relations": [],
          "sentence_en": "Traditional glucose-lowering drugs are not subject to this mandatory requirement and therefore lack CVOT evidence. Their cardiovascular safety assessment is usually based on large-scale RCT data on glucose-lowering treatment strategies or on meta-analysis results of multiple RCTs on glucose-lowering efficacy."
        },
        {
          "sentence_id": "3",
          "sentence": "根据目前已有的CVOT证据(表1)，本共识将降糖药物的心血管安全性分为获益、中性及其他3大类。",
          "start_idx": 182,
          "end_idx": 229,
          "entities": [],
          "relations": [],
          "sentence_en": "Based on the currently available CVOT evidence (Table 1), this consensus divides the cardiovascular safety of hypoglycemic drugs into three categories: beneficial, neutral, and others."
        }
      ],
      "paragraph_en": "In 2008, the U.S. Food and Drug Administration (FDA) issued mandatory guidance requiring that all newly approved glucose-lowering drugs must undergo cardiovascular safety assessment. Based on this requirement, a series of cardiovascular outcome studies (CVOTs) of new glucose-lowering drugs have been conducted worldwide. Traditional glucose-lowering drugs are not subject to this mandatory requirement, so there is a lack of CVOT evidence. Their cardiovascular safety assessment is usually based on large RCT data on glucose-lowering treatment strategies or on the results of multiple RCTs meta-analysis on glucose-lowering efficacy. Based on the existing CVOT evidence (Table 1), this consensus divides the cardiovascular safety of glucose-lowering drugs into three categories: benefit, neutral, and others."
    },
    {
      "paragraph_id": "28",
      "paragraph": "1.具有心血管获益证据的降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.具有心血管获益证据的降糖药物",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [],
          "relations": [],
          "sentence_en": "1. Glucose-lowering drugs with evidence of cardiovascular benefits"
        }
      ],
      "paragraph_en": "1. Glucose-lowering drugs with evidence of cardiovascular benefits"
    },
    {
      "paragraph_id": "29",
      "paragraph": "目前，明确具有心血管获益的降糖药物包括二甲双胍、恩格列净及利拉鲁肽。二甲双胍是T2DM降糖治疗的一线药物，其心血管安全性证据来自UKPDS及其后续的10年随访研究。UKPDS研究纳人1704例合并超重或肥胖的新诊断T2DM患者，随机分为给予传统治疗(饮食控制为主，n=411)、二甲双胍强化降糖治疗(n=342)或其他药物(SUs或胰岛素)强化降糖治疗(n=951)，中位随访时间为10.7年。结果显示，与传统治疗相比，二甲双胍可显著降低心血管事件风险，其中心肌梗死风险下降39%(P=0.010)，心血管事件复合终点(心肌梗死、猝死、心绞痛、卒中或周围血管疾病)风险下降30%(P=0.020)；二甲双胍与其他药物的两种强化降糖治疗方案之间相比，心血管事件风险差异无统计学意义。UKPDS研究结束后继续随访10年仍发现，二甲双胍的心血管获益具有延续效应，与传统治疗相比，其心肌梗死风险下降33%(P=0.005)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前，明确具有心血管获益的降糖药物包括二甲双胍、恩格列净及利拉鲁肽。二甲双胍是T2DM降糖治疗的一线药物，其心血管安全性证据来自UKPDS及其后续的10年随访研究。UKPDS研究纳人1704例合并超重或肥胖的新诊断T2DM患者，随机分为给予传统治疗(饮食控制为主，n=411)、二甲双胍强化降糖治疗(n=342)或其他药物(SUs或胰岛素)强化降糖治疗(n=951)，中位随访时间为10.7年。结果显示，与传统治疗相比，二甲双胍可显著降低心血管事件风险，其中心肌梗死风险下降39%(P=0.010)，心血管事件复合终点(心肌梗死、猝死、心绞痛、卒中或周围血管疾病)风险下降30%(P=0.020)；二甲双胍与其他药物的两种强化降糖治疗方案之间相比，心血管事件风险差异无统计学意义。UKPDS研究结束后继续随访10年仍发现，二甲双胍的心血管获益具有延续效应，与传统治疗相比，其心肌梗死风险下降33%(P=0.005)。",
          "start_idx": 0,
          "end_idx": 408,
          "entities": [
            {
              "entity_id": "T288",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T289",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T290",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T291",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T292",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T293",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "T2"
            },
            {
              "entity_id": "T294",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 100,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T295",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 103,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T296",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 111,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T297",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 107,
              "end_idx": 109,
              "entity_en": "T2"
            },
            {
              "entity_id": "T298",
              "entity": "饮食控制",
              "entity_type": "Treatment",
              "start_idx": 125,
              "end_idx": 129,
              "entity_en": "Diet control"
            },
            {
              "entity_id": "T299",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 139,
              "end_idx": 143,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T300",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 162,
              "end_idx": 165,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T301",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 169,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T302",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 210,
              "end_idx": 214,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T303",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 219,
              "end_idx": 224,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T304",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 219,
              "end_idx": 222,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T305",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 229,
              "end_idx": 233,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T306",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 229,
              "end_idx": 231,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T307",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 250,
              "end_idx": 255,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T308",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 250,
              "end_idx": 253,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T309",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 260,
              "end_idx": 264,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T310",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 260,
              "end_idx": 262,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T311",
              "entity": "猝死",
              "entity_type": "Disease",
              "start_idx": 265,
              "end_idx": 267,
              "entity_en": "sudden death"
            },
            {
              "entity_id": "T312",
              "entity": "心绞痛",
              "entity_type": "Disease",
              "start_idx": 268,
              "end_idx": 271,
              "entity_en": "Angina"
            },
            {
              "entity_id": "T313",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 268,
              "end_idx": 269,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T314",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 272,
              "end_idx": 274,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T315",
              "entity": "周围血管疾病",
              "entity_type": "Disease",
              "start_idx": 275,
              "end_idx": 281,
              "entity_en": "Peripheral vascular disease"
            },
            {
              "entity_id": "T316",
              "entity": "周围血管",
              "entity_type": "Anatomy",
              "start_idx": 275,
              "end_idx": 279,
              "entity_en": "Peripheral blood vessels"
            },
            {
              "entity_id": "T317",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 299,
              "end_idx": 303,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T318",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 324,
              "end_idx": 329,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T319",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 324,
              "end_idx": 327,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T320",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 361,
              "end_idx": 365,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T321",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 387,
              "end_idx": 391,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T322",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 387,
              "end_idx": 389,
              "entity_en": "Myocardium"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R136",
              "head_entity_id": "T291",
              "tail_entity_id": "T292"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R137",
              "head_entity_id": "T293",
              "tail_entity_id": "T292"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R138",
              "head_entity_id": "T297",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R139",
              "head_entity_id": "T298",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R140",
              "head_entity_id": "T299",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R141",
              "head_entity_id": "T300",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R142",
              "head_entity_id": "T301",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R143",
              "head_entity_id": "T304",
              "tail_entity_id": "T303"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R144",
              "head_entity_id": "T306",
              "tail_entity_id": "T305"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R145",
              "head_entity_id": "T308",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R146",
              "head_entity_id": "T310",
              "tail_entity_id": "T309"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R147",
              "head_entity_id": "T313",
              "tail_entity_id": "T312"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R148",
              "head_entity_id": "T316",
              "tail_entity_id": "T315"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R149",
              "head_entity_id": "T319",
              "tail_entity_id": "T318"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R150",
              "head_entity_id": "T322",
              "tail_entity_id": "T321"
            }
          ],
          "sentence_en": "At present, the glucose-lowering drugs with clear cardiovascular benefits include metformin, empagliflozin, and liraglutide. Metformin is the first-line drug for glucose-lowering treatment of T2DM, and its cardiovascular safety evidence comes from the UKPDS and its subsequent 10-year follow-up study. The UKPDS study included 1704 newly diagnosed T2DM patients with overweight or obesity, who were randomly divided into traditional treatment (diet control, n=411), intensive glucose-lowering treatment with metformin (n=342), or intensive glucose-lowering treatment with other drugs (SUs or insulin) (n=951), with a median follow-up time of 10.7 years. The results showed that compared with traditional treatment, metformin could significantly reduce the risk of cardiovascular events, including a 39% decrease in the risk of myocardial infarction (P=0.010) and a 30% decrease in the risk of the composite endpoint of cardiovascular events (myocardial infarction, sudden death, angina, stroke, or peripheral vascular disease) (P=0.020); there was no statistically significant difference in the risk of cardiovascular events between the two intensive glucose-lowering treatment regimens of metformin and other drugs. Ten years after the end of the UKPDS study, the cardiovascular benefits of metformin continued to be found, with a 33% reduction in the risk of myocardial infarction compared with traditional treatment (P=0.005)."
        }
      ],
      "paragraph_en": "At present, the glucose-lowering drugs with clear cardiovascular benefits include metformin, empagliflozin, and liraglutide. Metformin is the first-line drug for glucose-lowering treatment of T2DM, and its cardiovascular safety evidence comes from the UKPDS and its subsequent 10-year follow-up study. The UKPDS study included 1704 newly diagnosed T2DM patients with overweight or obesity, who were randomly divided into traditional treatment (diet control, n=411), intensive glucose-lowering treatment with metformin (n=342), or intensive glucose-lowering treatment with other drugs (SUs or insulin) (n=951), with a median follow-up time of 10.7 years. The results showed that compared with traditional treatment, metformin could significantly reduce the risk of cardiovascular events, including a 39% decrease in the risk of myocardial infarction (P=0.010) and a 30% decrease in the risk of the composite endpoint of cardiovascular events (myocardial infarction, sudden death, angina, stroke, or peripheral vascular disease) (P=0.020); there was no statistically significant difference in the risk of cardiovascular events between the two intensive glucose-lowering treatment regimens of metformin and other drugs. Ten years after the end of the UKPDS study, the cardiovascular benefits of metformin continued to be found, with a 33% reduction in the risk of myocardial infarction compared with traditional treatment (P=0.005)."
    },
    {
      "paragraph_id": "30",
      "paragraph": "SGLT-2抑制剂恩格列净是第一个通过CVOT证实具有明确心血管获益的新型降糖药物，但目前尚未在我国上市。恩格列净心血管事件结局(EM-PA-REG OUTCOME)研究纳入7020例伴有心血管疾病的T2DM患者，中位随访时间为3.1年。结果显示，在常规治疗基础上，与安慰剂相比，恩格列净可显著降低3终点的主要心血管不良事件(3终点MACE，包括心血管死亡、非致死性心肌梗死或非致死性卒中)风险14%(P=0.04)，降低心血管死亡风险38%(P<0.001)，降低心力衰竭住院风险35%(P=0.002)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂恩格列净是第一个通过CVOT证实具有明确心血管获益的新型降糖药物，但目前尚未在我国上市。恩格列净心血管事件结局(EM-PA-REG OUTCOME)研究纳入7020例伴有心血管疾病的T2DM患者，中位随访时间为3.1年。结果显示，在常规治疗基础上，与安慰剂相比，恩格列净可显著降低3终点的主要心血管不良事件(3终点MACE，包括心血管死亡、非致死性心肌梗死或非致死性卒中)风险14%(P=0.04)，降低心血管死亡风险38%(P<0.001)，降低心力衰竭住院风险35%(P=0.002)。",
          "start_idx": 0,
          "end_idx": 254,
          "entities": [
            {
              "entity_id": "T323",
              "entity": "SGLT-2抑制剂恩格列净",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 13,
              "entity_en": "SGLT-2 inhibitor empagliflozin"
            },
            {
              "entity_id": "T324",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T325",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 62,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T326",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T327",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 94,
              "end_idx": 99,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T328",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 94,
              "end_idx": 97,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T329",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 100,
              "end_idx": 104,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T330",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 100,
              "end_idx": 102,
              "entity_en": "T2"
            },
            {
              "entity_id": "T331",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 140,
              "end_idx": 144,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T332",
              "entity": "非致死性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 179,
              "end_idx": 187,
              "entity_en": "Nonfatal myocardial infarction"
            },
            {
              "entity_id": "T333",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 183,
              "end_idx": 185,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T334",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 179,
              "end_idx": 183,
              "entity_en": "Non-lethal"
            },
            {
              "entity_id": "T335",
              "entity": "非致死性卒中",
              "entity_type": "Disease",
              "start_idx": 188,
              "end_idx": 194,
              "entity_en": "Nonfatal stroke"
            },
            {
              "entity_id": "T336",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 188,
              "end_idx": 192,
              "entity_en": "Non-lethal"
            },
            {
              "entity_id": "T337",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 233,
              "end_idx": 237,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T338",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 233,
              "end_idx": 234,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T339",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 178,
              "entity_en": "Cardiovascular death"
            },
            {
              "entity_id": "T340",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 173,
              "end_idx": 176,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R151",
              "head_entity_id": "T326",
              "tail_entity_id": "T325"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R152",
              "head_entity_id": "T328",
              "tail_entity_id": "T327"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R153",
              "head_entity_id": "T330",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R154",
              "head_entity_id": "T333",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R155",
              "head_entity_id": "T334",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R156",
              "head_entity_id": "T336",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R157",
              "head_entity_id": "T338",
              "tail_entity_id": "T337"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R158",
              "head_entity_id": "T340",
              "tail_entity_id": "T339"
            }
          ],
          "sentence_en": "The SGLT-2 inhibitor empagliflozin is the first new glucose-lowering drug that has been confirmed to have clear cardiovascular benefits through CVOT, but it is not yet available in my country. The Empagliflozin Cardiovascular Event Outcome (EM-PA-REG OUTCOME) study included 7020 T2DM patients with cardiovascular disease, with a median follow-up time of 3.1 years. The results showed that on the basis of conventional treatment, compared with placebo, empagliflozin can significantly reduce the risk of major adverse cardiovascular events (3 endpoints MACE, including cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) by 14% (P=0.04), reduce the risk of cardiovascular death by 38% (P<0.001), and reduce the risk of hospitalization for heart failure by 35% (P=0.002)."
        }
      ],
      "paragraph_en": "The SGLT-2 inhibitor empagliflozin is the first new glucose-lowering drug that has been confirmed to have clear cardiovascular benefits through CVOT, but it is not yet available in my country. The Empagliflozin Cardiovascular Event Outcome (EM-PA-REG OUTCOME) study included 7020 T2DM patients with cardiovascular disease, with a median follow-up time of 3.1 years. The results showed that on the basis of conventional treatment, compared with placebo, empagliflozin can significantly reduce the risk of major adverse cardiovascular events (3 endpoints MACE, including cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) by 14% (P=0.04), reduce the risk of cardiovascular death by 38% (P<0.001), and reduce the risk of hospitalization for heart failure by 35% (P=0.002)."
    },
    {
      "paragraph_id": "31",
      "paragraph": "GLP-1受体激动剂利拉鲁肽是目前在中国上市的降糖药物中唯一被CVOT证实具有心血管获益的降糖药物。利拉鲁肽在糖尿病患者中的心血管结局评估(LEADER)研究纳入9340例伴有心血管疾或心血管危险因素的T2DM患者，其中81.3%的患者既往有心血管病史(包括心肌梗死、卒中或短暂性脑缺血发作、曾行血运重建术、冠状动脉或颈动脉或下肢动脉狭窄≥50%)，中位随访时间为3.8年。结果显示，在常规治疗基础上，与安慰剂相比利拉鲁肽可使3终点MACE风险降低13%(P<0.001)-心血管死亡风险降低22%(P=0.007)，扩展的心血管事件复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中、血运重建、不稳定性心绞痛住院或心力衰竭住院)风险降低12%(P=0.005)，且不增加心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GLP-1受体激动剂利拉鲁肽是目前在中国上市的降糖药物中唯一被CVOT证实具有心血管获益的降糖药物。利拉鲁肽在糖尿病患者中的心血管结局评估(LEADER)研究纳入9340例伴有心血管疾或心血管危险因素的T2DM患者，其中81.3%的患者既往有心血管病史(包括心肌梗死、卒中或短暂性脑缺血发作、曾行血运重建术、冠状动脉或颈动脉或下肢动脉狭窄≥50%)，中位随访时间为3.8年。结果显示，在常规治疗基础上，与安慰剂相比利拉鲁肽可使3终点MACE风险降低13%(P<0.001)-心血管死亡风险降低22%(P=0.007)，扩展的心血管事件复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中、血运重建、不稳定性心绞痛住院或心力衰竭住院)风险降低12%(P=0.005)，且不增加心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 346,
          "entities": [
            {
              "entity_id": "T341",
              "entity": "GLP-1受体激动剂利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 14,
              "entity_en": "GLP-1 receptor agonist liraglutide"
            },
            {
              "entity_id": "T342",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 54,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T343",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 58,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T344",
              "entity": "心血管疾",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 92,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T345",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T346",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T347",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 101,
              "end_idx": 103,
              "entity_en": "T2"
            },
            {
              "entity_id": "T348",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 133,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T349",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 129,
              "end_idx": 131,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T350",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 134,
              "end_idx": 136,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T351",
              "entity": "短暂性脑缺血发作",
              "entity_type": "Disease",
              "start_idx": 137,
              "end_idx": 145,
              "entity_en": "Transient ischemic attack"
            },
            {
              "entity_id": "T352",
              "entity": "脑",
              "entity_type": "Anatomy",
              "start_idx": 140,
              "end_idx": 141,
              "entity_en": "brain"
            },
            {
              "entity_id": "T353",
              "entity": "短暂性",
              "entity_type": "Class",
              "start_idx": 137,
              "end_idx": 140,
              "entity_en": "Transience"
            },
            {
              "entity_id": "T354",
              "entity": "血运重建术",
              "entity_type": "Operation",
              "start_idx": 148,
              "end_idx": 153,
              "entity_en": "Revascularization"
            },
            {
              "entity_id": "T355",
              "entity": "冠状动脉或颈动脉或下肢动脉狭窄",
              "entity_type": "Disease",
              "start_idx": 154,
              "end_idx": 169,
              "entity_en": "Stenosis of the coronary arteries, carotid arteries, or lower limb arteries"
            },
            {
              "entity_id": "T356",
              "entity": "冠状动脉",
              "entity_type": "Anatomy",
              "start_idx": 154,
              "end_idx": 158,
              "entity_en": "Coronary arteries"
            },
            {
              "entity_id": "T357",
              "entity": "颈动脉",
              "entity_type": "Anatomy",
              "start_idx": 159,
              "end_idx": 162,
              "entity_en": "Carotid artery"
            },
            {
              "entity_id": "T358",
              "entity": "下肢动脉",
              "entity_type": "Anatomy",
              "start_idx": 163,
              "end_idx": 167,
              "entity_en": "Lower limb arteries"
            },
            {
              "entity_id": "T359",
              "entity": "≥50%",
              "entity_type": "Level",
              "start_idx": 169,
              "end_idx": 173,
              "entity_en": "≥50%"
            },
            {
              "entity_id": "T360",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 207,
              "end_idx": 211,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T361",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 262,
              "end_idx": 267,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T362",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 262,
              "end_idx": 265,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T363",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 237,
              "end_idx": 242,
              "entity_en": "Cardiovascular death"
            },
            {
              "entity_id": "T364",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 237,
              "end_idx": 240,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T365",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 272,
              "end_idx": 277,
              "entity_en": "Cardiovascular death"
            },
            {
              "entity_id": "T366",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 272,
              "end_idx": 275,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T367",
              "entity": "非致死性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 278,
              "end_idx": 286,
              "entity_en": "Nonfatal myocardial infarction"
            },
            {
              "entity_id": "T368",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 278,
              "end_idx": 282,
              "entity_en": "Non-lethal"
            },
            {
              "entity_id": "T369",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 282,
              "end_idx": 284,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T370",
              "entity": "非致死性卒中",
              "entity_type": "Disease",
              "start_idx": 287,
              "end_idx": 293,
              "entity_en": "Nonfatal stroke"
            },
            {
              "entity_id": "T371",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 287,
              "end_idx": 291,
              "entity_en": "Non-lethal"
            },
            {
              "entity_id": "T372",
              "entity": "血运重建",
              "entity_type": "Operation",
              "start_idx": 294,
              "end_idx": 298,
              "entity_en": "Revascularization"
            },
            {
              "entity_id": "T373",
              "entity": "不稳定性心绞痛",
              "entity_type": "Disease",
              "start_idx": 299,
              "end_idx": 306,
              "entity_en": "Unstable angina"
            },
            {
              "entity_id": "T374",
              "entity": "不稳定性",
              "entity_type": "Class",
              "start_idx": 299,
              "end_idx": 303,
              "entity_en": "Instability"
            },
            {
              "entity_id": "T375",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 303,
              "end_idx": 304,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T376",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 309,
              "end_idx": 313,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T377",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 309,
              "end_idx": 310,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T378",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 337,
              "end_idx": 341,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T379",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 337,
              "end_idx": 338,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T380",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 62,
              "end_idx": 65,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T381",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 93,
              "end_idx": 96,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R159",
              "head_entity_id": "T342",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R160",
              "head_entity_id": "T380",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R161",
              "head_entity_id": "T345",
              "tail_entity_id": "T344"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R162",
              "head_entity_id": "T347",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R163",
              "head_entity_id": "T381",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R164",
              "head_entity_id": "T349",
              "tail_entity_id": "T348"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R165",
              "head_entity_id": "T352",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R166",
              "head_entity_id": "T353",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R167",
              "head_entity_id": "T356",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R168",
              "head_entity_id": "T357",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R169",
              "head_entity_id": "T358",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R170",
              "head_entity_id": "T362",
              "tail_entity_id": "T361"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R171",
              "head_entity_id": "T364",
              "tail_entity_id": "T363"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R172",
              "head_entity_id": "T366",
              "tail_entity_id": "T365"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R173",
              "head_entity_id": "T369",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R174",
              "head_entity_id": "T368",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R175",
              "head_entity_id": "T371",
              "tail_entity_id": "T370"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R176",
              "head_entity_id": "T374",
              "tail_entity_id": "T373"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R177",
              "head_entity_id": "T375",
              "tail_entity_id": "T373"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R178",
              "head_entity_id": "T377",
              "tail_entity_id": "T376"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R179",
              "head_entity_id": "T379",
              "tail_entity_id": "T378"
            }
          ],
          "sentence_en": "The GLP-1 receptor agonist liraglutide is the only glucose-lowering drug currently marketed in China that has been confirmed by CVOT to have cardiovascular benefits. The Liraglutide in Diabetes Evaluation of Cardiovascular Outcomes (LEADER) study included 9,340 T2DM patients with cardiovascular disease or cardiovascular risk factors, of whom 81.3% had a history of cardiovascular disease (including myocardial infarction, stroke or transient ischemic attack, previous revascularization, coronary artery, carotid artery or lower limb artery stenosis ≥50%), with a median follow-up time of 3.8 years. The results showed that on the basis of conventional treatment, liraglutide could reduce the risk of three endpoints, MACE, by 13% (P<0.001) compared with placebo - the risk of cardiovascular death was reduced by 22% (P=0.007), and the risk of the extended composite endpoint of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, revascularization, hospitalization for unstable angina, or hospitalization for heart failure) was reduced by 12% (P=0.005), without increasing the risk of hospitalization for heart failure."
        }
      ],
      "paragraph_en": "The GLP-1 receptor agonist liraglutide is the only glucose-lowering drug currently marketed in China that has been confirmed by CVOT to have cardiovascular benefits. The Liraglutide in Diabetes Evaluation of Cardiovascular Outcomes (LEADER) study included 9,340 T2DM patients with cardiovascular disease or cardiovascular risk factors, of whom 81.3% had a history of cardiovascular disease (including myocardial infarction, stroke or transient ischemic attack, previous revascularization, coronary artery, carotid artery or lower limb artery stenosis ≥50%), with a median follow-up time of 3.8 years. The results showed that on the basis of conventional treatment, liraglutide could reduce the risk of three endpoints, MACE, by 13% (P<0.001) compared with placebo - the risk of cardiovascular death was reduced by 22% (P=0.007), and the risk of the extended composite endpoint of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, revascularization, hospitalization for unstable angina, or hospitalization for heart failure) was reduced by 12% (P=0.005), without increasing the risk of hospitalization for heart failure."
    },
    {
      "paragraph_id": "32",
      "paragraph": "EMPA-REG OUTCOME和LEADER均为大型、多中心、随机、双盲、安慰剂对照的CVOT，这两项研究分别为恩格列净和利拉鲁肽的心血管保护作用提供了可靠证据，对于T2DM合并ASCVD患者的降糖治疗策略制定具有里程碑意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "EMPA-REG OUTCOME和LEADER均为大型、多中心、随机、双盲、安慰剂对照的CVOT，这两项研究分别为恩格列净和利拉鲁肽的心血管保护作用提供了可靠证据，对于T2DM合并ASCVD患者的降糖治疗策略制定具有里程碑意义。",
          "start_idx": 0,
          "end_idx": 114,
          "entities": [
            {
              "entity_id": "T382",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T383",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T384",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T385",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 84,
              "end_idx": 86,
              "entity_en": "T2"
            },
            {
              "entity_id": "T386",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 95,
              "entity_en": "ASCVD"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R180",
              "head_entity_id": "T382",
              "tail_entity_id": "T384"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R181",
              "head_entity_id": "T382",
              "tail_entity_id": "T386"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R182",
              "head_entity_id": "T383",
              "tail_entity_id": "T384"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R183",
              "head_entity_id": "T383",
              "tail_entity_id": "T386"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R184",
              "head_entity_id": "T385",
              "tail_entity_id": "T384"
            }
          ],
          "sentence_en": "Both EMPA-REG OUTCOME and LEADER are large, multicenter, randomized, double-blind, placebo-controlled CVOTs. These two studies provided reliable evidence for the cardiovascular protective effects of empagliflozin and liraglutide, respectively, and are of milestone significance for the formulation of glucose-lowering treatment strategies for patients with T2DM and ASCVD."
        }
      ],
      "paragraph_en": "Both EMPA-REG OUTCOME and LEADER are large, multicenter, randomized, double-blind, placebo-controlled CVOTs. These two studies provided reliable evidence for the cardiovascular protective effects of empagliflozin and liraglutide, respectively, and are of milestone significance for the formulation of glucose-lowering treatment strategies for patients with T2DM and ASCVD."
    },
    {
      "paragraph_id": "33",
      "paragraph": "2.具有心血管效应为中性证据的降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.具有心血管效应为中性证据的降糖药物",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [],
          "relations": [],
          "sentence_en": "2. Antidiabetic drugs with neutral evidence of cardiovascular effects"
        }
      ],
      "paragraph_en": "2. Antidiabetic drugs with neutral evidence of cardiovascular effects"
    },
    {
      "paragraph_id": "34",
      "paragraph": "在T2DM患者中CVOT证实心血管效应为中性的降糖药物包括罗格列酮、吡格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "在T2DM患者中CVOT证实心血管效应为中性的降糖药物包括罗格列酮、吡格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽。",
          "start_idx": 0,
          "end_idx": 65,
          "entities": [
            {
              "entity_id": "T387",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T388",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 1,
              "end_idx": 3,
              "entity_en": "T2"
            },
            {
              "entity_id": "T389",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T390",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T391",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 44,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T392",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T393",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 54,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T394",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T395",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Lixisenatide"
            },
            {
              "entity_id": "T396",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R185",
              "head_entity_id": "T388",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R186",
              "head_entity_id": "T396",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R187",
              "head_entity_id": "T389",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R188",
              "head_entity_id": "T390",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R189",
              "head_entity_id": "T391",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R190",
              "head_entity_id": "T392",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R191",
              "head_entity_id": "T393",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R192",
              "head_entity_id": "T394",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R193",
              "head_entity_id": "T395",
              "tail_entity_id": "T387"
            }
          ],
          "sentence_en": "In patients with T2DM, CVOTs have demonstrated that glucose-lowering drugs with neutral cardiovascular effects include rosiglitazone, pioglitazone, insulin glargine, sitagliptin, saxagliptin, alogliptin, and lixisenatide."
        }
      ],
      "paragraph_en": "In patients with T2DM, CVOTs have demonstrated that glucose-lowering drugs with neutral cardiovascular effects include rosiglitazone, pioglitazone, insulin glargine, sitagliptin, saxagliptin, alogliptin, and lixisenatide."
    },
    {
      "paragraph_id": "35",
      "paragraph": "评估罗格列酮对糖尿病患者心血管结局和血糖控制影响(RECORD)研究是一项开放标签的RCT研究，4447例二甲双胍或SUs单药治疗血糖控制不佳的T2DM患者随机分为两组：在原有治疗基础上联合罗格列酮或在原有治疗基础上联合SUs或双胍类，平均随访时间为5.5年。结果显示与二甲双胍联合SUs治疗组相比，罗格列酮联合二甲双胍或SUs组的首要心血管终点事件(心血管疾病住院或心血管死亡)风险达到非劣效性标准(HR为0.99.95%CI为0.85~1.16)；心力衰竭住院或死亡的相对风险显著增加(HR2.10，95%CI 1.35~3.27)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "评估罗格列酮对糖尿病患者心血管结局和血糖控制影响(RECORD)研究是一项开放标签的RCT研究，4447例二甲双胍或SUs单药治疗血糖控制不佳的T2DM患者随机分为两组：在原有治疗基础上联合罗格列酮或在原有治疗基础上联合SUs或双胍类，平均随访时间为5.5年。结果显示与二甲双胍联合SUs治疗组相比，罗格列酮联合二甲双胍或SUs组的首要心血管终点事件(心血管疾病住院或心血管死亡)风险达到非劣效性标准(HR为0.99.95%CI为0.85~1.16)；心力衰竭住院或死亡的相对风险显著增加(HR2.10，95%CI 1.35~3.27)",
          "start_idx": 0,
          "end_idx": 268,
          "entities": [
            {
              "entity_id": "T397",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T398",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T399",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T400",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T401",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T402",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 67,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T403",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 76,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T404",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 72,
              "end_idx": 74,
              "entity_en": "T2"
            },
            {
              "entity_id": "T405",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T406",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 110,
              "end_idx": 113,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T407",
              "entity": "双胍类",
              "entity_type": "Drug",
              "start_idx": 114,
              "end_idx": 117,
              "entity_en": "Biguanides"
            },
            {
              "entity_id": "T408",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 139,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T409",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 144,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T410",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T411",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 156,
              "end_idx": 160,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T412",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 161,
              "end_idx": 164,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T413",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 176,
              "end_idx": 181,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T414",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 184,
              "end_idx": 189,
              "entity_en": "Cardiovascular death"
            },
            {
              "entity_id": "T415",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 226,
              "end_idx": 230,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T416",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 176,
              "end_idx": 179,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T417",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 226,
              "end_idx": 227,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T418",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 187,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T419",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T420",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R194",
              "head_entity_id": "T397",
              "tail_entity_id": "T398"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R195",
              "head_entity_id": "T420",
              "tail_entity_id": "T398"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R196",
              "head_entity_id": "T399",
              "tail_entity_id": "T398"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R197",
              "head_entity_id": "T400",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R198",
              "head_entity_id": "T401",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R199",
              "head_entity_id": "T402",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R200",
              "head_entity_id": "T404",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R201",
              "head_entity_id": "T416",
              "tail_entity_id": "T413"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R202",
              "head_entity_id": "T418",
              "tail_entity_id": "T414"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R203",
              "head_entity_id": "T417",
              "tail_entity_id": "T415"
            }
          ],
          "sentence_en": "The RECORD study was an open-label RCT study in which 4447 patients with T2DM who were poorly controlled in blood sugar with metformin or SUs monotherapy were randomly divided into two groups: rosiglitazone combined with the original treatment or SUs or biguanides combined with the original treatment. The average follow-up time was 5.5 years. The results showed that compared with the metformin combined with SUs treatment group, the risk of the primary cardiovascular endpoint event (cardiovascular disease hospitalization or cardiovascular death) in the rosiglitazone combined with metformin or SUs group reached the non-inferiority standard (HR was 0.99.95% CI was 0.85-1.16); the relative risk of heart failure hospitalization or death was significantly increased (HR2.10, 95% CI 1.35-3.27)."
        }
      ],
      "paragraph_en": "The RECORD study was an open-label RCT study in which 4447 patients with T2DM who were poorly controlled in blood sugar with metformin or SUs monotherapy were randomly divided into two groups: rosiglitazone combined with the original treatment or SUs or biguanides combined with the original treatment. The average follow-up time was 5.5 years. The results showed that compared with the metformin combined with SUs treatment group, the risk of the primary cardiovascular endpoint event (cardiovascular disease hospitalization or cardiovascular death) in the rosiglitazone combined with metformin or SUs group reached the non-inferiority standard (HR was 0.99.95% CI was 0.85-1.16); the relative risk of heart failure hospitalization or death was significantly increased (HR2.10, 95% CI 1.35-3.27)."
    },
    {
      "paragraph_id": "36",
      "paragraph": "吡格列酮对大血管事件影响的前瞻性临床试验(PROactive)是一项随机、双盲、安慰剂对照的临床研究，在5238例伴有心血管疾病的T2DM患者中评估吡格列酮的心血管安全性。受试者在常规治疗基础上联合吡格列酮或安慰剂治疗，平均随访时间为34.5个月。结果显示，与安慰剂组相比，吡格列酮组的首要复合事件终点(全因死亡、非致死性心肌梗死、卒中、ACS、冠状动脉或下肢动脉的血运重建、踝关节以上的下肢截肢)风险差异无统计学意义(HR 0.90，95%CI 0.80~1.02，P=0.095)，主要次级终点(全因死亡、非致死性心肌梗死或卒中)相对风险下降16%(P=0.027)。PROactive研究结束后继续随访7.8年发现，两组间在首要终点和主要次级终点方面比较，差异均无统计学意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "吡格列酮对大血管事件影响的前瞻性临床试验(PROactive)是一项随机、双盲、安慰剂对照的临床研究，在5238例伴有心血管疾病的T2DM患者中评估吡格列酮的心血管安全性。受试者在常规治疗基础上联合吡格列酮或安慰剂治疗，平均随访时间为34.5个月。结果显示，与安慰剂组相比，吡格列酮组的首要复合事件终点(全因死亡、非致死性心肌梗死、卒中、ACS、冠状动脉或下肢动脉的血运重建、踝关节以上的下肢截肢)风险差异无统计学意义(HR 0.90，95%CI 0.80~1.02，P=0.095)，主要次级终点(全因死亡、非致死性心肌梗死或卒中)相对风险下降16%(P=0.027)。",
          "start_idx": 0,
          "end_idx": 286,
          "entities": [
            {
              "entity_id": "T421",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T422",
              "entity": "大血管事件",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Macrovascular events"
            },
            {
              "entity_id": "T423",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "Large blood vessels"
            },
            {
              "entity_id": "T424",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 64,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T425",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T426",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 69,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T427",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 65,
              "end_idx": 67,
              "entity_en": "T2"
            },
            {
              "entity_id": "T428",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 78,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T429",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 103,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T430",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 141,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T431",
              "entity": "非致死性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 157,
              "end_idx": 165,
              "entity_en": "Nonfatal myocardial infarction"
            },
            {
              "entity_id": "T432",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 157,
              "end_idx": 161,
              "entity_en": "Non-lethal"
            },
            {
              "entity_id": "T433",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 161,
              "end_idx": 163,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T434",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 168,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T435",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 169,
              "end_idx": 172,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T436",
              "entity": "冠状动脉或下肢动脉的血运重建",
              "entity_type": "Operation",
              "start_idx": 173,
              "end_idx": 187,
              "entity_en": "Coronary or lower extremity artery revascularization"
            },
            {
              "entity_id": "T437",
              "entity": "踝关节以上的下肢截肢",
              "entity_type": "Operation",
              "start_idx": 188,
              "end_idx": 198,
              "entity_en": "Amputation of lower limbs above the ankle"
            },
            {
              "entity_id": "T438",
              "entity": "非致死性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 255,
              "end_idx": 263,
              "entity_en": "Nonfatal myocardial infarction"
            },
            {
              "entity_id": "T439",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 255,
              "end_idx": 259,
              "entity_en": "Non-lethal"
            },
            {
              "entity_id": "T440",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 259,
              "end_idx": 261,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T441",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 264,
              "end_idx": 266,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T442",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 79,
              "end_idx": 82,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R204",
              "head_entity_id": "T421",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R205",
              "head_entity_id": "T423",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R206",
              "head_entity_id": "T425",
              "tail_entity_id": "T424"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R207",
              "head_entity_id": "T428",
              "tail_entity_id": "T424"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R208",
              "head_entity_id": "T442",
              "tail_entity_id": "T424"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R209",
              "head_entity_id": "T427",
              "tail_entity_id": "T426"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R210",
              "head_entity_id": "T428",
              "tail_entity_id": "T426"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R211",
              "head_entity_id": "T442",
              "tail_entity_id": "T426"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R212",
              "head_entity_id": "T432",
              "tail_entity_id": "T431"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R213",
              "head_entity_id": "T433",
              "tail_entity_id": "T431"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R214",
              "head_entity_id": "T440",
              "tail_entity_id": "T438"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R215",
              "head_entity_id": "T439",
              "tail_entity_id": "T438"
            }
          ],
          "sentence_en": "The Prospective Clinical Trial of the Effect of Pioglitazone on Macrovascular Events (PROactive) is a randomized, double-blind, placebo-controlled clinical study that evaluated the cardiovascular safety of pioglitazone in 5238 patients with T2DM and cardiovascular disease. The subjects were treated with pioglitazone or placebo on the basis of conventional treatment, and the average follow-up time was 34.5 months. The results showed that compared with the placebo group, there was no statistically significant difference in the risk of the primary composite endpoint (all-cause death, non-fatal myocardial infarction, stroke, ACS, coronary artery or lower limb artery revascularization, and lower limb amputation above the ankle) in the pioglitazone group (HR 0.90, 95%CI 0.80~1.02, P=0.095), and the relative risk of the primary secondary endpoint (all-cause death, non-fatal myocardial infarction or stroke) decreased by 16% (P=0.027)."
        },
        {
          "sentence_id": "1",
          "sentence": "PROactive研究结束后继续随访7.8年发现，两组间在首要终点和主要次级终点方面比较，差异均无统计学意义。",
          "start_idx": 286,
          "end_idx": 341,
          "entities": [],
          "relations": [],
          "sentence_en": "After the end of the PROactive study, the patients were followed up for 7.8 years and found that there was no statistically significant difference between the two groups in the primary endpoint and the main secondary endpoint."
        }
      ],
      "paragraph_en": "The Prospective Clinical Trial of the Effect of Pioglitazone on Macrovascular Events (PROactive) is a randomized, double-blind, placebo-controlled clinical study that evaluated the cardiovascular safety of pioglitazone in 5238 patients with T2DM and cardiovascular disease. The subjects were treated with pioglitazone or placebo on the basis of conventional treatment, and the average follow-up time was 34.5 months. The results showed that compared with the placebo group, there was no statistically significant difference in the risk of the primary composite event endpoint (all-cause death, non-fatal myocardial infarction, stroke, ACS, coronary artery or lower limb artery revascularization, and lower limb amputation above the ankle) in the pioglitazone group (HR 0.90, 95%CI 0.80~1.02, P=0.095), and the relative risk of the primary secondary endpoint (all-cause death, non-fatal myocardial infarction or stroke) was reduced by 16% (P=0.027). After the end of the PROactive study, the follow-up for 7.8 years found that there was no statistically significant difference between the two groups in the primary endpoint and the main secondary endpoint."
    },
    {
      "paragraph_id": "37",
      "paragraph": "甘精胰岛素初始干预转归(ORIGIN)研究采用随机、双盲、2×2析因设计，纳入12537例有心血管高危因素的IFG、IGT或T2DM患者，随机分为甘精胰岛素或常规治疗，中位随访时间为6.2年。结果显示，与常规治疗组相比，甘精胰岛素治疗组3终点MACE的风险差异无统计学意义(HR 1.02，95%CI 0.94~1.11，P=0.63)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "甘精胰岛素初始干预转归(ORIGIN)研究采用随机、双盲、2×2析因设计，纳入12537例有心血管高危因素的IFG、IGT或T2DM患者，随机分为甘精胰岛素或常规治疗，中位随访时间为6.2年。",
          "start_idx": 0,
          "end_idx": 96,
          "entities": [
            {
              "entity_id": "T443",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T444",
              "entity": "IFG",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57,
              "entity_en": "IFG"
            },
            {
              "entity_id": "T445",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "IGT"
            },
            {
              "entity_id": "T446",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T447",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 62,
              "end_idx": 64,
              "entity_en": "T2"
            },
            {
              "entity_id": "T448",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 78,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T450",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R216",
              "head_entity_id": "T450",
              "tail_entity_id": "T444"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R217",
              "head_entity_id": "T448",
              "tail_entity_id": "T444"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R218",
              "head_entity_id": "T450",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R219",
              "head_entity_id": "T448",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R220",
              "head_entity_id": "T447",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R221",
              "head_entity_id": "T450",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R222",
              "head_entity_id": "T448",
              "tail_entity_id": "T446"
            }
          ],
          "sentence_en": "The Outcomes with Initial Intervention with Glargine Insulin (ORIGIN) study used a randomized, double-blind, 2×2 factorial design and enrolled 12,537 patients with IFG, IGT, or T2DM and high cardiovascular risk factors. They were randomly assigned to receive either glargine insulin or conventional treatment with a median follow-up of 6.2 years."
        },
        {
          "sentence_id": "1",
          "sentence": "结果显示，与常规治疗组相比，甘精胰岛素治疗组3终点MACE的风险差异无统计学意义(HR 1.02，95%CI 0.94~1.11，P=0.63)。",
          "start_idx": 96,
          "end_idx": 169,
          "entities": [
            {
              "entity_id": "T449",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Insulin glargine"
            }
          ],
          "relations": [],
          "sentence_en": "The results showed that there was no significant difference in the risk of MACE of the 3 endpoints in the glargine insulin treatment group compared with the conventional treatment group (HR 1.02, 95%CI 0.94~1.11, P=0.63)."
        }
      ],
      "paragraph_en": "The Outcomes of Initial Intervention with Glargine Insulin (ORIGIN) study adopted a randomized, double-blind, 2×2 factorial design and enrolled 12,537 patients with IFG, IGT or T2DM with high cardiovascular risk factors, who were randomly divided into glargine insulin or conventional treatment, with a median follow-up time of 6.2 years. The results showed that there was no statistically significant difference in the risk of MACE of the three endpoints in the glargine insulin treatment group compared with the conventional treatment group (HR 1.02, 95%CI 0.94~1.11, P=0.63)."
    },
    {
      "paragraph_id": "38",
      "paragraph": "在二肽基肽酶4(DPP-4)抑制剂中进行的3项随机、双盲、安慰剂对照的CVOT均显示，DPP-4抑制剂既不增加也不降低心血管事件发生风险。评估T2DM患者中西格列汀心血管安全性(TECOS)研究纳入14671例有心血管病史的T2DM患者，中位随访时间为3年。结果显示，在常规降糖治疗基上，与安慰剂组相比，西格列汀组首要心血管事件复合终点(3终点MACE+不稳定型心绞痛住院)的风险达到非劣效性标准(HR 0.98，95%CI 0.88~1.09)。且不增加心力衰竭住院风险。评价沙格列汀在糖尿病患者中的心血管结局(SAVOR-TIMI53)研究纳入16492例伴有心血管疾病或心血管危险因素的T2DM患者，中位随访时间为2.1年。结果显示，在常规降糖治疗基础上，与安慰剂组相比，沙格列汀组3终点MACE的风险达到非劣效性标准(HR 1.00，95%CI 0.89~1.12)，但心力衰竭住院相对风险增加27%(P=0.007)。阿格列汀与标准治疗在T2DM合并ACS患者中心血管结局比较(EXAMINE)研究在5380例既往15~90d内发生过ACS的T2DM患者中评估阿格列汀的心血管安全性，中位随访时间为18个月。结果显示，在常规降糖治疗基上，与安慰剂组相比，阿格列汀组3终点MACE的风险达到非劣效性标准(HR 0.96，单侧重复CI上限1.16)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "在二肽基肽酶4(DPP-4)抑制剂中进行的3项随机、双盲、安慰剂对照的CVOT均显示，DPP-4抑制剂既不增加也不降低心血管事件发生风险。评估T2DM患者中西格列汀心血管安全性(TECOS)研究纳入14671例有心血管病史的T2DM患者，中位随访时间为3年。结果显示，在常规降糖治疗基上，与安慰剂组相比，西格列汀组首要心血管事件复合终点(3终点MACE+不稳定型心绞痛住院)的风险达到非劣效性标准(HR 0.98，95%CI 0.88~1.09)。且不增加心力衰竭住院风险。评价沙格列汀在糖尿病患者中的心血管结局(SAVOR-TIMI53)研究纳入16492例伴有心血管疾病或心血管危险因素的T2DM患者，中位随访时间为2.1年。结果显示，在常规降糖治疗基础上，与安慰剂组相比，沙格列汀组3终点MACE的风险达到非劣效性标准(HR 1.00，95%CI 0.89~1.12)，但心力衰竭住院相对风险增加27%(P=0.007)。阿格列汀与标准治疗在T2DM合并ACS患者中心血管结局比较(EXAMINE)研究在5380例既往15~90d内发生过ACS的T2DM患者中评估阿格列汀的心血管安全性，中位随访时间为18个月。",
          "start_idx": 0,
          "end_idx": 509,
          "entities": [
            {
              "entity_id": "T451",
              "entity": "二肽基肽酶4(DPP-4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 17,
              "entity_en": "Dipeptidyl peptidase 4 (DPP-4) inhibitors"
            },
            {
              "entity_id": "T452",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 51,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T453",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 64,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T454",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T455",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 75,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T456",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 71,
              "end_idx": 73,
              "entity_en": "T2"
            },
            {
              "entity_id": "T457",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T458",
              "entity": "心血管病",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T459",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 106,
              "end_idx": 109,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T460",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 116,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T461",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 112,
              "end_idx": 114,
              "entity_en": "T2"
            },
            {
              "entity_id": "T462",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 152,
              "end_idx": 156,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T463",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 159,
              "end_idx": 164,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T464",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 159,
              "end_idx": 162,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T465",
              "entity": "不稳定型心绞痛",
              "entity_type": "Disease",
              "start_idx": 177,
              "end_idx": 184,
              "entity_en": "Unstable angina"
            },
            {
              "entity_id": "T466",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 181,
              "end_idx": 182,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T467",
              "entity": "不稳定型",
              "entity_type": "Class",
              "start_idx": 177,
              "end_idx": 181,
              "entity_en": "Unstable"
            },
            {
              "entity_id": "T468",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 228,
              "end_idx": 232,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T469",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 228,
              "end_idx": 229,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T470",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 239,
              "end_idx": 243,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T471",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 244,
              "end_idx": 247,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T472",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 282,
              "end_idx": 287,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T473",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 282,
              "end_idx": 285,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T474",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 296,
              "end_idx": 300,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T475",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 296,
              "end_idx": 298,
              "entity_en": "T2"
            },
            {
              "entity_id": "T476",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 339,
              "end_idx": 343,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T477",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 389,
              "end_idx": 393,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T478",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 389,
              "end_idx": 390,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T479",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 414,
              "end_idx": 418,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T480",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 424,
              "end_idx": 428,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T481",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 424,
              "end_idx": 426,
              "entity_en": "T2"
            },
            {
              "entity_id": "T482",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 430,
              "end_idx": 433,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T483",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 472,
              "end_idx": 475,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T484",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 476,
              "end_idx": 480,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T485",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 476,
              "end_idx": 478,
              "entity_en": "T2"
            },
            {
              "entity_id": "T486",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 485,
              "end_idx": 489,
              "entity_en": "Alogliptin"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R223",
              "head_entity_id": "T452",
              "tail_entity_id": "T453"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R224",
              "head_entity_id": "T454",
              "tail_entity_id": "T453"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R225",
              "head_entity_id": "T456",
              "tail_entity_id": "T455"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R226",
              "head_entity_id": "T457",
              "tail_entity_id": "T455"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R227",
              "head_entity_id": "T459",
              "tail_entity_id": "T458"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R228",
              "head_entity_id": "T461",
              "tail_entity_id": "T460"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R229",
              "head_entity_id": "T462",
              "tail_entity_id": "T463"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R230",
              "head_entity_id": "T464",
              "tail_entity_id": "T463"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R231",
              "head_entity_id": "T466",
              "tail_entity_id": "T465"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R232",
              "head_entity_id": "T467",
              "tail_entity_id": "T465"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R233",
              "head_entity_id": "T469",
              "tail_entity_id": "T468"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R234",
              "head_entity_id": "T470",
              "tail_entity_id": "T471"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R235",
              "head_entity_id": "T473",
              "tail_entity_id": "T472"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R236",
              "head_entity_id": "T475",
              "tail_entity_id": "T474"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R237",
              "head_entity_id": "T478",
              "tail_entity_id": "T477"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R238",
              "head_entity_id": "T479",
              "tail_entity_id": "T480"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R239",
              "head_entity_id": "T479",
              "tail_entity_id": "T482"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R240",
              "head_entity_id": "T481",
              "tail_entity_id": "T480"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R241",
              "head_entity_id": "T486",
              "tail_entity_id": "T483"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R242",
              "head_entity_id": "T486",
              "tail_entity_id": "T484"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R243",
              "head_entity_id": "T485",
              "tail_entity_id": "T484"
            }
          ],
          "sentence_en": "Three randomized, double-blind, placebo-controlled CVOTs conducted on dipeptidyl peptidase 4 (DPP-4) inhibitors have shown that DPP-4 inhibitors neither increase nor reduce the risk of cardiovascular events. The Evaluation of Cardiovascular Safety of Sitagliptin in T2DM Patients (TECOS) study included 14,671 T2DM patients with a history of cardiovascular disease, with a median follow-up of 3 years. The results showed that on the basis of conventional glucose-lowering therapy, the risk of the primary cardiovascular event composite endpoint (3 endpoints MACE + unstable angina hospitalization) in the sitagliptin group reached the non-inferiority standard compared with the placebo group (HR 0.98, 95% CI 0.88~1.09). And it did not increase the risk of hospitalization for heart failure. The Evaluation of Cardiovascular Outcomes of Saxagliptin in Diabetes Patients (SAVOR-TIMI53) study included 16,492 T2DM patients with cardiovascular disease or cardiovascular risk factors, with a median follow-up of 2.1 years. The results showed that on the basis of conventional glucose-lowering therapy, the risk of MACE in the saxagliptin group reached the non-inferiority standard compared with the placebo group (HR 1.00, 95% CI 0.89-1.12), but the relative risk of hospitalization for heart failure increased by 27% (P=0.007). The Comparison of Cardiovascular Outcomes between Alogliptin and Standard Treatment in Patients with T2DM and ACS (EXAMINE) study evaluated the cardiovascular safety of alogliptin in 5380 patients with T2DM who had ACS within the previous 15-90 days, with a median follow-up time of 18 months."
        },
        {
          "sentence_id": "1",
          "sentence": "结果显示，在常规降糖治疗基上，与安慰剂组相比，阿格列汀组3终点MACE的风险达到非劣效性标准(HR 0.96，单侧重复CI上限1.16)。",
          "start_idx": 509,
          "end_idx": 578,
          "entities": [
            {
              "entity_id": "T487",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Alogliptin"
            }
          ],
          "relations": [],
          "sentence_en": "The results showed that on the basis of conventional glucose-lowering treatment, the risk of the 3 endpoint MACE in the alogliptin group reached the non-inferiority criterion compared with the placebo group (HR 0.96, upper limit of the unilateral repeated CI 1.16)."
        }
      ],
      "paragraph_en": "Three randomized, double-blind, placebo-controlled CVOTs conducted on dipeptidyl peptidase 4 (DPP-4) inhibitors have shown that DPP-4 inhibitors neither increase nor reduce the risk of cardiovascular events. The Evaluation of Cardiovascular Safety of Sitagliptin in T2DM Patients (TECOS) study included 14,671 T2DM patients with a history of cardiovascular disease, with a median follow-up of 3 years. The results showed that on the basis of conventional glucose-lowering therapy, the risk of the composite endpoint of the primary cardiovascular event (3 endpoints MACE + unstable angina hospitalization) in the sitagliptin group reached the non-inferiority criterion compared with the placebo group (HR 0.98, 95% CI 0.88~1.09). And it did not increase the risk of hospitalization for heart failure. The Evaluation of Cardiovascular Outcomes of Saxagliptin in Diabetes Patients (SAVOR-TIMI53) study included 16,492 T2DM patients with cardiovascular disease or cardiovascular risk factors, with a median follow-up of 2.1 years. The results showed that on the basis of conventional glucose-lowering therapy, compared with the placebo group, the risk of MACE for the three endpoints in the saxagliptin group reached the non-inferiority standard (HR 1.00, 95%CI 0.89-1.12), but the relative risk of hospitalization for heart failure increased by 27% (P=0.007). The Comparison of Cardiovascular Outcomes between Alogliptin and Standard Treatment in Patients with T2DM and ACS (EXAMINE) study evaluated the cardiovascular safety of alogliptin in 5380 T2DM patients who had ACS within the previous 15-90 days, with a median follow-up time of 18 months. The results showed that on the basis of conventional glucose-lowering therapy, compared with the placebo group, the risk of MACE for the three endpoints in the alogliptin group reached the non-inferiority standard (HR 0.96, upper limit of unilateral repeated CI 1.16)."
    },
    {
      "paragraph_id": "39",
      "paragraph": "利司那肽治疗T2DM合并ACS患者的心血管事件评估(ELIXA)研究是一项随机、双盲、安慰剂对照的临床试验，纳入6068例在既往180d内发生过ACS的T2DM患者，中位随访时间为25个月。结果显示，在常规降糖治疗基础上，与安慰剂组相比，利司那肽组首要心血管事件复合终点(3终点MACE+不稳定性心绞痛住院)的风险达到非劣效性标准( HR 1.02，95%CI 0.89~1.17)，且不增加心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "利司那肽治疗T2DM合并ACS患者的心血管事件评估(ELIXA)研究是一项随机、双盲、安慰剂对照的临床试验，纳入6068例在既往180d内发生过ACS的T2DM患者，中位随访时间为25个月。结果显示，在常规降糖治疗基础上，与安慰剂组相比，利司那肽组首要心血管事件复合终点(3终点MACE+不稳定性心绞痛住院)的风险达到非劣效性标准( HR 1.02，95%CI 0.89~1.17)，且不增加心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 205,
          "entities": [
            {
              "entity_id": "T488",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Lixisenatide"
            },
            {
              "entity_id": "T489",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T490",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "T2"
            },
            {
              "entity_id": "T491",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T492",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T493",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T494",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 75,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T495",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 80,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T496",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 76,
              "end_idx": 78,
              "entity_en": "T2"
            },
            {
              "entity_id": "T497",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123,
              "entity_en": "Lixisenatide"
            },
            {
              "entity_id": "T498",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 126,
              "end_idx": 131,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T499",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 126,
              "end_idx": 129,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T500",
              "entity": "不稳定性心绞痛",
              "entity_type": "Disease",
              "start_idx": 144,
              "end_idx": 151,
              "entity_en": "Unstable angina"
            },
            {
              "entity_id": "T501",
              "entity": "不稳定性",
              "entity_type": "Class",
              "start_idx": 144,
              "end_idx": 148,
              "entity_en": "Instability"
            },
            {
              "entity_id": "T502",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 148,
              "end_idx": 149,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T503",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 196,
              "end_idx": 200,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T504",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 196,
              "end_idx": 197,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R244",
              "head_entity_id": "T488",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R245",
              "head_entity_id": "T488",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R246",
              "head_entity_id": "T490",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R247",
              "head_entity_id": "T493",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R248",
              "head_entity_id": "T496",
              "tail_entity_id": "T495"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R249",
              "head_entity_id": "T497",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R250",
              "head_entity_id": "T499",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R251",
              "head_entity_id": "T501",
              "tail_entity_id": "T500"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R252",
              "head_entity_id": "T502",
              "tail_entity_id": "T500"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R253",
              "head_entity_id": "T504",
              "tail_entity_id": "T503"
            }
          ],
          "sentence_en": "The Lixisenatide Treatment for Cardiovascular Events Evaluation in T2DM Patients with ACS (ELIXA) study is a randomized, double-blind, placebo-controlled clinical trial that included 6068 T2DM patients who had ACS within the previous 180 days, with a median follow-up of 25 months. The results showed that on the basis of conventional glucose-lowering treatment, compared with the placebo group, the risk of the primary cardiovascular event composite endpoint (3 endpoints MACE + unstable angina hospitalization) in the lixisenatide group reached the non-inferiority standard (HR 1.02, 95%CI 0.89~1.17), and did not increase the risk of hospitalization for heart failure."
        }
      ],
      "paragraph_en": "The Lixisenatide Treatment for Cardiovascular Events Evaluation in T2DM Patients with ACS (ELIXA) study is a randomized, double-blind, placebo-controlled clinical trial that included 6068 T2DM patients who had ACS within the previous 180 days, with a median follow-up of 25 months. The results showed that on the basis of conventional glucose-lowering treatment, compared with the placebo group, the risk of the primary cardiovascular event composite endpoint (3 endpoints MACE + unstable angina hospitalization) in the lixisenatide group reached the non-inferiority standard (HR 1.02, 95%CI 0.89~1.17), and did not increase the risk of hospitalization for heart failure."
    },
    {
      "paragraph_id": "40",
      "paragraph": "上述研究数据表明，罗格列酮、毗格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽的心血管效应为中性，既不增加也不降低心血管事件发生风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "上述研究数据表明，罗格列酮、毗格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽的心血管效应为中性，既不增加也不降低心血管事件发生风险。",
          "start_idx": 0,
          "end_idx": 72,
          "entities": [
            {
              "entity_id": "T505",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T506",
              "entity": "毗格列酮",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T507",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T508",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 29,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T509",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 34,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T510",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 39,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T511",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Lixisenatide"
            },
            {
              "entity_id": "T512",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T513",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 62,
              "end_idx": 65,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R254",
              "head_entity_id": "T513",
              "tail_entity_id": "T512"
            }
          ],
          "sentence_en": "The above research data show that the cardiovascular effects of rosiglitazone, pioglitazone, insulin glargine, sitagliptin, saxagliptin, alogliptin and lixisenatide are neutral, neither increasing nor reducing the risk of cardiovascular events."
        }
      ],
      "paragraph_en": "The above research data show that the cardiovascular effects of rosiglitazone, pioglitazone, insulin glargine, sitagliptin, saxagliptin, alogliptin and lixisenatide are neutral, neither increasing nor reducing the risk of cardiovascular events."
    },
    {
      "paragraph_id": "41",
      "paragraph": "3.其他降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.其他降糖药物",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": [],
          "sentence_en": "3. Other hypoglycemic drugs"
        }
      ],
      "paragraph_en": "3. Other hypoglycemic drugs"
    },
    {
      "paragraph_id": "42",
      "paragraph": "(1)目前缺少在T2DM患者中评估心血管安全性的CVOT证据的降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)目前缺少在T2DM患者中评估心血管安全性的CVOT证据的降糖药物",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [
            {
              "entity_id": "T514",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T515",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "T2"
            },
            {
              "entity_id": "T516",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R255",
              "head_entity_id": "T515",
              "tail_entity_id": "T514"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R256",
              "head_entity_id": "T516",
              "tail_entity_id": "T514"
            }
          ],
          "sentence_en": "(1) There is currently a lack of CVOT evidence for evaluating the cardiovascular safety of glucose-lowering drugs in patients with T2DM"
        }
      ],
      "paragraph_en": "(1) There is currently a lack of CVOT evidence for evaluating the cardiovascular safety of glucose-lowering drugs in patients with T2DM"
    },
    {
      "paragraph_id": "43",
      "paragraph": "对于那些未进行CVOT的传统降糖药物而言，其心血管安全性证据主要源自针对降糖治疗策略的RCT研究数据或基于针对降糖疗效的多项RCTs的荟萃分析结果，这些药物包括SUs、格列奈类、维格列汀及大部分胰岛素制剂。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于那些未进行CVOT的传统降糖药物而言，其心血管安全性证据主要源自针对降糖治疗策略的RCT研究数据或基于针对降糖疗效的多项RCTs的荟萃分析结果，这些药物包括SUs、格列奈类、维格列汀及大部分胰岛素制剂。",
          "start_idx": 0,
          "end_idx": 103,
          "entities": [
            {
              "entity_id": "T517",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 80,
              "end_idx": 83,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T518",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T519",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T520",
              "entity": "胰岛素制剂",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 102,
              "entity_en": "Insulin preparations"
            }
          ],
          "relations": [],
          "sentence_en": "For traditional glucose-lowering drugs that have not undergone CVOT, the evidence for their cardiovascular safety mainly comes from RCT research data on glucose-lowering treatment strategies or meta-analysis results based on multiple RCTs on glucose-lowering efficacy. These drugs include SUs, glinides, vildagliptin, and most insulin preparations."
        }
      ],
      "paragraph_en": "For traditional glucose-lowering drugs that have not undergone CVOT, the evidence for their cardiovascular safety mainly comes from RCT research data on glucose-lowering treatment strategies or meta-analysis results based on multiple RCTs on glucose-lowering efficacy. These drugs include SUs, glinides, vildagliptin, and most insulin preparations."
    },
    {
      "paragraph_id": "44",
      "paragraph": "47项RCTs研究的荟萃分析显示，与安慰剂或活性对照药相比，SUs不增加T2DM患者全因死亡、心血管死亡、心肌梗死及卒中的风险.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "47项RCTs研究的荟萃分析显示，与安慰剂或活性对照药相比，SUs不增加T2DM患者全因死亡、心血管死亡、心肌梗死及卒中的风险.。",
          "start_idx": 0,
          "end_idx": 65,
          "entities": [
            {
              "entity_id": "T521",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 33,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T522",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 40,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T523",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 38,
              "entity_en": "T2"
            },
            {
              "entity_id": "T524",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 52,
              "entity_en": "Cardiovascular death"
            },
            {
              "entity_id": "T525",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T526",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 60,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T527",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 47,
              "end_idx": 50,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T528",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 53,
              "end_idx": 55,
              "entity_en": "Myocardium"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R257",
              "head_entity_id": "T521",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R258",
              "head_entity_id": "T523",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R259",
              "head_entity_id": "T527",
              "tail_entity_id": "T524"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R260",
              "head_entity_id": "T528",
              "tail_entity_id": "T525"
            }
          ],
          "sentence_en": "A meta-analysis of 47 RCTs showed that SUs did not increase the risk of all-cause mortality, cardiovascular mortality, myocardial infarction, and stroke in patients with T2DM compared with placebo or active control drugs."
        }
      ],
      "paragraph_en": "A meta-analysis of 47 RCTs showed that SUs did not increase the risk of all-cause mortality, cardiovascular mortality, myocardial infarction, and stroke in patients with T2DM compared with placebo or active control drugs."
    },
    {
      "paragraph_id": "45",
      "paragraph": "那格列奈和缬沙坦在IGT人群中的结局研究(NAVIGATOR)显示，在有心血管事件病史或心血管危险因素的IGT患者中，与安慰剂相比，那格列奈治疗5年后，首要心血管事件复合终点(3终点MACE+心力衰竭住院)风险差异无统计学意义( HR 0.94，95%CI 0.82~1.09，P=0.43)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "那格列奈和缬沙坦在IGT人群中的结局研究(NAVIGATOR)显示，在有心血管事件病史或心血管危险因素的IGT患者中，与安慰剂相比，那格列奈治疗5年后，首要心血管事件复合终点(3终点MACE+心力衰竭住院)风险差异无统计学意义( HR 0.94，95%CI 0.82~1.09，P=0.43)。",
          "start_idx": 0,
          "end_idx": 147,
          "entities": [
            {
              "entity_id": "T529",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T530",
              "entity": "缬沙坦",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "Valsartan"
            },
            {
              "entity_id": "T531",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "IGT"
            },
            {
              "entity_id": "T532",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 41,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T533",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T534",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 55,
              "entity_en": "IGT"
            },
            {
              "entity_id": "T535",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 70,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T536",
              "entity": "5年",
              "entity_type": "Duration",
              "start_idx": 72,
              "end_idx": 74,
              "entity_en": "5 years"
            },
            {
              "entity_id": "T537",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 83,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T538",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 78,
              "end_idx": 81,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T539",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 100,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T540",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 96,
              "end_idx": 97,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R261",
              "head_entity_id": "T529",
              "tail_entity_id": "T531"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R262",
              "head_entity_id": "T530",
              "tail_entity_id": "T531"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R263",
              "head_entity_id": "T533",
              "tail_entity_id": "T532"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R264",
              "head_entity_id": "T536",
              "tail_entity_id": "T535"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R265",
              "head_entity_id": "T538",
              "tail_entity_id": "T537"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R266",
              "head_entity_id": "T540",
              "tail_entity_id": "T539"
            }
          ],
          "sentence_en": "The Nateglinide and Valsartan Outcomes Study in the IGT Population (NAVIGATOR) showed that in IGT patients with a history of cardiovascular events or cardiovascular risk factors, there was no statistically significant difference in the risk of the composite endpoint of primary cardiovascular events (3 endpoints MACE + heart failure hospitalization) after 5 years of treatment with nateglinide compared with placebo (HR 0.94, 95%CI 0.82~1.09, P=0.43)."
        }
      ],
      "paragraph_en": "The Nateglinide and Valsartan Outcomes Study in the IGT Population (NAVIGATOR) showed that in IGT patients with a history of cardiovascular events or cardiovascular risk factors, there was no statistically significant difference in the risk of the composite endpoint of primary cardiovascular events (3 endpoints MACE + heart failure hospitalization) after 5 years of nateglinide treatment compared with placebo (HR 0.94, 95%CI 0.82~1.09, P=0.43)."
    },
    {
      "paragraph_id": "46",
      "paragraph": "25项Ⅲ期临床试验的荟萃分析显示，与安慰剂或活性对照药相比，维格列汀不增加T2DM患者心脑血管事件风险，其中50mg/d组的相对风险为0.88(95%CI 0.37~2.11)、100mg/d组的相对风险0.84(95%CI 0.62~1.14).。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "25项Ⅲ期临床试验的荟萃分析显示，与安慰剂或活性对照药相比，维格列汀不增加T2DM患者心脑血管事件风险，其中50mg/d组的相对风险为0.88(95%CI 0.37~2.11)、100mg/d组的相对风险0.84(95%CI 0.62~1.14).。",
          "start_idx": 0,
          "end_idx": 125,
          "entities": [
            {
              "entity_id": "T541",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 34,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T542",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T543",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 37,
              "end_idx": 39,
              "entity_en": "T2"
            },
            {
              "entity_id": "T544",
              "entity": "心脑血管事件",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 49,
              "entity_en": "Cardiovascular and cerebrovascular events"
            },
            {
              "entity_id": "T545",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T546",
              "entity": "50mg/d",
              "entity_type": "Amount",
              "start_idx": 54,
              "end_idx": 60,
              "entity_en": "50 mg/day"
            },
            {
              "entity_id": "T547",
              "entity": "100mg/d",
              "entity_type": "Amount",
              "start_idx": 89,
              "end_idx": 96,
              "entity_en": "100 mg/day"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R267",
              "head_entity_id": "T546",
              "tail_entity_id": "T541"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R268",
              "head_entity_id": "T547",
              "tail_entity_id": "T541"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R269",
              "head_entity_id": "T541",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R270",
              "head_entity_id": "T543",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R271",
              "head_entity_id": "T545",
              "tail_entity_id": "T544"
            }
          ],
          "sentence_en": "A meta-analysis of 25 Phase III clinical trials showed that compared with placebo or active control drugs, vildagliptin did not increase the risk of cardiovascular and cerebrovascular events in patients with T2DM. The relative risk in the 50 mg/d group was 0.88 (95% CI 0.37~2.11) and the relative risk in the 100 mg/d group was 0.84 (95% CI 0.62~1.14)."
        }
      ],
      "paragraph_en": "A meta-analysis of 25 Phase III clinical trials showed that compared with placebo or active control drugs, vildagliptin did not increase the risk of cardiovascular and cerebrovascular events in patients with T2DM. The relative risk in the 50 mg/d group was 0.88 (95% CI 0.37~2.11) and the relative risk in the 100 mg/d group was 0.84 (95% CI 0.62~1.14)."
    },
    {
      "paragraph_id": "47",
      "paragraph": "T2DM心血管结局(HEART2D)研究显示，在急性心肌梗死后的T2DM患者中，餐时胰岛素或基础胰岛素治疗2.7年后，首要心血管事件复合终点(3终点MACE+冠状动脉血运重建或ACS住院)的风险相似( HR 0.98，95%CI 0.88~1.21)。事后亚组分析提示，在年龄>65.7岁亚组中，与基础胰岛素组相比，餐时胰岛素组首次心血管事件的发生风险更低(HR 0.69，95%CI 0.49~0.96)，表现为发生比例更低、时间更晚。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM心血管结局(HEART2D)研究显示，在急性心肌梗死后的T2DM患者中，餐时胰岛素或基础胰岛素治疗2.7年后，首要心血管事件复合终点(3终点MACE+冠状动脉血运重建或ACS住院)的风险相似( HR 0.98，95%CI 0.88~1.21)。事后亚组分析提示，在年龄>65.7岁亚组中，与基础胰岛素组相比，餐时胰岛素组首次心血管事件的发生风险更低(HR 0.69，95%CI 0.49~0.96)，表现为发生比例更低、时间更晚。",
          "start_idx": 0,
          "end_idx": 219,
          "entities": [
            {
              "entity_id": "T548",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T549",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "T2"
            },
            {
              "entity_id": "T550",
              "entity": "急性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 30,
              "entity_en": "Acute myocardial infarction"
            },
            {
              "entity_id": "T551",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "acute"
            },
            {
              "entity_id": "T552",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T553",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T554",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "T2"
            },
            {
              "entity_id": "T555",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 45,
              "entity_en": "Mealtime insulin"
            },
            {
              "entity_id": "T556",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 51,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T557",
              "entity": "2.7年",
              "entity_type": "Duration",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "2.7 years"
            },
            {
              "entity_id": "T558",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T559",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 66,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T560",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T561",
              "entity": "冠状动脉血运重建",
              "entity_type": "Operation",
              "start_idx": 79,
              "end_idx": 87,
              "entity_en": "Coronary revascularization"
            },
            {
              "entity_id": "T562",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T563",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 149,
              "end_idx": 154,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T564",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "Mealtime insulin"
            },
            {
              "entity_id": "T565",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 171,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T566",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 166,
              "end_idx": 169,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R272",
              "head_entity_id": "T549",
              "tail_entity_id": "T548"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R273",
              "head_entity_id": "T558",
              "tail_entity_id": "T548"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R274",
              "head_entity_id": "T551",
              "tail_entity_id": "T550"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R275",
              "head_entity_id": "T552",
              "tail_entity_id": "T550"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R276",
              "head_entity_id": "T554",
              "tail_entity_id": "T553"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R277",
              "head_entity_id": "T555",
              "tail_entity_id": "T553"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R278",
              "head_entity_id": "T556",
              "tail_entity_id": "T553"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R279",
              "head_entity_id": "T557",
              "tail_entity_id": "T555"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R280",
              "head_entity_id": "T557",
              "tail_entity_id": "T556"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R281",
              "head_entity_id": "T560",
              "tail_entity_id": "T559"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R282",
              "head_entity_id": "T566",
              "tail_entity_id": "T565"
            }
          ],
          "sentence_en": "The T2DM Cardiovascular Outcomes (HEART2D) study showed that in T2DM patients after acute myocardial infarction, the risk of the composite endpoint of the primary cardiovascular event (3 endpoints MACE + coronary artery revascularization or ACS hospitalization) was similar after 2.7 years of treatment with mealtime insulin or basal insulin (HR 0.98, 95%CI 0.88~1.21). Post hoc subgroup analysis suggested that in the subgroup aged >65.7 years, the mealtime insulin group had a lower risk of first cardiovascular event compared with the basal insulin group (HR 0.69, 95%CI 0.49~0.96), which was manifested as a lower incidence and later time."
        }
      ],
      "paragraph_en": "The T2DM Cardiovascular Outcomes (HEART2D) study showed that in T2DM patients after acute myocardial infarction, the risk of the composite endpoint of the primary cardiovascular event (3 endpoints MACE + coronary artery revascularization or ACS hospitalization) was similar after 2.7 years of treatment with mealtime insulin or basal insulin (HR 0.98, 95%CI 0.88~1.21). Post hoc subgroup analysis suggested that in the subgroup aged >65.7 years, the mealtime insulin group had a lower risk of first cardiovascular event compared with the basal insulin group (HR 0.69, 95%CI 0.49~0.96), which was manifested as a lower incidence and later time."
    },
    {
      "paragraph_id": "48",
      "paragraph": "(2)CVOT尚在进行中的降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)CVOT尚在进行中的降糖药物",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": [],
          "sentence_en": "(2) Antidiabetic drugs whose CVOT is still in progress"
        }
      ],
      "paragraph_en": "(2) Antidiabetic drugs whose CVOT is still in progress"
    },
    {
      "paragraph_id": "49",
      "paragraph": "目前，正在进行CVOT的降糖药物包括阿卡波糖、利格列汀、艾塞那肽(周制剂)、度拉唐肽、阿必鲁肽、达格列净、坎格列净及德谷胰岛素。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前，正在进行CVOT的降糖药物包括阿卡波糖、利格列汀、艾塞那肽(周制剂)、度拉唐肽、阿必鲁肽、达格列净、坎格列净及德谷胰岛素。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T567",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T568",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T569",
              "entity": "艾塞那肽(周制剂)",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 37,
              "entity_en": "Exenatide (weekly preparation)"
            },
            {
              "entity_id": "T570",
              "entity": "度拉唐肽",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Dulatan"
            },
            {
              "entity_id": "T571",
              "entity": "阿必鲁肽",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "Albiglutide"
            },
            {
              "entity_id": "T572",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 52,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T573",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Canagliflozin"
            },
            {
              "entity_id": "T574",
              "entity": "德谷胰岛素",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "Insulin degludec"
            }
          ],
          "relations": [],
          "sentence_en": "Currently, the glucose-lowering drugs undergoing CVOT include acarbose, linagliptin, exenatide (weekly formulation), dulatantide, albiglutide, dapagliflozin, canagliflozin and degludec insulin."
        }
      ],
      "paragraph_en": "Currently, the glucose-lowering drugs undergoing CVOT include acarbose, linagliptin, exenatide (weekly formulation), dulatantide, albiglutide, dapagliflozin, canagliflozin and degludec insulin."
    },
    {
      "paragraph_id": "50",
      "paragraph": "(二)降糖药物的用药原则",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)降糖药物的用药原则",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [],
          "relations": [],
          "sentence_en": "(II) Principles of using hypoglycemic drugs"
        }
      ],
      "paragraph_en": "(II) Principles of using hypoglycemic drugs"
    },
    {
      "paragraph_id": "51",
      "paragraph": "降糖治疗的目标不仅仅是单纯控制血糖，更重要的是减少糖尿病并发症（特别是心血管事件）、降低死亡风险，从而改善患者的远期预后。生活方式干预是T2DM患者降糖治疗的基础性措施，应贯穿于降糖治疗的始终。如果单纯生活方式干预不能使血糖达标，应开始药物治疗。对于合并ASCVD的T2DM患者，尤应注意心血管安全性问题，并且优先考虑选择具有心血管获益证据的降糖药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "降糖治疗的目标不仅仅是单纯控制血糖，更重要的是减少糖尿病并发症（特别是心血管事件）、降低死亡风险，从而改善患者的远期预后。生活方式干预是T2DM患者降糖治疗的基础性措施，应贯穿于降糖治疗的始终。如果单纯生活方式干预不能使血糖达标，应开始药物治疗。对于合并ASCVD的T2DM患者，尤应注意心血管安全性问题，并且优先考虑选择具有心血管获益证据的降糖药物。",
          "start_idx": 0,
          "end_idx": 176,
          "entities": [
            {
              "entity_id": "T575",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T576",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T577",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 40,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T578",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 38,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T579",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 61,
              "end_idx": 67,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T580",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 72,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T581",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 68,
              "end_idx": 70,
              "entity_en": "T2"
            },
            {
              "entity_id": "T582",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 101,
              "end_idx": 107,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T583",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 110,
              "end_idx": 112,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T584",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 112,
              "end_idx": 114,
              "entity_en": "Meet the Standard"
            },
            {
              "entity_id": "T585",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 132,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T586",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 133,
              "end_idx": 137,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T587",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 133,
              "end_idx": 135,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R283",
              "head_entity_id": "T578",
              "tail_entity_id": "T577"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R284",
              "head_entity_id": "T579",
              "tail_entity_id": "T580"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R285",
              "head_entity_id": "T581",
              "tail_entity_id": "T580"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R286",
              "head_entity_id": "T587",
              "tail_entity_id": "T586"
            }
          ],
          "sentence_en": "The goal of glucose-lowering therapy is not only to simply control blood sugar, but more importantly to reduce diabetic complications (especially cardiovascular events) and reduce the risk of death, thereby improving the patient's long-term prognosis. Lifestyle intervention is a basic measure for glucose-lowering therapy in patients with T2DM and should be used throughout the entire glucose-lowering therapy. If lifestyle intervention alone cannot bring blood sugar to the target, drug therapy should be started. For T2DM patients with ASCVD, special attention should be paid to cardiovascular safety issues, and glucose-lowering drugs with evidence of cardiovascular benefits should be given priority."
        }
      ],
      "paragraph_en": "The goal of glucose-lowering therapy is not only to simply control blood sugar, but more importantly to reduce diabetic complications (especially cardiovascular events) and reduce the risk of death, thereby improving the patient's long-term prognosis. Lifestyle intervention is a basic measure for glucose-lowering therapy in patients with T2DM and should be used throughout the entire glucose-lowering therapy. If lifestyle intervention alone cannot bring blood sugar to the target, drug therapy should be started. For T2DM patients with ASCVD, special attention should be paid to cardiovascular safety issues, and glucose-lowering drugs with evidence of cardiovascular benefits should be given priority."
    },
    {
      "paragraph_id": "52",
      "paragraph": "1.一线治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.一线治疗",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "1. First-line treatment"
        }
      ],
      "paragraph_en": "1. First-line treatment"
    },
    {
      "paragraph_id": "53",
      "paragraph": "大多数国内外指南均推荐二甲双胍作为T2DM",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "大多数国内外指南均推荐二甲双胍作为T2DM",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T588",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T589",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T590",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R287",
              "head_entity_id": "T588",
              "tail_entity_id": "T589"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R288",
              "head_entity_id": "T590",
              "tail_entity_id": "T589"
            }
          ],
          "sentence_en": "Most domestic and international guidelines recommend metformin as a treatment for T2DM."
        }
      ],
      "paragraph_en": "Most domestic and international guidelines recommend metformin as a treatment for T2DM."
    },
    {
      "paragraph_id": "54",
      "paragraph": "患者单药治疗的一线首选药物和联合治疗的基本用药，如无禁忌证且能够耐受，二甲双胍应一直保留在T2DM患者的降糖治疗方案中。若存在禁忌证或无法耐受，建议视患者的具体情况考虑选择具有心血管保护或中性的降糖药物.",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "患者单药治疗的一线首选药物和联合治疗的基本用药，如无禁忌证且能够耐受，二甲双胍应一直保留在T2DM患者的降糖治疗方案中。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [
            {
              "entity_id": "T591",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 39,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T592",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T593",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R289",
              "head_entity_id": "T591",
              "tail_entity_id": "T592"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R290",
              "head_entity_id": "T593",
              "tail_entity_id": "T592"
            }
          ],
          "sentence_en": "Metformin is the first-line drug for monotherapy and the basic drug for combination therapy. If there are no contraindications and it can be tolerated, metformin should always be retained in the glucose-lowering treatment plan for patients with T2DM."
        },
        {
          "sentence_id": "1",
          "sentence": "若存在禁忌证或无法耐受，建议视患者的具体情况考虑选择具有心血管保护或中性的降糖药物.",
          "start_idx": 60,
          "end_idx": 102,
          "entities": [],
          "relations": [],
          "sentence_en": "If there are contraindications or intolerance, it is recommended to consider choosing hypoglycemic drugs with cardiovascular protection or neutrality according to the patient's specific situation."
        }
      ],
      "paragraph_en": "Metformin is the first-line drug of choice for monotherapy and the basic drug for combination therapy. If there are no contraindications and it can be tolerated, it should always be retained in the glucose-lowering treatment plan for patients with T2DM. If there are contraindications or intolerance, it is recommended to consider choosing glucose-lowering drugs with cardiovascular protection or neutrality according to the specific situation of the patient."
    },
    {
      "paragraph_id": "55",
      "paragraph": "2.联合治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.联合治疗",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "2. Combination therapy"
        }
      ],
      "paragraph_en": "2. Combination therapy"
    },
    {
      "paragraph_id": "56",
      "paragraph": "若一线降药物单药治疗3个月不能使血糖控制达标，需考虑两种降糖药物联合治疗。根据患者的不同情况，选择个体化的联合用药方案。对于T2DM合并ASCVD患者，可优先考虑联合具有明确心血管获益证据的降常药物(如利拉鲁肽或恩格列净)治疗，",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "若一线降药物单药治疗3个月不能使血糖控制达标，需考虑两种降糖药物联合治疗。根据患者的不同情况，选择个体化的联合用药方案。对于T2DM合并ASCVD患者，可优先考虑联合具有明确心血管获益证据的降常药物(如利拉鲁肽或恩格列净)治疗，",
          "start_idx": 0,
          "end_idx": 114,
          "entities": [
            {
              "entity_id": "T594",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T595",
              "entity": "控制达标",
              "entity_type": "Test_Value",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Control compliance"
            },
            {
              "entity_id": "T596",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T597",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 62,
              "end_idx": 64,
              "entity_en": "T2"
            },
            {
              "entity_id": "T598",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 73,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T599",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T600",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Empagliflozin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R291",
              "head_entity_id": "T597",
              "tail_entity_id": "T596"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R292",
              "head_entity_id": "T599",
              "tail_entity_id": "T596"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R293",
              "head_entity_id": "T600",
              "tail_entity_id": "T596"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R294",
              "head_entity_id": "T599",
              "tail_entity_id": "T598"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R295",
              "head_entity_id": "T600",
              "tail_entity_id": "T598"
            }
          ],
          "sentence_en": "If first-line glucose-lowering drugs alone cannot achieve target blood sugar control after 3 months of treatment, combination therapy with two glucose-lowering drugs should be considered. According to the different conditions of the patients, individualized combination therapy should be selected. For patients with T2DM and ASCVD, combination therapy with glucose-lowering drugs with clear evidence of cardiovascular benefits (such as liraglutide or empagliflozin) can be given priority."
        }
      ],
      "paragraph_en": "If first-line glucose-lowering drugs alone cannot achieve target blood sugar control after 3 months of treatment, combination therapy with two glucose-lowering drugs should be considered. According to the different conditions of the patients, individualized combination therapy should be selected. For patients with T2DM and ASCVD, combination therapy with glucose-lowering drugs with clear evidence of cardiovascular benefits (such as liraglutide or empagliflozin) can be given priority."
    },
    {
      "paragraph_id": "57",
      "paragraph": "以最大限度降低患者心血管事件和死亡的风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "以最大限度降低患者心血管事件和死亡的风险。",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T601",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T602",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R296",
              "head_entity_id": "T602",
              "tail_entity_id": "T601"
            }
          ],
          "sentence_en": "To minimize the risk of cardiovascular events and death in patients."
        }
      ],
      "paragraph_en": "To minimize the risk of cardiovascular events and death in patients."
    },
    {
      "paragraph_id": "58",
      "paragraph": "若两种降糖药物联合治疗3个月不能使患者血糖控制达标，可考虑联合第3种降糖药物或者联合胰岛素治疗.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "若两种降糖药物联合治疗3个月不能使患者血糖控制达标，可考虑联合第3种降糖药物或者联合胰岛素治疗.。",
          "start_idx": 0,
          "end_idx": 49,
          "entities": [
            {
              "entity_id": "T603",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T604",
              "entity": "控制达标",
              "entity_type": "Test_Value",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Control compliance"
            },
            {
              "entity_id": "T605",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 45,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "If combined treatment with two glucose-lowering drugs for 3 months fails to bring the patient's blood sugar under control, a third glucose-lowering drug or insulin therapy may be considered."
        }
      ],
      "paragraph_en": "If combined treatment with two glucose-lowering drugs for 3 months fails to bring the patient's blood sugar under control, a third glucose-lowering drug or insulin therapy may be considered."
    },
    {
      "paragraph_id": "59",
      "paragraph": "(三)降糖治疗的药物选择",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)降糖治疗的药物选择",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [],
          "relations": [],
          "sentence_en": "3. Drug selection for hypoglycemic treatment"
        }
      ],
      "paragraph_en": "3. Drug selection for hypoglycemic treatment"
    },
    {
      "paragraph_id": "60",
      "paragraph": "1.非胰岛素降糖药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.非胰岛素降糖药",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T606",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "1. Non-insulin hypoglycemic drugs"
        }
      ],
      "paragraph_en": "1. Non-insulin hypoglycemic drugs"
    },
    {
      "paragraph_id": "61",
      "paragraph": "表2总结了常用非胰岛素降糖药的作用机制、使用方法、降糖疗效、低血糖风险、对体重的影响、注意事项等主要信息。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "表2总结了常用非胰岛素降糖药的作用机制、使用方法、降糖疗效、低血糖风险、对体重的影响、注意事项等主要信息。",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T607",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T608",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 30,
              "end_idx": 33,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [],
          "sentence_en": "Table 2 summarizes the main information of commonly used non-insulin hypoglycemic drugs, including the mechanism of action, usage, hypoglycemic efficacy, risk of hypoglycemia, effect on body weight, precautions, etc."
        }
      ],
      "paragraph_en": "Table 2 summarizes the main information of commonly used non-insulin hypoglycemic drugs, including the mechanism of action, usage, hypoglycemic efficacy, risk of hypoglycemia, effect on body weight, precautions, etc."
    },
    {
      "paragraph_id": "62",
      "paragraph": "(四)其他特殊情况",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(四)其他特殊情况",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "(IV) Other special circumstances"
        }
      ],
      "paragraph_en": "(IV) Other special circumstances"
    },
    {
      "paragraph_id": "63",
      "paragraph": "1.ASCVD急性期",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.ASCVD急性期",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T609",
              "entity": "ASCVD急性期",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 10,
              "entity_en": "Acute ASCVD"
            },
            {
              "entity_id": "T610",
              "entity": "急性期",
              "entity_type": "Class",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "Acute phase"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R297",
              "head_entity_id": "T610",
              "tail_entity_id": "T609"
            }
          ],
          "sentence_en": "1. Acute phase of ASCVD"
        }
      ],
      "paragraph_en": "1. Acute phase of ASCVD"
    },
    {
      "paragraph_id": "64",
      "paragraph": "对于处在ASCVD急性期(如ACS、缺血性卒中急性期、冠状动脉血运重建围手术期等)的T2DM患者，其降糖治疗方案需要充分考虑疾病特点、机体应激状况以及严格降糖治疗的获益/风险比。对于合并ACS的患者，若血糖>10.0mmol/L，可采用以胰岛素为基础的降糖治疗方案，使血糖水平控制在7.8~10.0mmol/L，同时注意避免发生低血糖。对于接受经皮冠状动脉介人治疗(PCI)的患者，使用对比剂前可以不停用二甲双胍，但应密切监测肾功能，造影后应连续两日检验血清肌酐(Scr)。若Scr值比造影前上升26.5μmol/L，则应考虑对比剂肾病发生，应立即停用二甲双胍，直至肾功能恢复至基础水平，方可重新开始二甲双胍治疗。目前尚无充分的证据提示，不同降糖药物对接受PCI治疗患者的预后存在不同的影响。对于接受冠状动脉旁路移植术(CABG)的患者，围手术期不",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于处在ASCVD急性期(如ACS、缺血性卒中急性期、冠状动脉血运重建围手术期等)的T2DM患者，其降糖治疗方案需要充分考虑疾病特点、机体应激状况以及严格降糖治疗的获益/风险比。对于合并ACS的患者，若血糖>10.0mmol/L，可采用以胰岛素为基础的降糖治疗方案，使血糖水平控制在7.8~10.0mmol/L，同时注意避免发生低血糖。对于接受经皮冠状动脉介人治疗(PCI)的患者，使用对比剂前可以不停用二甲双胍，但应密切监测肾功能，造影后应连续两日检验血清肌酐(Scr)。若Scr值比造影前上升26.5μmol/L，则应考虑对比剂肾病发生，应立即停用二甲双胍，直至肾功能恢复至基础水平，方可重新开始二甲双胍治疗。",
          "start_idx": 0,
          "end_idx": 307,
          "entities": [
            {
              "entity_id": "T611",
              "entity": "ASCVD急性期",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 12,
              "entity_en": "Acute ASCVD"
            },
            {
              "entity_id": "T612",
              "entity": "急性期",
              "entity_type": "Class",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "Acute phase"
            },
            {
              "entity_id": "T613",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T614",
              "entity": "缺血性卒中急性期",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 26,
              "entity_en": "Acute ischemic stroke"
            },
            {
              "entity_id": "T615",
              "entity": "急性期",
              "entity_type": "Class",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "Acute phase"
            },
            {
              "entity_id": "T616",
              "entity": "冠状动脉血运重建",
              "entity_type": "Operation",
              "start_idx": 27,
              "end_idx": 35,
              "entity_en": "Coronary revascularization"
            },
            {
              "entity_id": "T617",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T618",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "T2"
            },
            {
              "entity_id": "T619",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 93,
              "end_idx": 96,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T620",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 103,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T621",
              "entity": ">10.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 103,
              "end_idx": 114,
              "entity_en": ">10.0mmol/L"
            },
            {
              "entity_id": "T622",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 122,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T623",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 134,
              "end_idx": 136,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T624",
              "entity": "7.8~10.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 141,
              "end_idx": 155,
              "entity_en": "7.8~10.0mmol/L"
            },
            {
              "entity_id": "T625",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 164,
              "end_idx": 167,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T626",
              "entity": "经皮冠状动脉介人治疗(PCI)",
              "entity_type": "Operation",
              "start_idx": 172,
              "end_idx": 187,
              "entity_en": "Percutaneous Coronary Intervention (PCI)"
            },
            {
              "entity_id": "T627",
              "entity": "对比剂",
              "entity_type": "Drug",
              "start_idx": 193,
              "end_idx": 196,
              "entity_en": "Contrast agents"
            },
            {
              "entity_id": "T628",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 202,
              "end_idx": 206,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T629",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 213,
              "end_idx": 216,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T630",
              "entity": "造影",
              "entity_type": "Test",
              "start_idx": 217,
              "end_idx": 219,
              "entity_en": "Imaging"
            },
            {
              "entity_id": "T631",
              "entity": "血清肌酐(Scr)",
              "entity_type": "Test_items",
              "start_idx": 227,
              "end_idx": 236,
              "entity_en": "Serum creatinine (Scr)"
            },
            {
              "entity_id": "T632",
              "entity": "Scr",
              "entity_type": "Test_items",
              "start_idx": 238,
              "end_idx": 241,
              "entity_en": "Scr"
            },
            {
              "entity_id": "T633",
              "entity": "上升26.5μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 246,
              "end_idx": 258,
              "entity_en": "Increased by 26.5 μmol/L"
            },
            {
              "entity_id": "T634",
              "entity": "造影",
              "entity_type": "Test",
              "start_idx": 243,
              "end_idx": 245,
              "entity_en": "Imaging"
            },
            {
              "entity_id": "T635",
              "entity": "对比剂",
              "entity_type": "Drug",
              "start_idx": 263,
              "end_idx": 266,
              "entity_en": "Contrast agents"
            },
            {
              "entity_id": "T636",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 266,
              "end_idx": 268,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T637",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 266,
              "end_idx": 267,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T638",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 276,
              "end_idx": 280,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T639",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 283,
              "end_idx": 286,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T640",
              "entity": "恢复至基础水平",
              "entity_type": "Test_Value",
              "start_idx": 286,
              "end_idx": 293,
              "entity_en": "Return to basic level"
            },
            {
              "entity_id": "T641",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 300,
              "end_idx": 304,
              "entity_en": "Metformin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R298",
              "head_entity_id": "T612",
              "tail_entity_id": "T611"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R299",
              "head_entity_id": "T616",
              "tail_entity_id": "T611"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R300",
              "head_entity_id": "T615",
              "tail_entity_id": "T614"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R301",
              "head_entity_id": "T618",
              "tail_entity_id": "T617"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R302",
              "head_entity_id": "T620",
              "tail_entity_id": "T619"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R303",
              "head_entity_id": "T622",
              "tail_entity_id": "T619"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R304",
              "head_entity_id": "T623",
              "tail_entity_id": "T619"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R305",
              "head_entity_id": "T632",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R306",
              "head_entity_id": "T634",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R307",
              "head_entity_id": "T635",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R308",
              "head_entity_id": "T637",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R309",
              "head_entity_id": "T639",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R310",
              "head_entity_id": "T641",
              "tail_entity_id": "T636"
            }
          ],
          "sentence_en": "For T2DM patients in the acute phase of ASCVD (such as ACS, acute phase of ischemic stroke, perioperative period of coronary artery revascularization, etc.), their glucose-lowering treatment plan needs to fully consider the characteristics of the disease, the body's stress status, and the benefit/risk ratio of strict glucose-lowering treatment. For patients with ACS, if blood glucose is >10.0mmol/L, an insulin-based glucose-lowering treatment plan can be used to control blood glucose levels at 7.8~10.0mmol/L, and care should be taken to avoid hypoglycemia. For patients undergoing percutaneous coronary intervention (PCI), metformin can be continued before contrast agent use, but renal function should be closely monitored, and serum creatinine (Scr) should be tested for two consecutive days after angiography. If the Scr value increases by 26.5μmol/L compared to before angiography, contrast-induced nephropathy should be considered, and metformin should be discontinued immediately until renal function returns to the baseline level before metformin treatment can be restarted."
        },
        {
          "sentence_id": "1",
          "sentence": "目前尚无充分的证据提示，不同降糖药物对接受PCI治疗患者的预后存在不同的影响。",
          "start_idx": 307,
          "end_idx": 346,
          "entities": [
            {
              "entity_id": "T642",
              "entity": "PCI",
              "entity_type": "Operation",
              "start_idx": 21,
              "end_idx": 24,
              "entity_en": "PCI"
            }
          ],
          "relations": [],
          "sentence_en": "There is currently no sufficient evidence to suggest that different glucose-lowering drugs have different effects on the prognosis of patients undergoing PCI."
        },
        {
          "sentence_id": "2",
          "sentence": "对于接受冠状动脉旁路移植术(CABG)的患者，围手术期不",
          "start_idx": 346,
          "end_idx": 374,
          "entities": [
            {
              "entity_id": "T643",
              "entity": "冠状动脉旁路移植术(CABG)",
              "entity_type": "Operation",
              "start_idx": 4,
              "end_idx": 19,
              "entity_en": "Coronary Artery Bypass Graft (CABG)"
            }
          ],
          "relations": [],
          "sentence_en": "For patients undergoing coronary artery bypass grafting (CABG), the perioperative period is not"
        }
      ],
      "paragraph_en": "For T2DM patients in the acute phase of ASCVD (such as ACS, acute phase of ischemic stroke, perioperative period of coronary artery revascularization, etc.), their glucose-lowering treatment regimen needs to fully consider the characteristics of the disease, the body's stress status, and the benefit/risk ratio of strict glucose-lowering treatment. For patients with ACS, if blood glucose is >10.0mmol/L, an insulin-based glucose-lowering treatment regimen can be used to control blood glucose levels at 7.8~10.0mmol/L, and care should be taken to avoid hypoglycemia. For patients undergoing percutaneous coronary intervention (PCI), metformin can be continued before contrast agent use, but renal function should be closely monitored, and serum creatinine (Scr) should be tested for two consecutive days after angiography. If the Scr value increases by 26.5μmol/L compared to before angiography, contrast-induced nephropathy should be considered, and metformin should be discontinued immediately until renal function returns to the baseline level before metformin treatment can be restarted. There is currently no sufficient evidence to suggest that different glucose-lowering drugs have different effects on the prognosis of patients undergoing PCI. For patients undergoing coronary artery bypass grafting (CABG), the perioperative period is not"
    },
    {
      "paragraph_id": "65",
      "paragraph": "推荐口服降糖药，应使用胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐口服降糖药，应使用胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T644",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T645",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "oral"
            }
          ],
          "relations": [],
          "sentence_en": "Oral hypoglycemic drugs are recommended, and insulin treatment should be used."
        }
      ],
      "paragraph_en": "Oral hypoglycemic drugs are recommended, and insulin treatment should be used."
    },
    {
      "paragraph_id": "66",
      "paragraph": "2.心力衰竭",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.心力衰竭",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [
            {
              "entity_id": "T646",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T647",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R311",
              "head_entity_id": "T647",
              "tail_entity_id": "T646"
            }
          ],
          "sentence_en": "2. Heart failure"
        }
      ],
      "paragraph_en": "2. Heart failure"
    },
    {
      "paragraph_id": "67",
      "paragraph": "T2DM和ASCVD患者常合并心力衰竭。对于合并心力衰竭的T2DM患者，制定降糖治疗方案时，应关注某些降糖药物对心力衰竭的潜在不良影响。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM和ASCVD患者常合并心力衰竭。对于合并心力衰竭的T2DM患者，制定降糖治疗方案时，应关注某些降糖药物对心力衰竭的潜在不良影响。",
          "start_idx": 0,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T648",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T649",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "T2"
            },
            {
              "entity_id": "T650",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T651",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T652",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 15,
              "end_idx": 16,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T653",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T654",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 25,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T655",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 33,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T656",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 29,
              "end_idx": 31,
              "entity_en": "T2"
            },
            {
              "entity_id": "T657",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 60,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T658",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 56,
              "end_idx": 57,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R312",
              "head_entity_id": "T649",
              "tail_entity_id": "T648"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R313",
              "head_entity_id": "T652",
              "tail_entity_id": "T651"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R314",
              "head_entity_id": "T654",
              "tail_entity_id": "T653"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R315",
              "head_entity_id": "T656",
              "tail_entity_id": "T655"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R316",
              "head_entity_id": "T658",
              "tail_entity_id": "T657"
            }
          ],
          "sentence_en": "Patients with T2DM and ASCVD often have heart failure. When formulating glucose-lowering treatment plans for T2DM patients with heart failure, attention should be paid to the potential adverse effects of certain glucose-lowering drugs on heart failure."
        }
      ],
      "paragraph_en": "Patients with T2DM and ASCVD often have heart failure. When formulating glucose-lowering treatment plans for T2DM patients with heart failure, attention should be paid to the potential adverse effects of certain glucose-lowering drugs on heart failure."
    },
    {
      "paragraph_id": "68",
      "paragraph": "二甲双胍：在定期检查心、肾功能的情况下，稳定期的慢性心力衰竭患者可以服用二甲双胍，但因存在乳酸性酸中毒的潜在风险，急性、病情不稳定或住院的心力衰竭患者禁用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍：在定期检查心、肾功能的情况下，稳定期的慢性心力衰竭患者可以服用二甲双胍，但因存在乳酸性酸中毒的潜在风险，急性、病情不稳定或住院的心力衰竭患者禁用。",
          "start_idx": 0,
          "end_idx": 78,
          "entities": [
            {
              "entity_id": "T659",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T660",
              "entity": "心、肾功能",
              "entity_type": "Test",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Heart and kidney function"
            },
            {
              "entity_id": "T661",
              "entity": "慢性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 30,
              "entity_en": "Chronic heart failure"
            },
            {
              "entity_id": "T662",
              "entity": "慢性",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Chronic"
            },
            {
              "entity_id": "T663",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 26,
              "end_idx": 27,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T664",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 40,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T665",
              "entity": "乳酸性酸中毒",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 51,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T666",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 73,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T667",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 69,
              "end_idx": 70,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T668",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "acute"
            },
            {
              "entity_id": "T669",
              "entity": "稳定期",
              "entity_type": "Class",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "Stable period"
            },
            {
              "entity_id": "T670",
              "entity": "乳酸性",
              "entity_type": "Class",
              "start_idx": 45,
              "end_idx": 48,
              "entity_en": "Lactic acid"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R317",
              "head_entity_id": "T660",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R318",
              "head_entity_id": "T663",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R319",
              "head_entity_id": "T669",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R320",
              "head_entity_id": "T662",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R321",
              "head_entity_id": "T664",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R322",
              "head_entity_id": "T670",
              "tail_entity_id": "T665"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R323",
              "head_entity_id": "T668",
              "tail_entity_id": "T666"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R324",
              "head_entity_id": "T667",
              "tail_entity_id": "T666"
            }
          ],
          "sentence_en": "Metformin: Under the condition of regular checks of heart and kidney function, patients with stable chronic heart failure can take metformin. However, due to the potential risk of lactic acidosis, it is contraindicated for patients with acute, unstable or hospitalized heart failure."
        }
      ],
      "paragraph_en": "Metformin: Under the condition of regular checks of heart and kidney function, patients with stable chronic heart failure can take metformin. However, due to the potential risk of lactic acidosis, it is contraindicated for patients with acute, unstable or hospitalized heart failure."
    },
    {
      "paragraph_id": "69",
      "paragraph": "TZDs：可引起水钠潴留和血容量扩张，诱发或加重心力衰竭，故急性心力衰竭、NYHA心功能Ⅱ~IV级的慢性心力衰竭患者禁用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "TZDs：可引起水钠潴留和血容量扩张，诱发或加重心力衰竭，故急性心力衰竭、NYHA心功能Ⅱ~IV级的慢性心力衰竭患者禁用。",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T671",
              "entity": "TZDs",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "TZD"
            },
            {
              "entity_id": "T672",
              "entity": "水钠潴留",
              "entity_type": "ADE",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Water and sodium retention"
            },
            {
              "entity_id": "T673",
              "entity": "血容量扩张",
              "entity_type": "ADE",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Blood volume expansion"
            },
            {
              "entity_id": "T674",
              "entity": "急性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 36,
              "entity_en": "Acute heart failure"
            },
            {
              "entity_id": "T675",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "acute"
            },
            {
              "entity_id": "T676",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 32,
              "end_idx": 33,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T677",
              "entity": "NYHA心功能Ⅱ~IV级",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 49,
              "entity_en": "NYHA heart function class II~IV"
            },
            {
              "entity_id": "T678",
              "entity": "Ⅱ~IV级",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 49,
              "entity_en": "Level II to IV"
            },
            {
              "entity_id": "T679",
              "entity": "慢性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 56,
              "entity_en": "Chronic heart failure"
            },
            {
              "entity_id": "T680",
              "entity": "慢性",
              "entity_type": "Class",
              "start_idx": 50,
              "end_idx": 52,
              "entity_en": "Chronic"
            },
            {
              "entity_id": "T681",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 52,
              "end_idx": 53,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T682",
              "entity": "诱发或加重心力衰竭",
              "entity_type": "ADE",
              "start_idx": 19,
              "end_idx": 28,
              "entity_en": "Induce or aggravate heart failure"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R325",
              "head_entity_id": "T672",
              "tail_entity_id": "T671"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R326",
              "head_entity_id": "T673",
              "tail_entity_id": "T671"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R327",
              "head_entity_id": "T682",
              "tail_entity_id": "T671"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R328",
              "head_entity_id": "T676",
              "tail_entity_id": "T674"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R329",
              "head_entity_id": "T675",
              "tail_entity_id": "T674"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R330",
              "head_entity_id": "T678",
              "tail_entity_id": "T677"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R331",
              "head_entity_id": "T680",
              "tail_entity_id": "T679"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R332",
              "head_entity_id": "T681",
              "tail_entity_id": "T679"
            }
          ],
          "sentence_en": "TZDs: They can cause water and sodium retention and blood volume expansion, inducing or aggravating heart failure. Therefore, they are contraindicated in patients with acute heart failure or chronic heart failure with NYHA heart function class II to IV."
        }
      ],
      "paragraph_en": "TZDs: They can cause water and sodium retention and blood volume expansion, inducing or aggravating heart failure. Therefore, they are contraindicated in patients with acute heart failure or chronic heart failure with NYHA heart function class II to IV."
    },
    {
      "paragraph_id": "70",
      "paragraph": "DPP-4抑制剂：SAVOR-TIMI53研究显示，对于伴有心血管事件病史或心血管危险因素的T2DM患者，沙格列汀可增加心力衰竭住院风险。EXAMINE研究事后分析显示，对于无心力衰竭病史、近期发生过ACS的T2DM患者，阿格列汀增加心力衰竭住院风险( HR 1.76，P=0.026)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "DPP-4抑制剂：SAVOR-TIMI53研究显示，对于伴有心血管事件病史或心血管危险因素的T2DM患者，沙格列汀可增加心力衰竭住院风险。EXAMINE研究事后分析显示，对于无心力衰竭病史、近期发生过ACS的T2DM患者，阿格列汀增加心力衰竭住院风险( HR 1.76，P=0.026)。",
          "start_idx": 0,
          "end_idx": 144,
          "entities": [
            {
              "entity_id": "T683",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 8,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T684",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T685",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 30,
              "end_idx": 33,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T686",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 38,
              "end_idx": 41,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T687",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T688",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 46,
              "end_idx": 48,
              "entity_en": "T2"
            },
            {
              "entity_id": "T689",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T690",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T691",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 60,
              "end_idx": 61,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T692",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 92,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T693",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 88,
              "end_idx": 89,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T694",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 100,
              "end_idx": 103,
              "entity_en": "ACS"
            },
            {
              "entity_id": "T695",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 104,
              "end_idx": 108,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T696",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 104,
              "end_idx": 106,
              "entity_en": "T2"
            },
            {
              "entity_id": "T697",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 115,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T698",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T699",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 117,
              "end_idx": 118,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R333",
              "head_entity_id": "T685",
              "tail_entity_id": "T684"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R334",
              "head_entity_id": "T686",
              "tail_entity_id": "T687"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R335",
              "head_entity_id": "T688",
              "tail_entity_id": "T687"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R336",
              "head_entity_id": "T689",
              "tail_entity_id": "T687"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R337",
              "head_entity_id": "T691",
              "tail_entity_id": "T690"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R338",
              "head_entity_id": "T693",
              "tail_entity_id": "T692"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R339",
              "head_entity_id": "T697",
              "tail_entity_id": "T694"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R340",
              "head_entity_id": "T696",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R341",
              "head_entity_id": "T697",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R342",
              "head_entity_id": "T699",
              "tail_entity_id": "T698"
            }
          ],
          "sentence_en": "DPP-4 inhibitors: The SAVOR-TIMI53 study showed that saxagliptin could increase the risk of hospitalization for heart failure in T2DM patients with a history of cardiovascular events or cardiovascular risk factors. A post hoc analysis of the EXAMINE study showed that alogliptin increased the risk of hospitalization for heart failure in T2DM patients with no history of heart failure and recent ACS (HR 1.76, P=0.026)."
        }
      ],
      "paragraph_en": "DPP-4 inhibitors: The SAVOR-TIMI53 study showed that saxagliptin could increase the risk of hospitalization for heart failure in T2DM patients with a history of cardiovascular events or cardiovascular risk factors. A post hoc analysis of the EXAMINE study showed that alogliptin increased the risk of hospitalization for heart failure in T2DM patients with no history of heart failure and recent ACS (HR 1.76, P=0.026)."
    },
    {
      "paragraph_id": "71",
      "paragraph": "2015年4月，美国FDA对沙格列汀和阿格列汀提出警示，要求在说明书中增加对心力衰竭风险的标示。TECOS研究显示，在有心血管病史的T2DM患者中，西格列汀不增加心力衰竭住院风险，维格列汀的相关研究证据尚不充分.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2015年4月，美国FDA对沙格列汀和阿格列汀提出警示，要求在说明书中增加对心力衰竭风险的标示。TECOS研究显示，在有心血管病史的T2DM患者中，西格列汀不增加心力衰竭住院风险，维格列汀的相关研究证据尚不充分.。",
          "start_idx": 0,
          "end_idx": 107,
          "entities": [
            {
              "entity_id": "T700",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T701",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T702",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T703",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 38,
              "end_idx": 39,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T704",
              "entity": "心血管病",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T705",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T706",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 70,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T707",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 66,
              "end_idx": 68,
              "entity_en": "T2"
            },
            {
              "entity_id": "T708",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 78,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T709",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 85,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T710",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 81,
              "end_idx": 82,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T711",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 94,
              "entity_en": "Vildagliptin"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R343",
              "head_entity_id": "T700",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R344",
              "head_entity_id": "T701",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R345",
              "head_entity_id": "T703",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R346",
              "head_entity_id": "T705",
              "tail_entity_id": "T704"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R347",
              "head_entity_id": "T707",
              "tail_entity_id": "T706"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R348",
              "head_entity_id": "T708",
              "tail_entity_id": "T706"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R349",
              "head_entity_id": "T711",
              "tail_entity_id": "T706"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R350",
              "head_entity_id": "T710",
              "tail_entity_id": "T709"
            }
          ],
          "sentence_en": "In April 2015, the US FDA issued a warning to saxagliptin and alogliptin, requiring the risk of heart failure to be indicated in the instructions. The TECOS study showed that sitagliptin did not increase the risk of hospitalization for heart failure in T2DM patients with a history of cardiovascular disease, and the relevant research evidence for vildagliptin is not sufficient."
        }
      ],
      "paragraph_en": "In April 2015, the US FDA issued a warning to saxagliptin and alogliptin, requiring the risk of heart failure to be indicated in the instructions. The TECOS study showed that sitagliptin did not increase the risk of hospitalization for heart failure in T2DM patients with a history of cardiovascular disease, and the relevant research evidence for vildagliptin is not sufficient."
    },
    {
      "paragraph_id": "72",
      "paragraph": "GLP-1受体激动剂：LEADER和ELIXA研究显示，在心血管事件高危的T2DM患者中利拉鲁肽和利司那肽治疗不增加心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GLP-1受体激动剂：LEADER和ELIXA研究显示，在心血管事件高危的T2DM患者中利拉鲁肽和利司那肽治疗不增加心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 67,
          "entities": [
            {
              "entity_id": "T712",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 10,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T713",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T714",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T715",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T716",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 37,
              "end_idx": 39,
              "entity_en": "T2"
            },
            {
              "entity_id": "T717",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T718",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "Lixisenatide"
            },
            {
              "entity_id": "T719",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T720",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 58,
              "end_idx": 59,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R351",
              "head_entity_id": "T714",
              "tail_entity_id": "T713"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R352",
              "head_entity_id": "T716",
              "tail_entity_id": "T715"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R353",
              "head_entity_id": "T717",
              "tail_entity_id": "T715"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R354",
              "head_entity_id": "T718",
              "tail_entity_id": "T715"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R355",
              "head_entity_id": "T720",
              "tail_entity_id": "T719"
            }
          ],
          "sentence_en": "GLP-1 receptor agonists: The LEADER and ELIXA studies showed that treatment with liraglutide and lixisenatide did not increase the risk of hospitalization for heart failure in patients with T2DM at high risk of cardiovascular events."
        }
      ],
      "paragraph_en": "GLP-1 receptor agonists: The LEADER and ELIXA studies showed that treatment with liraglutide and lixisenatide did not increase the risk of hospitalization for heart failure in patients with T2DM at high risk of cardiovascular events."
    },
    {
      "paragraph_id": "73",
      "paragraph": "SGLT-2抑制剂：EMPA-REG OUTCOME研究显示，在伴有心血管疾病的T2DM患者中，恩格列净可降低心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂：EMPA-REG OUTCOME研究显示，在伴有心血管疾病的T2DM患者中，恩格列净可降低心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T721",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T722",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T723",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T724",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T725",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "T2"
            },
            {
              "entity_id": "T726",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 52,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T727",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T728",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 55,
              "end_idx": 56,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R356",
              "head_entity_id": "T723",
              "tail_entity_id": "T722"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R357",
              "head_entity_id": "T725",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R358",
              "head_entity_id": "T726",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R359",
              "head_entity_id": "T728",
              "tail_entity_id": "T727"
            }
          ],
          "sentence_en": "SGLT-2 inhibitors: The EMPA-REG OUTCOME study showed that empagliflozin can reduce the risk of hospitalization for heart failure in patients with T2DM and cardiovascular disease."
        }
      ],
      "paragraph_en": "SGLT-2 inhibitors: The EMPA-REG OUTCOME study showed that empagliflozin can reduce the risk of hospitalization for heart failure in patients with T2DM and cardiovascular disease."
    },
    {
      "paragraph_id": "74",
      "paragraph": "胰岛素：胰岛素治疗不增加心力衰竭患者的死亡风险。ORIGIN研究显示，在有心血管高危因素的糖代谢异常患者中，与二甲双胍或SUs相比，甘精膝岛素治疗不增加心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "胰岛素：胰岛素治疗不增加心力衰竭患者的死亡风险。ORIGIN研究显示，在有心血管高危因素的糖代谢异常患者中，与二甲双胍或SUs相比，甘精膝岛素治疗不增加心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 85,
          "entities": [
            {
              "entity_id": "T729",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T730",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T731",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T732",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T733",
              "entity": "糖代谢异常",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 50,
              "entity_en": "Abnormal glucose metabolism"
            },
            {
              "entity_id": "T734",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T735",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T736",
              "entity": "甘精膝岛素",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 71,
              "entity_en": "Insulin Glargine"
            },
            {
              "entity_id": "T737",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 80,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T738",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 76,
              "end_idx": 77,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R360",
              "head_entity_id": "T732",
              "tail_entity_id": "T731"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R361",
              "head_entity_id": "T738",
              "tail_entity_id": "T737"
            }
          ],
          "sentence_en": "Insulin: Insulin therapy does not increase the risk of death in patients with heart failure. The ORIGIN study showed that in patients with abnormal glucose metabolism and high cardiovascular risk factors, glargine insulin therapy did not increase the risk of hospitalization for heart failure compared with metformin or SUs."
        }
      ],
      "paragraph_en": "Insulin: Insulin therapy does not increase the risk of death in patients with heart failure. The ORIGIN study showed that in patients with abnormal glucose metabolism and high cardiovascular risk factors, glargine insulin therapy did not increase the risk of hospitalization for heart failure compared with metformin or SUs."
    },
    {
      "paragraph_id": "75",
      "paragraph": "其他降糖药物在心力衰竭患者中应用的安全性尚待进一步评估。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "其他降糖药物在心力衰竭患者中应用的安全性尚待进一步评估。",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T739",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T740",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 8,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R362",
              "head_entity_id": "T740",
              "tail_entity_id": "T739"
            }
          ],
          "sentence_en": "The safety of other glucose-lowering drugs in patients with heart failure needs further evaluation."
        }
      ],
      "paragraph_en": "The safety of other glucose-lowering drugs in patients with heart failure needs further evaluation."
    },
    {
      "paragraph_id": "76",
      "paragraph": "3.低血糖",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.低血糖",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [
            {
              "entity_id": "T741",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [],
          "sentence_en": "3. Hypoglycemia"
        }
      ],
      "paragraph_en": "3. Hypoglycemia"
    },
    {
      "paragraph_id": "77",
      "paragraph": "低血糖对心血管系统具有显著的不良影响.其短期风险包括诱发心律失常、心血管事件，长期风险为认知障碍和痴呆，严重低血糖甚至可导致患者猝死。因此，对于合并ASCVD的T2DM患者，在降糖治疗过程中尤其应尽量避免出现低血糖。胰岛素和胰岛素促泌剂均可引起低血糖，与SUs相比，格列奈类药物的低血糖风险相对较低。二甲双胍、a-糖苷酶抑制剂、TZDs、GLP-1受体激动剂、DPP-4抑制剂以及SGLT-2抑制剂单独使用时通常不会导致低血糖，在接受降糖治疗的患者中，一旦发生低血糖，应迅速补充葡萄糖或含糖食物，以使血糖水平恢复正常，并及时调整降糖治疗方案。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "低血糖对心血管系统具有显著的不良影响.其短期风险包括诱发心律失常、心血管事件，长期风险为认知障碍和痴呆，严重低血糖甚至可导致患者猝死。因此，对于合并ASCVD的T2DM患者，在降糖治疗过程中尤其应尽量避免出现低血糖。胰岛素和胰岛素促泌剂均可引起低血糖，与SUs相比，格列奈类药物的低血糖风险相对较低。二甲双胍、a-糖苷酶抑制剂、TZDs、GLP-1受体激动剂、DPP-4抑制剂以及SGLT-2抑制剂单独使用时通常不会导致低血糖，在接受降糖治疗的患者中，一旦发生低血糖，应迅速补充葡萄糖或含糖食物，以使血糖水平恢复正常，并及时调整降糖治疗方案。",
          "start_idx": 0,
          "end_idx": 271,
          "entities": [
            {
              "entity_id": "T742",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T743",
              "entity": "心血管系统",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Cardiovascular system"
            },
            {
              "entity_id": "T744",
              "entity": "心律失常",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 32,
              "entity_en": "Arrhythmias"
            },
            {
              "entity_id": "T745",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T746",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T747",
              "entity": "认知障碍",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Cognitive impairment"
            },
            {
              "entity_id": "T748",
              "entity": "痴呆",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "dementia"
            },
            {
              "entity_id": "T749",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T750",
              "entity": "猝死",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "sudden death"
            },
            {
              "entity_id": "T751",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 79,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T752",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 80,
              "end_idx": 84,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T753",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 80,
              "end_idx": 82,
              "entity_en": "T2"
            },
            {
              "entity_id": "T754",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 104,
              "end_idx": 107,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T755",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 111,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T756",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 118,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T757",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 122,
              "end_idx": 125,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T758",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 130,
              "entity_en": "S Us"
            },
            {
              "entity_id": "T759",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 133,
              "end_idx": 139,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T760",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 140,
              "end_idx": 143,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T761",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T762",
              "entity": "a-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 163,
              "entity_en": "a-Glucosidase inhibitors"
            },
            {
              "entity_id": "T763",
              "entity": "TZDs",
              "entity_type": "Drug",
              "start_idx": 164,
              "end_idx": 168,
              "entity_en": "TZD"
            },
            {
              "entity_id": "T764",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 179,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T765",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 188,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T766",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 199,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T767",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 210,
              "end_idx": 213,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T768",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 230,
              "end_idx": 233,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T769",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 250,
              "end_idx": 252,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T770",
              "entity": "恢复正常",
              "entity_type": "Test_Value",
              "start_idx": 254,
              "end_idx": 258,
              "entity_en": "Back to normal"
            },
            {
              "entity_id": "T771",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 239,
              "end_idx": 242,
              "entity_en": "glucose"
            },
            {
              "entity_id": "T772",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 52,
              "end_idx": 54,
              "entity_en": "serious"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R363",
              "head_entity_id": "T743",
              "tail_entity_id": "T742"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R364",
              "head_entity_id": "T746",
              "tail_entity_id": "T745"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R365",
              "head_entity_id": "T753",
              "tail_entity_id": "T752"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R366",
              "head_entity_id": "T757",
              "tail_entity_id": "T755"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R367",
              "head_entity_id": "T757",
              "tail_entity_id": "T756"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R368",
              "head_entity_id": "T760",
              "tail_entity_id": "T758"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R369",
              "head_entity_id": "T760",
              "tail_entity_id": "T759"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R370",
              "head_entity_id": "T767",
              "tail_entity_id": "T761"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R371",
              "head_entity_id": "T767",
              "tail_entity_id": "T762"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R372",
              "head_entity_id": "T767",
              "tail_entity_id": "T763"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R373",
              "head_entity_id": "T767",
              "tail_entity_id": "T764"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R374",
              "head_entity_id": "T767",
              "tail_entity_id": "T765"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R375",
              "head_entity_id": "T767",
              "tail_entity_id": "T766"
            }
          ],
          "sentence_en": "Hypoglycemia has significant adverse effects on the cardiovascular system. Its short-term risks include inducing arrhythmias and cardiovascular events, and its long-term risks include cognitive impairment and dementia. Severe hypoglycemia can even lead to sudden death in patients. Therefore, for T2DM patients with ASCVD, hypoglycemia should be avoided as much as possible during glucose-lowering treatment. Both insulin and insulin secretagogues can cause hypoglycemia. Compared with SUs, the risk of hypoglycemia with glinides is relatively low. Metformin, a-glucosidase inhibitors, TZDs, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors do not usually cause hypoglycemia when used alone. In patients receiving glucose-lowering treatment, once hypoglycemia occurs, glucose or sugary foods should be supplemented quickly to restore blood sugar levels to normal, and the glucose-lowering treatment plan should be adjusted in a timely manner."
        }
      ],
      "paragraph_en": "Hypoglycemia has significant adverse effects on the cardiovascular system. Its short-term risks include inducing arrhythmias and cardiovascular events, and its long-term risks include cognitive impairment and dementia. Severe hypoglycemia can even lead to sudden death in patients. Therefore, for T2DM patients with ASCVD, hypoglycemia should be avoided as much as possible during glucose-lowering treatment. Both insulin and insulin secretagogues can cause hypoglycemia. Compared with SUs, the risk of hypoglycemia with glinides is relatively low. Metformin, a-glucosidase inhibitors, TZDs, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors do not usually cause hypoglycemia when used alone. In patients receiving glucose-lowering treatment, once hypoglycemia occurs, glucose or sugary foods should be supplemented quickly to restore blood sugar levels to normal, and the glucose-lowering treatment plan should be adjusted in a timely manner."
    },
    {
      "paragraph_id": "78",
      "paragraph": "4.肾功能不全",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.肾功能不全",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T773",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T774",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R376",
              "head_entity_id": "T774",
              "tail_entity_id": "T773"
            }
          ],
          "sentence_en": "4. Renal insufficiency"
        }
      ],
      "paragraph_en": "4. Renal insufficiency"
    },
    {
      "paragraph_id": "79",
      "paragraph": "T2DM和ASCVD患者常合并CKD。当患者存在肾功能不全[eGFR<60ml/(min.1.73m2)]时，大多数非胰岛素降糖药物的药代动力学会发生",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM和ASCVD患者常合并CKD。当患者存在肾功能不全[eGFR<60ml/(min.1.73m2)]时，大多数非胰岛素降糖药物的药代动力学会发生",
          "start_idx": 0,
          "end_idx": 75,
          "entities": [
            {
              "entity_id": "T775",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T776",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "T2"
            },
            {
              "entity_id": "T777",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T778",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T779",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T780",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 25,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T781",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 34,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T782",
              "entity": "<60ml/(min.1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 51,
              "entity_en": "<60ml/(min.1.73m2"
            },
            {
              "entity_id": "T783",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R377",
              "head_entity_id": "T776",
              "tail_entity_id": "T775"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R378",
              "head_entity_id": "T780",
              "tail_entity_id": "T779"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R379",
              "head_entity_id": "T781",
              "tail_entity_id": "T779"
            }
          ],
          "sentence_en": "Patients with T2DM and ASCVD often have CKD. When patients have renal insufficiency [eGFR < 60 ml/(min.1.73 m2)], the pharmacokinetics of most non-insulin glucose-lowering drugs will change."
        }
      ],
      "paragraph_en": "Patients with T2DM and ASCVD often have CKD. When patients have renal insufficiency [eGFR < 60 ml/(min.1.73 m2)], the pharmacokinetics of most non-insulin glucose-lowering drugs will change."
    },
    {
      "paragraph_id": "80",
      "paragraph": "改变。因此，对于合并CKD的患者.降糖药物的选择应基于药物的药代动力学特征和患者肾功能状态进行综合判断，以确保在有效降糖的同时不增加低血糖风险，并避免诱发乳酸性酸中毒.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "改变。",
          "start_idx": 0,
          "end_idx": 3,
          "entities": [],
          "relations": [],
          "sentence_en": "Change."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，对于合并CKD的患者.降糖药物的选择应基于药物的药代动力学特征和患者肾功能状态进行综合判断，以确保在有效降糖的同时不增加低血糖风险，并避免诱发乳酸性酸中毒.。",
          "start_idx": 3,
          "end_idx": 85,
          "entities": [
            {
              "entity_id": "T784",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T785",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 63,
              "end_idx": 66,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T786",
              "entity": "乳酸性酸中毒",
              "entity_type": "ADE",
              "start_idx": 74,
              "end_idx": 80,
              "entity_en": "Lactic acidosis"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, for patients with CKD, the choice of hypoglycemic drugs should be based on a comprehensive judgment of the pharmacokinetic characteristics of the drugs and the patient's renal function status to ensure that the risk of hypoglycemia is not increased while effectively lowering blood sugar and avoiding inducing lactic acidosis."
        }
      ],
      "paragraph_en": "Therefore, for patients with CKD, the choice of hypoglycemic drugs should be based on a comprehensive judgment of the pharmacokinetic characteristics of the drugs and the patient's renal function status to ensure that the risk of hypoglycemia is not increased while effectively lowering blood sugar and avoiding inducing lactic acidosis."
    },
    {
      "paragraph_id": "81",
      "paragraph": "瑞格列奈和利格列汀在CKD1~5期全程均可使用，且无需调整剂量。其他非胰岛素降糖药的使用均可因肾功能不全的不同程度而受到一定的影响。二甲双胍在CKD3a期[eGFR45~59ml/(min.1.73m2)]时应减量，在CKD3b期[eGFR30--45ml/(min.1.73m2)]时证据相对有限，谨慎观察下减量使用，在CKD4期[eGFR<30ml/(min.1.73m2)]时禁用。基于LEADER研究和LIRA-RENAL研究的数据.推荐利拉鲁肽可用于CKD1~3期，从CKD4期开始禁用。根据美国FDA批准的药品说明书，恩格列净可用于CKD1~3a期，从3b期开始不推荐使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "瑞格列奈和利格列汀在CKD1~5期全程均可使用，且无需调整剂量。其他非胰岛素降糖药的使用均可因肾功能不全的不同程度而受到一定的影响。二甲双胍在CKD3a期[eGFR45~59ml/(min.1.73m2)]时应减量，在CKD3b期[eGFR30--45ml/(min.1.73m2)]时证据相对有限，谨慎观察下减量使用，在CKD4期[eGFR<30ml/(min.1.73m2)]时禁用。基于LEADER研究和LIRA-RENAL研究的数据.推荐利拉鲁肽可用于CKD1~3期，从CKD4期开始禁用。根据美国FDA批准的药品说明书，恩格列净可用于CKD1~3a期，从3b期开始不推荐使用。",
          "start_idx": 0,
          "end_idx": 293,
          "entities": [
            {
              "entity_id": "T787",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T788",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T789",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T790",
              "entity": "1~5期",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "1~5th period"
            },
            {
              "entity_id": "T791",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 38,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T792",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 52,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T793",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 47,
              "end_idx": 48,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T794",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 70,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T795",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 74,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T796",
              "entity": "3a期",
              "entity_type": "Class",
              "start_idx": 74,
              "end_idx": 77,
              "entity_en": "Phase 3a"
            },
            {
              "entity_id": "T797",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T798",
              "entity": "45~59ml/(min.1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 82,
              "end_idx": 101,
              "entity_en": "45~59ml/(min.1.73m2"
            },
            {
              "entity_id": "T799",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 109,
              "end_idx": 112,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T800",
              "entity": "3b期",
              "entity_type": "Class",
              "start_idx": 112,
              "end_idx": 115,
              "entity_en": "Phase 3b"
            },
            {
              "entity_id": "T801",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 116,
              "end_idx": 120,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T802",
              "entity": "30--45ml/(min.1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 120,
              "end_idx": 140,
              "entity_en": "30--45ml/(min.1.73m2"
            },
            {
              "entity_id": "T803",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 161,
              "end_idx": 164,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T804",
              "entity": "4期",
              "entity_type": "Class",
              "start_idx": 164,
              "end_idx": 166,
              "entity_en": "4th phase"
            },
            {
              "entity_id": "T805",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 167,
              "end_idx": 171,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T806",
              "entity": "<30ml/(min.1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 171,
              "end_idx": 188,
              "entity_en": "<30ml/(min.1.73m2"
            },
            {
              "entity_id": "T807",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 223,
              "end_idx": 227,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T808",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 230,
              "end_idx": 233,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T809",
              "entity": "1~3期",
              "entity_type": "Class",
              "start_idx": 233,
              "end_idx": 237,
              "entity_en": "Phase 1~3"
            },
            {
              "entity_id": "T810",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 239,
              "end_idx": 242,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T811",
              "entity": "4期",
              "entity_type": "Class",
              "start_idx": 242,
              "end_idx": 244,
              "entity_en": "4th phase"
            },
            {
              "entity_id": "T812",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T813",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 272,
              "end_idx": 275,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T814",
              "entity": "1~3a期",
              "entity_type": "Class",
              "start_idx": 275,
              "end_idx": 280,
              "entity_en": "Stage 1~3a"
            },
            {
              "entity_id": "T815",
              "entity": "3b期",
              "entity_type": "Class",
              "start_idx": 282,
              "end_idx": 285,
              "entity_en": "Phase 3b"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R380",
              "head_entity_id": "T787",
              "tail_entity_id": "T789"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R381",
              "head_entity_id": "T788",
              "tail_entity_id": "T789"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R382",
              "head_entity_id": "T790",
              "tail_entity_id": "T789"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R383",
              "head_entity_id": "T793",
              "tail_entity_id": "T792"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R384",
              "head_entity_id": "T794",
              "tail_entity_id": "T795"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R385",
              "head_entity_id": "T796",
              "tail_entity_id": "T795"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R386",
              "head_entity_id": "T797",
              "tail_entity_id": "T795"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R387",
              "head_entity_id": "T801",
              "tail_entity_id": "T799"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R388",
              "head_entity_id": "T800",
              "tail_entity_id": "T799"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R389",
              "head_entity_id": "T805",
              "tail_entity_id": "T803"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R390",
              "head_entity_id": "T804",
              "tail_entity_id": "T803"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R391",
              "head_entity_id": "T807",
              "tail_entity_id": "T808"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R392",
              "head_entity_id": "T809",
              "tail_entity_id": "T808"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R393",
              "head_entity_id": "T811",
              "tail_entity_id": "T810"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R394",
              "head_entity_id": "T812",
              "tail_entity_id": "T813"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R395",
              "head_entity_id": "T814",
              "tail_entity_id": "T813"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R396",
              "head_entity_id": "T815",
              "tail_entity_id": "T813"
            }
          ],
          "sentence_en": "Repaglinide and linagliptin can be used throughout CKD stages 1 to 5 without adjusting the dose. The use of other non-insulin hypoglycemic drugs may be affected to a certain extent by varying degrees of renal insufficiency. Metformin should be reduced in CKD stage 3a [eGFR45~59ml/(min.1.73m2)], and the evidence is relatively limited in CKD stage 3b [eGFR30--45ml/(min.1.73m2)]. It should be used in a reduced dose under careful observation, and is contraindicated in CKD stage 4 [eGFR<30ml/(min.1.73m2)]. Based on the data from the LEADER study and the LIRA-RENAL study, liraglutide is recommended for CKD stages 1 to 3 and is contraindicated starting from CKD stage 4. According to the drug instructions approved by the US FDA, empagliflozin can be used in CKD stages 1 to 3a and is not recommended starting from stage 3b."
        }
      ],
      "paragraph_en": "Repaglinide and linagliptin can be used throughout CKD stages 1 to 5 without adjusting the dose. The use of other non-insulin hypoglycemic drugs may be affected to a certain extent by varying degrees of renal insufficiency. Metformin should be reduced in CKD stage 3a [eGFR45~59ml/(min.1.73m2)], and the evidence is relatively limited in CKD stage 3b [eGFR30--45ml/(min.1.73m2)]. It should be used in a reduced dose under careful observation, and is contraindicated in CKD stage 4 [eGFR<30ml/(min.1.73m2)]. Based on the data from the LEADER study and the LIRA-RENAL study, liraglutide is recommended for use in CKD stages 1 to 3 and is contraindicated starting from CKD stage 4. According to the drug instructions approved by the US FDA, empagliflozin can be used in CKD stages 1 to 3a and is not recommended starting from stage 3b."
    },
    {
      "paragraph_id": "82",
      "paragraph": "在CVOT中，包括肾脏不良事件在内的微血管事件通常作为研究的次要终点。在LEADER研究中，24.7%的患者基线时合并CKD3期或以上，利拉鲁肽可使肾脏事件复合终点(包括新发大量蛋白尿、Scr倍增、终末期肾病或肾病导致的死亡)的风险显著降低22%(P=0.003)。在EMPA-REGOUTCOME研究中，25.9%的患者基线时伴有CKD3期，恩格列净可使肾脏事件复合终点(Scr倍增、起始肾脏替代治疗或因肾病死亡)的风险显著降低46%(P<0.001)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "在CVOT中，包括肾脏不良事件在内的微血管事件通常作为研究的次要终点。在LEADER研究中，24.7%的患者基线时合并CKD3期或以上，利拉鲁肽可使肾脏事件复合终点(包括新发大量蛋白尿、Scr倍增、终末期肾病或肾病导致的死亡)的风险显著降低22%(P=0.003)。在EMPA-REGOUTCOME研究中，25.9%的患者基线时伴有CKD3期，恩格列净可使肾脏事件复合终点(Scr倍增、起始肾脏替代治疗或因肾病死亡)的风险显著降低46%(P<0.001)。",
          "start_idx": 0,
          "end_idx": 228,
          "entities": [
            {
              "entity_id": "T816",
              "entity": "肾脏不良事件",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 15,
              "entity_en": "Renal adverse events"
            },
            {
              "entity_id": "T817",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T818",
              "entity": "微血管事件",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Microvascular events"
            },
            {
              "entity_id": "T819",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T820",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T821",
              "entity": "3期",
              "entity_type": "Class",
              "start_idx": 62,
              "end_idx": 64,
              "entity_en": "Phase 3"
            },
            {
              "entity_id": "T822",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 72,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T823",
              "entity": "肾脏事件",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 78,
              "entity_en": "Renal events"
            },
            {
              "entity_id": "T824",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 74,
              "end_idx": 76,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T825",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 92,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T826",
              "entity": "大量",
              "entity_type": "Level",
              "start_idx": 87,
              "end_idx": 89,
              "entity_en": "Large"
            },
            {
              "entity_id": "T827",
              "entity": "Scr",
              "entity_type": "Test_items",
              "start_idx": 93,
              "end_idx": 96,
              "entity_en": "Scr"
            },
            {
              "entity_id": "T828",
              "entity": "倍增",
              "entity_type": "Test_Value",
              "start_idx": 96,
              "end_idx": 98,
              "entity_en": "Multiplication"
            },
            {
              "entity_id": "T829",
              "entity": "终末期肾病",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "End-stage renal disease"
            },
            {
              "entity_id": "T830",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 99,
              "end_idx": 102,
              "entity_en": "Terminal stage"
            },
            {
              "entity_id": "T831",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 102,
              "end_idx": 103,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T832",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 107,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T833",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 106,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T834",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 169,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T835",
              "entity": "3期",
              "entity_type": "Class",
              "start_idx": 169,
              "end_idx": 171,
              "entity_en": "Phase 3"
            },
            {
              "entity_id": "T836",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 172,
              "end_idx": 176,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T837",
              "entity": "肾脏事件",
              "entity_type": "Disease",
              "start_idx": 178,
              "end_idx": 182,
              "entity_en": "Renal events"
            },
            {
              "entity_id": "T838",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 178,
              "end_idx": 180,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T839",
              "entity": "Scr",
              "entity_type": "Test_items",
              "start_idx": 187,
              "end_idx": 190,
              "entity_en": "Scr"
            },
            {
              "entity_id": "T840",
              "entity": "倍增",
              "entity_type": "Test_Value",
              "start_idx": 190,
              "end_idx": 192,
              "entity_en": "Multiplication"
            },
            {
              "entity_id": "T841",
              "entity": "起始肾脏替代治疗",
              "entity_type": "Operation",
              "start_idx": 193,
              "end_idx": 201,
              "entity_en": "Initiation of renal replacement therapy"
            },
            {
              "entity_id": "T842",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 203,
              "end_idx": 205,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T843",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 203,
              "end_idx": 204,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R397",
              "head_entity_id": "T817",
              "tail_entity_id": "T816"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R398",
              "head_entity_id": "T819",
              "tail_entity_id": "T818"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R399",
              "head_entity_id": "T821",
              "tail_entity_id": "T820"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R400",
              "head_entity_id": "T822",
              "tail_entity_id": "T820"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R401",
              "head_entity_id": "T827",
              "tail_entity_id": "T820"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R402",
              "head_entity_id": "T824",
              "tail_entity_id": "T823"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R403",
              "head_entity_id": "T830",
              "tail_entity_id": "T829"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R404",
              "head_entity_id": "T831",
              "tail_entity_id": "T829"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R405",
              "head_entity_id": "T833",
              "tail_entity_id": "T832"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R406",
              "head_entity_id": "T835",
              "tail_entity_id": "T834"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R407",
              "head_entity_id": "T836",
              "tail_entity_id": "T834"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R408",
              "head_entity_id": "T839",
              "tail_entity_id": "T834"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R409",
              "head_entity_id": "T838",
              "tail_entity_id": "T837"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R410",
              "head_entity_id": "T843",
              "tail_entity_id": "T842"
            }
          ],
          "sentence_en": "In CVOT, microvascular events including adverse renal events are usually used as secondary endpoints of the study. In the LEADER study, 24.7% of patients had CKD stage 3 or above at baseline, and liraglutide significantly reduced the risk of the composite endpoint of renal events (including new-onset massive proteinuria, Scr doubling, end-stage renal disease, or death due to renal disease) by 22% (P=0.003). In the EMPA-REGOUTCOME study, 25.9% of patients had CKD stage 3 at baseline, and empagliflozin significantly reduced the risk of the composite endpoint of renal events (Scr doubling, initiation of renal replacement therapy, or death due to renal disease) by 46% (P<0.001)."
        }
      ],
      "paragraph_en": "In CVOT, microvascular events including adverse renal events are usually used as secondary endpoints of the study. In the LEADER study, 24.7% of patients had CKD stage 3 or above at baseline, and liraglutide significantly reduced the risk of the composite endpoint of renal events (including new-onset massive proteinuria, Scr doubling, end-stage renal disease, or death due to renal disease) by 22% (P=0.003). In the EMPA-REGOUTCOME study, 25.9% of patients had CKD stage 3 at baseline, and empagliflozin significantly reduced the risk of the composite endpoint of renal events (Scr doubling, initiation of renal replacement therapy, or death due to renal disease) by 46% (P<0.001)."
    },
    {
      "paragraph_id": "83",
      "paragraph": "2016年6月，美国FDA修改坎格列净和达格列净的药物说明书，新增急性肾损伤风险的标签警示信息，建议处方这两种药物之前全面考虑增加急性肾损伤风险的各种因素，并在服药期间监测肾功能的动态变化。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2016年6月，美国FDA修改坎格列净和达格列净的药物说明书，新增急性肾损伤风险的标签警示信息，建议处方这两种药物之前全面考虑增加急性肾损伤风险的各种因素，并在服药期间监测肾功能的动态变化。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T844",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "Canagliflozin"
            },
            {
              "entity_id": "T845",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T846",
              "entity": "急性肾损伤",
              "entity_type": "ADE",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Acute kidney injury"
            },
            {
              "entity_id": "T847",
              "entity": "急性肾损伤",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 70,
              "entity_en": "Acute kidney injury"
            },
            {
              "entity_id": "T848",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 65,
              "end_idx": 67,
              "entity_en": "acute"
            },
            {
              "entity_id": "T849",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 67,
              "end_idx": 68,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T850",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "Renal function"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R411",
              "head_entity_id": "T846",
              "tail_entity_id": "T844"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R412",
              "head_entity_id": "T846",
              "tail_entity_id": "T845"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R413",
              "head_entity_id": "T849",
              "tail_entity_id": "T847"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R414",
              "head_entity_id": "T848",
              "tail_entity_id": "T847"
            }
          ],
          "sentence_en": "In June 2016, the U.S. FDA revised the drug instructions for canagliflozin and dapagliflozin, adding new label warning information on the risk of acute kidney injury, recommending that various factors that increase the risk of acute kidney injury be fully considered before prescribing these two drugs, and that dynamic changes in renal function be monitored during medication."
        }
      ],
      "paragraph_en": "In June 2016, the U.S. FDA revised the drug instructions for canagliflozin and dapagliflozin, adding new label warning information on the risk of acute kidney injury, recommending that various factors that increase the risk of acute kidney injury be fully considered before prescribing these two drugs, and that dynamic changes in renal function be monitored during medication."
    },
    {
      "paragraph_id": "84",
      "paragraph": "表4总结了T2DM合并ASCVD患者降糖药物使用应着重关注的主要安全性问题，其中包括药物的心血管效应、低血糖风险、对体重的影响、在心力衰竭或肝肾功能不全等特殊患者中应用的注意事项。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "表4总结了T2DM合并ASCVD患者降糖药物使用应着重关注的主要安全性问题，其中包括药物的心血管效应、低血糖风险、对体重的影响、在心力衰竭或肝肾功能不全等特殊患者中应用的注意事项。",
          "start_idx": 0,
          "end_idx": 90,
          "entities": [
            {
              "entity_id": "T851",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T852",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "T2"
            },
            {
              "entity_id": "T853",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T854",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 69,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T855",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 65,
              "end_idx": 66,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T856",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 70,
              "end_idx": 76,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T857",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 70,
              "end_idx": 71,
              "entity_en": "liver"
            },
            {
              "entity_id": "T858",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 71,
              "end_idx": 72,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T859",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R415",
              "head_entity_id": "T852",
              "tail_entity_id": "T851"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R416",
              "head_entity_id": "T855",
              "tail_entity_id": "T854"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R417",
              "head_entity_id": "T857",
              "tail_entity_id": "T856"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R418",
              "head_entity_id": "T858",
              "tail_entity_id": "T856"
            }
          ],
          "sentence_en": "Table 4 summarizes the main safety issues that should be focused on when using glucose-lowering drugs in patients with T2DM and ASCVD, including the cardiovascular effects of the drugs, the risk of hypoglycemia, the effect on body weight, and precautions for use in special patients such as those with heart failure or hepatic and renal insufficiency."
        }
      ],
      "paragraph_en": "Table 4 summarizes the main safety issues that should be focused on when using glucose-lowering drugs in patients with T2DM and ASCVD, including the cardiovascular effects of the drugs, the risk of hypoglycemia, the effect on body weight, and precautions for use in special patients such as those with heart failure or hepatic and renal insufficiency."
    },
    {
      "paragraph_id": "85",
      "paragraph": "五、结语与展望",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "五、结语与展望",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "V. Conclusion and Outlook"
        }
      ],
      "paragraph_en": "V. Conclusion and Outlook"
    },
    {
      "paragraph_id": "86",
      "paragraph": "对于T2DM合并ASCVD患者，应采取综合管理策略，全面控制高血糖、高血压、血脂异常、超重或肥胖等多重心血管危险因素。在血糖管理方面，临床医师应充分考虑降糖药物的疗效与安全性之间的平衡，并且全面了解常用降糖药物的心血管安全性，这样才能熟练掌握其应用原则。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于T2DM合并ASCVD患者，应采取综合管理策略，全面控制高血糖、高血压、血脂异常、超重或肥胖等多重心血管危险因素。在血糖管理方面，临床医师应充分考虑降糖药物的疗效与安全性之间的平衡，并且全面了解常用降糖药物的心血管安全性，这样才能熟练掌握其应用原则。",
          "start_idx": 0,
          "end_idx": 127,
          "entities": [
            {
              "entity_id": "T860",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T861",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "T2"
            },
            {
              "entity_id": "T862",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T863",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 33,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T864",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T865",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Dyslipidemia"
            },
            {
              "entity_id": "T866",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T867",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 48,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T868",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T869",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 62,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R419",
              "head_entity_id": "T861",
              "tail_entity_id": "T860"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R420",
              "head_entity_id": "T868",
              "tail_entity_id": "T860"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R421",
              "head_entity_id": "T868",
              "tail_entity_id": "T862"
            }
          ],
          "sentence_en": "For patients with T2DM and ASCVD, a comprehensive management strategy should be adopted to comprehensively control multiple cardiovascular risk factors such as hyperglycemia, hypertension, dyslipidemia, overweight or obesity. In terms of blood sugar management, clinicians should fully consider the balance between the efficacy and safety of hypoglycemic drugs, and fully understand the cardiovascular safety of commonly used hypoglycemic drugs, so that they can master their application principles."
        }
      ],
      "paragraph_en": "For patients with T2DM and ASCVD, a comprehensive management strategy should be adopted to comprehensively control multiple cardiovascular risk factors such as hyperglycemia, hypertension, dyslipidemia, overweight or obesity. In terms of blood sugar management, clinicians should fully consider the balance between the efficacy and safety of hypoglycemic drugs, and fully understand the cardiovascular safety of commonly used hypoglycemic drugs, so as to master their application principles."
    },
    {
      "paragraph_id": "87",
      "paragraph": "随着CVOT的广泛开展，其研究结果将陆续公布。最新公布的SUSTAIN-6研究显示，新型长效GLP-1受体激动剂索马鲁肽(semaglutide，尚未被批准上市)同样也可显著降低心血管事件风险。因此，有理由相信未来将会出现越来越多可为T2DM患者带来心血管保护作用的降糖药物，这将推动T2DM(特别是合并ASCVD)患者的治疗策略和理念发生巨大的变革。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "随着CVOT的广泛开展，其研究结果将陆续公布。最新公布的SUSTAIN-6研究显示，新型长效GLP-1受体激动剂索马鲁肽(semaglutide，尚未被批准上市)同样也可显著降低心血管事件风险。因此，有理由相信未来将会出现越来越多可为T2DM患者带来心血管保护作用的降糖药物，这将推动T2DM(特别是合并ASCVD)患者的治疗策略和理念发生巨大的变革。",
          "start_idx": 0,
          "end_idx": 176,
          "entities": [
            {
              "entity_id": "T870",
              "entity": "长效GLP-1受体激动剂索马鲁肽(semaglutide，尚未被批准上市)",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 81,
              "entity_en": "Long-acting GLP-1 receptor agonist semaglutide (not yet approved for marketing)"
            },
            {
              "entity_id": "T871",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 94,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T872",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 89,
              "end_idx": 92,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T873",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T874",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 117,
              "end_idx": 119,
              "entity_en": "T2"
            },
            {
              "entity_id": "T875",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 146,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T876",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": "T2"
            },
            {
              "entity_id": "T877",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 152,
              "end_idx": 157,
              "entity_en": "ASCVD"
            },
            {
              "entity_id": "T878",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 125,
              "end_idx": 128,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R422",
              "head_entity_id": "T872",
              "tail_entity_id": "T871"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R423",
              "head_entity_id": "T874",
              "tail_entity_id": "T873"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R424",
              "head_entity_id": "T878",
              "tail_entity_id": "T873"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R425",
              "head_entity_id": "T876",
              "tail_entity_id": "T875"
            }
          ],
          "sentence_en": "As CVOT is widely carried out, its research results will be announced one after another. The latest SUSTAIN-6 study shows that the new long-acting GLP-1 receptor agonist semaglutide (not yet approved for marketing) can also significantly reduce the risk of cardiovascular events. Therefore, there is reason to believe that in the future there will be more and more hypoglycemic drugs that can provide cardiovascular protection for T2DM patients, which will promote a huge change in the treatment strategies and concepts of T2DM patients (especially those with ASCVD)."
        }
      ],
      "paragraph_en": "As CVOT is widely carried out, its research results will be announced one after another. The latest SUSTAIN-6 study shows that the new long-acting GLP-1 receptor agonist semaglutide (not yet approved for marketing) can also significantly reduce the risk of cardiovascular events. Therefore, there is reason to believe that in the future there will be more and more hypoglycemic drugs that can provide cardiovascular protection for T2DM patients, which will promote a huge change in the treatment strategies and concepts of T2DM patients (especially those with ASCVD)."
    }
  ]
}